<SEC-DOCUMENT>0001144204-13-027499.txt : 20130509
<SEC-HEADER>0001144204-13-027499.hdr.sgml : 20130509
<ACCEPTANCE-DATETIME>20130509171529
ACCESSION NUMBER:		0001144204-13-027499
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130331
FILED AS OF DATE:		20130509
DATE AS OF CHANGE:		20130509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		13829974

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v343144_10q.htm
<DESCRIPTION>FORM10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(Mark One)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-indent: -30.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the quarterly period ended March 31, 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.6pt"><FONT STYLE="font-family: Wingdings; color: black"><B>&uml;</B></FONT></TD><TD><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-indent: -30.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>For the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
to</B>&nbsp;_________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>001-33357</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Commission file number)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center; border-bottom: Black 1pt solid"><B><U STYLE="text-decoration: none">Florida</U></B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 49%"><B>65-0643773</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(State or other jurisdiction</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(I.R.S. Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>of incorporation or organization)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Identification No.)</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>2 Snunit Street</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>Science Park</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><B>POB 455</B></TD>
    <TD STYLE="text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B><U STYLE="text-decoration: none">Carmiel, Israel</U></B></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><B><U STYLE="text-decoration: none">20100</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><B><U>+972-4-988-9488</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Registrant&rsquo;s telephone number, including area code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; text-align: center"><B><U>N/A</U></B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Former name, former address and former fiscal year, if changed since last report)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject
to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &ldquo;large accelerated filer&rdquo;
and &ldquo;accelerated filer&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%; text-indent: 0in">Large accelerated filer</TD>
    <TD STYLE="width: 51%; text-indent: 0in"><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD>
    <TD STYLE="width: 26%; text-indent: 0in">Accelerated filer</TD>
    <TD STYLE="width: 2%; text-indent: 0in"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Non-accelerated filer</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings; color: black">&uml; </FONT>(Do not check if a smaller reporting company)</TD>
    <TD STYLE="text-indent: 0in">Smaller reporting company</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Wingdings; color: black">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">On May 1, 2013, approximately 93,503,268 shares
of the Registrant&rsquo;s common stock, $0.001 par value, were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 10-Q</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 82%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center; border-bottom: Black 1pt solid; vertical-align: bottom"><B>Page</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>PART I &ndash; FINANCIAL INFORMATION</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD><B>Cautionary Statement Regarding Forward-Looking Statements</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item&nbsp;1.</TD>
    <TD>Financial Statements</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in">Condensed Consolidated Balance Sheets &ndash;<BR>
As of March 31, 2013 (Unaudited) and December 31, 2012</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in">Condensed Consolidated Statements of Operations (Unaudited) &ndash;<BR>
For the Three Months Ended March 31, 2013 and 2012</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in">Condensed Consolidated Statement of Changes in Capital Deficiency (Unaudited) &ndash;<BR>
For the Three Months Ended March 31, 2013 and 2012</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in">Condensed Consolidated Statements of Cash Flows (Unaudited) &ndash;<BR>
For the Three Months Ended March 31, 2013 and 2012</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in">Notes to Condensed Consolidated Financial Statements</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item&nbsp;2.</TD>
    <TD>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item 3.</TD>
    <TD>Quantitative and Qualitative Disclosures About Market Risk</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">14</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item&nbsp;4.</TD>
    <TD>Controls and Procedures</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">15</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><B>PART II &ndash; OTHER INFORMATION</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item&nbsp;1.</TD>
    <TD>Legal Proceedings</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item&nbsp;1A.</TD>
    <TD>Risk Factors</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item&nbsp;2.</TD>
    <TD>Unregistered Sales of Equity Securities and Use of Proceeds</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item&nbsp;3.</TD>
    <TD>Defaults Upon Senior Securities</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item&nbsp;4.</TD>
    <TD>Mine Safety Disclosures</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>Item&nbsp;5.</TD>
    <TD>Other Information</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>Item&nbsp;6.</TD>
    <TD>Exhibits</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">Signatures</TD>
    <TD NOWRAP STYLE="text-align: center; vertical-align: bottom">18</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Except where the context otherwise requires, the terms, &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or &ldquo;the Company,&rdquo; refer to the business of Protalix BioTherapeutics, Inc. and its
consolidated subsidiaries, and &ldquo;Protalix&rdquo; or &ldquo;Protalix Ltd.&rdquo; refers to the business of Protalix Ltd., our
wholly-owned subsidiary and sole operating unit.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements set forth under the captions &ldquo;Business,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and &ldquo;Risk Factors,&rdquo;
and other statements included elsewhere in this Quarterly Report on Form 10-Q, which are not historical, constitute &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section
21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs,
intentions or strategies for the future. When used in this report, the terms &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo;
&ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo;
&ldquo;would&rdquo; and words or phrases of similar import, as they relate to our company or our subsidiaries or our management,
are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor
provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect
our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation
to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances
after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under
applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ
materially from any future results expressed or implied by the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of the risks and uncertainties include, but are not
limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the commercialization efforts for taliglucerase alfa in the United States, Israel and Brazil;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk of significant delays in the commercial introduction of taliglucerase alfa in other markets as planned;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to enter into supply arrangements with the Brazilian Ministry of Health, or the Brazilian MOH, or other parties
and to supply drug product pursuant to such arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that we will not be able to develop a successful sales and marketing organization for any of our product candidates
in a timely manner, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks related to the acceptance and use of taliglucerase alfa or any of our product candidates, if approved, by physicians,
patients and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in the approval or the potential rejection of any application filed with or submitted to the regulatory authorities
reviewing taliglucerase alfa outside of the United States, Israel, Brazil and other countries in which taliglucerase alfa is already
approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to establish and maintain strategic license, collaboration and distribution arrangements, and to manage our relationships
with Pfizer Inc., or Pfizer, or any other collaborator, distributor or partner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to our ability to finance our research programs, the expansion of our manufacturing capabilities and the ongoing
costs in the case of delays in regulatory approvals for taliglucerase alfa outside of the United States, Israel, Brazil and other
countries in which taliglucerase alfa is already approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in our preparation and filing of applications for regulatory approval of our other product candidates in the United
States, the European Union and elsewhere;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations with respect to the potential commercial value of our product and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the risk that products that are competitive to our product candidates may be granted orphan drug status in certain territories
and, therefore, our product candidates may be subject to potential marketing and commercialization restrictions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of the development of competing therapies and/or technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>any lack of progress of our research and development activities and our clinical activities with respect to any product candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inherent risks and uncertainties in developing the types of drug platforms and products we are developing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>potential product liability risks, and risks of securing adequate levels of product liability and clinical trial insurance
coverage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possibility of infringing a third party&rsquo;s patents or other intellectual property rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the uncertainty of obtaining patents covering our products and processes and in successfully enforcing our intellectual property
rights against third parties;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>risks relating to biosimilar legislation and/or healthcare reform in the United States or elsewhere; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption
of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors,
collaborative partners, licensees and clinical trial sites<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies in the pharmaceutical and biotechnology industries
have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results
or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product,
the U.S. Food and Drug Administration, or the FDA, or foreign regulatory authorities may not accept or approve a marketing application
filed by a pharmaceutical or biotechnology company for the drug product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should
not place undue reliance on these forward-looking statements. These and other risks and uncertainties are detailed under the heading
<FONT STYLE="text-transform: uppercase">&quot;</FONT>Risk Factors<FONT STYLE="text-transform: uppercase">&quot;</FONT> in our
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2012, and are described from time to time in the reports we
file with the Securities and Exchange Commission, or the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART I &ndash; FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1. Financial
Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2013</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2012</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0.125in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">41,870</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">52,035</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts receivable- Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,698</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,410</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,686</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.125in">Inventories</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,773</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52,894</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">61,170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">FUNDS IN RESPECT OF EMPLOYEE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.125in">RIGHTS UPON RETIREMENT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,343</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,247</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">PROPERTY AND EQUIPMENT, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,705</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16,310</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">69,942</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,727</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES NET OF CAPITAL DEFICIENCY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Accounts payable and accruals:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Trade</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,762</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,267</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.25in">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,051</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Deferred revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,591</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,437</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,408</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25,755</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Deferred revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Liability in connection with collaboration operation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,700</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Liability for employee rights upon retirement</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,123</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,016</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total long term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51,817</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">56,329</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">76,225</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">82,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.375in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">COMMITMENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">CAPITAL DEFICIENCY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,283</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in">Total liabilities net of capital deficiency</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">69,942</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">78,727</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands, except share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2013</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 70%; font-weight: bold">REVENUES</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,568</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">COMPANY&rsquo;S SHARE IN COLLABORATION AGREEMENT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(133</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF REVENUES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(971</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,320</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">GROSS PROFIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,997</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,408</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">RESEARCH AND DEVELOPMENT EXPENSES (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,754</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,847</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Less &ndash; grants and reimbursements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,431</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,003</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">RESEARCH AND DEVELOPMENT EXPENSES, NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(5,323</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(6,844</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt"><B>GENERAL AND ADMINISTRATIVE <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: black">EXPENSES (2)</FONT></B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(2,103</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(1,629</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="color: black; font-weight: bold; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,429</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,065</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="color: black; font-weight: bold; text-align: left; padding-bottom: 1pt">FINANCIAL INCOME &ndash; NET</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">108</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">161</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS FOR THE PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(4,321</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(5,904</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt"><B>NET LOSS PER SHARE OF COMMON STOCK &ndash; BASIC AND DILUTED</B></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.05</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.07</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 2.5pt">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK <BR>
USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">92,184,220</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">87,821,078</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt"><B>(1)</B> Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">870</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">61</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt"><B>(2)</B> Includes share-based compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">497</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">68</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN CAPITAL DEFICIENCY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands, except share
data)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Additional</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Common</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">paid&ndash;in</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock (1)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Stock</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">capital</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">deficit</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 50%; font-weight: bold">Balance at December 31, 2011</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">85,630,157</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left"><B>$</B></TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">86</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">145,814</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">(171,977</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 7%; font-weight: bold; text-align: right">(26,077</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Changes during three-month period ended March 31, 2012:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Common stock&nbsp;issued for cash (net of issuance costs of $1,780)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,388</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Exercise of options granted to employees and non-employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,095</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">*</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net Loss&#9;for the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,904</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,904</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2012</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">90,822,252</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">91</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">171,333</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(177,881</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,457</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Balance at December 31, 2012</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">93,489,809</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">93</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">180,145</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(183,595</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(3,357</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold">Changes during three-month period ended March 31, 2013:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation related to stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left">Share-based compensation related to restricted stock award</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,020</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Exercise of options granted to employees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net Loss&#9;for the period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,321</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Balance at March 31, 2013</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">93,502,230</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">94</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">181,539</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(187,916</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,283</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">* Represents an amount less than $1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Common Stock, $0.001 par value; Authorized &ndash; as
of March 31, 2013 and 2012 - 150,000,000 shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2013</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0.125in">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(4,321</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(5,904</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.375in; text-indent: -0.25in">Adjustments required to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,367</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Depreciation and write down of fixed assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">926</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">930</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in; text-indent: -0.25in">Financial income, net (mainly exchange differences)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(78</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(114</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Changes in accrued liability for employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; text-indent: -0.125in">Gain on amounts funded in respect of employee rights upon retirement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.125in">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.375in; text-indent: -0.125in">Decrease in deferred revenues (including non-current portion)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,740</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,405</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.375in; text-indent: -0.125in">Decrease (increase) in accounts receivable and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(42</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,270</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Decrease (increase) in inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,734</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.375in; padding-bottom: 1pt; text-indent: -0.125in">Decrease in accounts payable and accruals (including long term )</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(3,005</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(242</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(9,586</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(6,281</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 0.25in; text-indent: -0.25in">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in">Purchase of property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(642</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(810</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-bottom: 1pt; text-indent: -0.125in">Amounts funded in respect of employee rights upon retirement, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(47</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(42</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(689</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">(852</TD><TD STYLE="text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Issuance of shares, net of issuance cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25,538</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 1pt">Exercise of options</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">36</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-bottom: 1pt; text-indent: -0.125in">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">25,574</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">EFFECT OF EXCHANGE RATE CHANGES ON CASH</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">110</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">163</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,165</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,604</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; padding-left: 0.125in; text-indent: -0.125in">BALANCE OF CASH AND CASH <FONT STYLE="font-size: 10pt"><B>EQUIVALENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT>AT
    BEGINNING OF PERIOD</B></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">52,035</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">27,001</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.125in; text-indent: -0.125in">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">41,870</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">45,605</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(U.S. dollars in thousands)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Continued) - 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="color: black; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended</TD><TD NOWRAP STYLE="color: black; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2013</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">SUPPLEMENTARY INFORMATION ON
    <BR>
INVESTING AND FINANCING ACTIVITIES <BR>
NOT INVOLVING CASH FLOWS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-bottom: 1pt">Purchase of property and equipment</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 12%; text-align: right; border-bottom: Black 1pt solid">815</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="width: 12%; text-align: right; border-bottom: Black 1pt solid">829</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Issuance cost not yet paid</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">150</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Exercise of options granted to employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">28</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>The accompanying notes are an integral
part of the condensed consolidated financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS,
INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B><BR>
(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>a.</B></TD><TD><B>General</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD><B>Operation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix BioTherapeutics, Inc. (collectively with its
subsidiaries, the &ldquo;Company&rdquo;), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused
on the development and commercialization of recombinant therapeutic proteins based on the Company&rsquo;s proprietary ProCellEx<SUP>&reg;</SUP>
protein expression system (&ldquo;ProCellEx&rdquo;). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under
the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency (&ldquo;EMA&rdquo;) application process
in the European Union. The Company&rsquo;s two subsidiaries are referred to collectively herein as the &ldquo;Subsidiaries.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On May 1, 2012, the U.S. Food and Drug Administration
(&ldquo;FDA&rdquo;) approved taliglucerase alfa for injection, the Company&rsquo;s first approved drug product, as an enzyme replacement
therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase
alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa
was also approved by the Israeli Ministry of Health (the &ldquo;Israeli MOH&rdquo;) in September 2012, by the Brazilian Ministry
of Health in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first
plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Taliglucerase alfa is being marketed in the United States
under the brand name ELELYSO&trade; by Pfizer Inc. (<FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Pfizer<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>),
the Company&rsquo;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix
Ltd. and Pfizer (the <FONT STYLE="text-transform: uppercase">&ldquo;</FONT>Pfizer Agreement<FONT STYLE="text-transform: uppercase">&rdquo;</FONT>).
The Company, through Protalix Ltd., markets ELELYSO in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Protalix Ltd. granted Pfizer an exclusive, worldwide
license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company
has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development
efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution
of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company
received an additional $25.0 million milestone payment in connection with the FDA&rsquo;s approval of taliglucerase alfa in the
United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded
as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the
net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively,
except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive
marketing rights. <FONT STYLE="color: black">In calculating the net profits or losses under the agreement, there are certain agreed
upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In December 2012, Protalix Ltd. entered into a Clinical
Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical
trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment
of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment
made, in December 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS,
INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B><BR>
(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company is cooperating with Pfizer to obtain marketing
approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have
been filed in a number of countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Currently, patients are being treated with taliglucerase
alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&rsquo;s
clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other
programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments.
On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&rsquo;Utilisation
(ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory
mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when
a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before
marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through
government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special
access agreements or named patient provisions in Brazil and in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to taliglucerase alfa, the Company is working
on the development of certain other products using ProCellEx.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD>Liquidity and Financial Resources</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">In addition to the approval of taliglucerase alfa for
marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&rsquo;s development
programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell
its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0
million milestone payment in connection with the FDA&rsquo;s approval of taliglucerase alfa in the United States. A substantial
amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company
also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates
during their respective developmental periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Obtaining marketing approval with respect to any product
candidate is directly dependent on the Company&rsquo;s ability to implement the necessary regulatory steps required to obtain such
approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Based on its current cash resources
and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding
level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds
prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses,
the Company may need to seek additional financing during the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>PROTALIX BIOTHERAPEUTICS,
INC.</B><BR>
<B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B><BR>
(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES </B>(continued)<B>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>b.</B></TD><TD><B>Basis of Presentation</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United
States (&ldquo;GAAP&rdquo;) for interim financial information. Accordingly, they do not include all of the information and notes
required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature)
considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results
for the interim period are not necessarily indicative of the results that may be expected for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">These unaudited condensed consolidated financial
statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for
the year ended December 31, 2012, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet
at December 31, 2012 has been derived from the audited financial statements at that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><B>c.</B></TD><TD><B>Net loss per share</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Basic and diluted loss per share (&ldquo;LPS&rdquo;)
are computed by dividing net loss by the weighted average number of shares of the Company&rsquo;s Common Stock, par value $0.001
per share (the &ldquo;Common Stock&rdquo;) outstanding for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">Diluted LPS does not include 7,373,768 and 7,471,571
<FONT STYLE="color: black">shares of Common Stock underlying outstanding options and restricted shares of Common Stock</FONT> for
the three months ended March 31, 2012 and 2013, respectively, because the effect would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 2 - INVENTORIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0in">Inventory at March 31, 2013 and December&nbsp;31,
2012 consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">March 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">December 31,</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">(U.S. dollars in thousands)</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; text-align: left">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,418</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 15%; text-align: right">2,118</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">341</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">3,014</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,729</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventory</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">5,773</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">4,039</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="color: black">Prior to the FDA's approval
of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed
as research and development expenses</FONT>. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company
capitalizes all manufacturing costs associated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NOTE 3 - STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">During the three months ended March
31, 2013, the Company issued a total of 12,421 shares of Common Stock in connection with the exercise of a total of 12,421 options
by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $28,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&nbsp;2. Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>You should read the following discussion
and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial
statements and the related notes included elsewhere in this Form 10-Q and in our Annual Report on Form 10-K for the year ended
December 31, 2012. Some of the information contained in this discussion and analysis, particularly with respect to our plans and
strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You
should read &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the year ended December 31, 2012 for a discussion
of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking
statements contained in the following discussion and analysis.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biopharmaceutical company focused on the development
and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx<SUP>&reg;</SUP> protein expression
system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar versions of recombinant
therapeutic proteins based on our plant cell-based expression technology that primarily target large, established pharmaceutical
markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic
proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe ProCellEx
will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant
proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent versions of highly
active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with
relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 1, 2012, the FDA approved for sale our first commercial
product, taliglucerase alfa for injection, which is being marketed under the brand name ELELYSO&trade;, as an enzyme replacement
therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Subsequently,
taliglucerase alfa was approved by the Brazilian National Health Surveillance Agency (ANVISA, Agencia Nacional de Vigilancia Sanitaria)
in March 2013, by the Israeli Ministry of Health, or the Israeli MOH, in September 2012, and by the applicable regulatory authorities
in Uruguay, Mexico and Chile. Taliglucerase alfa is our proprietary, recombinant form of glucocerebrosidase (GCD) that is produced
or expressed through ProCellEx. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein to be approved
by each of the FDA and the Israeli MOH, or by the regulatory agencies with jurisdiction over any substantial market. Gaucher disease
is a rare and serious lysosomal storage disorder with severe and debilitating symptoms. Gaucher patients suffer from mutations
in or deficiencies of GCD, an enzyme that is naturally found in human cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since May 2012, taliglucerase alfa has been marketed in the
United States by Pfizer, our commercialization partner, as provided in the exclusive license and supply agreement by and between
Protalix Ltd., our wholly-owned subsidiary, and Pfizer, which we refer to as the Pfizer Agreement. We granted Pfizer an exclusive,
worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel.
We have agreed to a specific allocation between Protalix Ltd. and Pfizer of the responsibilities for the continued development
efforts for taliglucerase alfa outside of Israel. Since 2013, taliglucerase alfa has been marketed in Israel by Protalix Ltd.,
our wholly-owned subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are cooperating with Pfizer to obtain marketing approval
for taliglucerase alfa in additional countries and jurisdictions. In addition to those countries in which taliglucerase alfa has
been approved, marketing authorization applications have been filed in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: black">In December 2012, we entered into
a Clinical Development Agreement with </FONT>Pfizer under which we will continue to manage, administer and sponsor current, ongoing
clinical trials relating to taliglucerase alfa. We are currently sponsoring adult and pediatric extension studies of taliglucerase
alfa. New clinical trials for taliglucerase alfa<SUP> </SUP>will be conducted and sponsored by Pfizer. Under the terms of the agreement,
we were eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The
goals were achieved prior to the end of fiscal year 2012 and the $8.3 million payment has been paid in full. This agreement helps
to maintain the continuity of the ongoing clinical trials for Gaucher patients and physicians and reinforces the companies&rsquo;
mutual commitment to the Gaucher community.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We performed a number of studies on taliglucerase alfa to supplement
the pivotal phase III clinical trial which we completed in September 2009. We initiated a double-blind, follow-on extension study
in 2008 which consisted of eligible patients who had completed nine months of treatment in the pivotal phase III clinical trial.
The patients were offered the opportunity to continue to receive taliglucerase alfa at the same dose they received in the pivotal
trial for an additional 15 months in a blinded manner. We also conducted a nine-month, worldwide, multi-center, open-label, switch-over
clinical study evaluating the safety and efficacy of switching Gaucher patients currently treated with Cerezyme<SUP>&reg;</SUP>,
which is produced by Genzyme Corporation, or Genzyme (A Sanofi-Aventis company), with taliglucerase alfa which was successfully
completed in 2011. We also conducted a 12-month clinical trial of na&iuml;ve and switchover pediatric patients which was successfully
completed in 2012. Patients in the extension trials are still being treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Currently, patients are being treated with ELELYSO on a commercial
basis in the United States and in Israel. Globally, patients are being treated through our extension trials and related studies,
compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments
are available to Gaucher patients in light of recent shortages of approved treatments. In France, Gaucher patients are being treated
with taliglucerase alfa through an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, a regulatory
mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when
a genuine public health need exists. In addition to the United States and France, taliglucerase alfa is currently being provided
to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries. Hundreds of patients,
in the aggregate, have been treated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On August 10, 2010, Pfizer entered into a $30 million
short-term supply agreement with the Brazilian Ministry of Health, or the Brazilian MOH, pursuant to which Protalix and
Pfizer have provided taliglucerase alfa to the Brazilian MOH for the treatment of Gaucher patients. During the remainder of
2010 and the first quarter of 2011, we and Pfizer completed the supply of products deliverable under the short-term supply
agreement. During 2011, the Brazilian MOH requested that Pfizer consider the replacement of certain vials that might expire
during 2012. During the third quarter of 2012, we and Pfizer resupplied a portion of the returned vials. In addition, we and
the Brazilian MOH are in advanced discussions relating to a possible long-term supply agreement that contemplates, among
other matters, providing certain components of our manufacturing technology to the Brazilian MOH for implementation by it in
Brazil. We are currently unable to assess whether these discussions will result in an agreement and we can make no assurance
that we will be able to enter into such an agreement on favorable terms, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to taliglucerase alfa, we are developing an innovative
product pipeline using our ProCellEx protein expression system. Our product pipeline currently includes, among other candidates:
(1) PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder in humans,
currently in a phase I/II clinical trial, for which the first patient was treated in December 2012; (2) PRX-105, a plant cell expressed
pegylated recombinant acetylcholinesterase product candidate for biodefense and other indications, which was the subject of a completed
phase I clinical trial; (3) PRX-112, an orally-administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing
oral delivery of the recombinant GCD enzyme produced and encapsulated within carrot cells, currently in a phase I clinical study
for which the first patient was treated in April 2013; (4) PRX-106, or pr-antiTNF, a plant cell expressed recombinant fusion protein
made from the soluble form of the human TNF receptor (TNFR) and an antibody portion, which is being developed as a treatment of
certain immune diseases such as rheumatoid arthritis, Chrohn's disease, placque psoriasis and other autoimmune disorders, for which
we have performed animal studies; and (5) two additional undisclosed therapeutic proteins, both of which are being evaluated in
animal studies. We participated in a pre-investigational new drug, or IND, meeting with respect to one of the undisclosed product
candidates in the first quarter of 2012 and a pre-IND meeting for the second candidate is planned for 2013. In December 2011, we
held a pre-IND meeting with respect to PRX-106 and we expect to submit an IND during 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except for the rights to commercialize taliglucerase alfa worldwide
(other than Israel) which we licensed to Pfizer, we hold the worldwide commercialization rights to all our proprietary development
candidates. We have built an internal marketing team designed to serve the Israeli market for taliglucerase alfa and we intend
to establish internal commercialization and marketing teams for our other product candidates in North America, the European Union
and in other significant markets, including Israel, subject to required marketing approvals, as the need arises. In addition, we
continuously evaluate potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical
companies and academic research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our significant accounting policies are more fully described
in Note&nbsp;1 to our consolidated financial statements appearing in this Quarterly Report. There have not been any changes to
our significant accounting policies since the Annual Report on Form 10-K for the year ended December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The discussion and analysis of our financial condition and results
of operations is based on our financial statements, which we prepared in accordance with U.S. generally accepted accounting principles.
The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments.
We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Three months ended March 31, 2013 compared to the three
months ended March 31, 2012</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenues of $3.6&nbsp;million during the three months
ended March 31, 2013, a decrease of $293,000, or 8%, from revenues of $3.9&nbsp;million for the three months ended March 31, 2012.
The revenues represent a pro rata amortization of the $65.0&nbsp;million upfront and milestone payments of $1.1&nbsp;million in
each quarterly period, $1.0&nbsp;million for the quarter ended March 31, 2013 in connection with products we sold in Israel and
$1.5 million in connection with products we delivered to Pfizer under our license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Our share in the Collaboration Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recorded revenue of $400,000 as our share of net income from
the collaboration under the Pfizer Agreement during the three months ended March 31, 2013 compared to $133,000 of loss for the
three months ended March 31, 2012. Our share in the collaboration agreement recorded during the three months ended March 31, 2013
represents our 40% share of the net income generated during the period, which was primarily the result of revenues generated by
Pfizer in the United States which exceeded the expenses during such period. Under the terms and conditions of the Pfizer Agreement,
financial information of Pfizer&rsquo;s subsidiaries that operate outside the United States is included based on the fiscal year
ending November&nbsp;30, while financial information for the U.S. entity is included based on the fiscal year ending December&nbsp;31.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cost of Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cost of revenues was $971,000 and $1.3 million for the three
months ended March 31, 2013 and 2012, respectively. Cost of revenues for the three months ended March 31, 2013 consists primarily
of certain fixed costs relating to our manufacturing facility, including rent, depreciation, salary and maintenance expenses, and
to a much lesser extent, the direct cost of products we sold in Israel and products we delivered to Pfizer for which revenues were
recognized during the period. Prior to the FDA's approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa
were not capitalized; rather, such costs were expensed as research and development expenses. Effective as of the FDA approval of
taliglucerase alfa on May 1, 2012, we capitalize all manufacturing costs associated with taliglucerase alfa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Research and Development Expenses, Net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses were $7.8&nbsp;million for
the three months ended March 31, 2013, a decrease of $1.1&nbsp;million, or 12%, from $8.8&nbsp;million for the three months ended
March 31, 2012. The decrease resulted primarily from a decrease of $854,000 in rent and other overhead costs and $1.2 million in
materials which have been classified as cost of revenues or capitalized as inventory after the FDA's approval of taliglucerase
alfa in May 2012. The decrease was partially offset by an increase of $1.2 million in costs related to salaries expense resulting
primarily from share based compensation. The decrease also resulted from increased reimbursement of expenses equal to $1.5 million
in accordance with the terms and conditions of the Pfizer Agreement during the three months ended March 31, 2013, compared to the
total reimbursement of approximately $434,000 from Pfizer during the three months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We expect research and development expenses
for our various development programs to continue to be our primary expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">General and administrative expenses were $2.1&nbsp;million
for the three months ended March 31, 2013, an increase of $474,000, or 29%, from $1.6&nbsp;million for the three months ended March
31, 2012. The increase resulted primarily from an increase of $605,000 in salaries expense primarily due to share-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Financial Expenses and Income</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Financial income was $108,000 for the three
months ended March 31, 2013, compared to financial income of $161,000 for the three months ended March 31, 2012. Financial income
resulted primarily from interest earned on short term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Sources of Liquidity</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">As a result of our significant research
and development expenditures and the lack of significant product sales revenue due to the recent launch of taliglucerase alfa
in the United States and Israel, we have not been profitable and have generated operating losses since our inception with the
exception of the quarter ended on June 30, 2012 due to the $25.0 million milestone payment we received from Pfizer in
connection with FDA approval of taliglucerase alfa in that period. To date, we have funded our operations primarily with
proceeds equal to $31.3&nbsp;million from the sale of shares of convertible preferred and ordinary shares of Protalix Ltd.,
and an additional $14.1&nbsp;million in connection with the exercise of warrants issued in connection with the sale of such
shares, through December 31, 2008. In addition, on October 25, 2007, we generated gross proceeds of $50&nbsp;million in
connection with an underwritten public offering of our common stock and on each of March 23, 2011 and February 22, 2012, we
generated gross proceeds of $22.0 million and $27.2 million, respectively, in connection with underwritten public offerings
of our common stock. In 2012, the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor awarded
us a grant of up to approximately $4.3 million for the calendar years 2011 and 2012. The award was granted to promote the
advancement of our drug development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">In addition to the foregoing, <FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer
paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently
paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd.'s meeting a certain milestone. Protalix Ltd. also received
a milestone payment of $25.0 in connection with the FDA's approval of taliglucerase alfa in May 2012. Protalix Ltd. is also entitled
to payments equal to 40% of the net profits earned by Pfizer on its global sales of taliglucerase alfa (except in Israel). In calculat</FONT>ing
net profits there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and
costs of goods sold. Pfizer has also paid Protalix Ltd. $8.3 million in connection with the successful achievement of certain milestones
under the Clinical Development Agreement between Pfizer and Protalix Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that the funds currently available
to us as are sufficient to satisfy our capital needs for at least the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Flows</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $9.6&nbsp;million
for the three months ended March 31, 2013. The net loss for the three months ended March 31, 2013 of $4.3 million was further increased
by a decrease of $2.7 million in deferred revenues, a decrease of $3.0 million in accounts payable and an increase in inventories,
but was partially offset by share based compensation of $1.4 million and $926,000 in depreciation. Net cash used in investing activities
for the three months ended March 31, 2013 was $689,000 and consisted primarily of purchases of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Net cash used in operations was $6.3&nbsp;million
for the three months ended March 31, 2012. The net loss for the three months ended March 31, 2012 of $5.9 million was further increased
by a decrease of $2.4 million in deferred revenues but was partially offset by a decrease of $1.2 million in accounts receivable.
Net cash used in investing activities for the three months ended March 31, 2012 was $852,000 and consisted primarily of purchases
of property and equipment. Net cash provided by financing activities for the three months ended March 31, 2012 was $25.6 million,
consisting primarily of net proceeds from our February 2012 underwritten public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>Future Funding Requirements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We <FONT STYLE="color: black">expect to continue to incur significant
expenditures in the near future. However, we anticipate that we will generate revenues to offset such losses as Pfizer's commercialization
efforts for taliglucerase alfa in the United States and as our commercialization efforts for taliglucerase alfa in Israel continue
to progress, and as taliglucerase alfa is launched by Pfizer in other countries in which taliglucerase alfa was recently approved.
We also anticipate that we will generate additional revenues after additional anticipated marketing approvals of taliglucerase
alfa are granted outside of the United States, Israel, Brazil, Mexico and other countries. We expect to continue to incur significant
research and development expenses, including expenses related to the clinical trials of PRX-102 and oral glucocerebrosidase and
the advancement of other product candidates into clinical trials. We expect that general and administrative expenses will marginally
increase as we expand our administrative staff, add infrastructure and incur additional costs related to the continued progression
of the commercialization of taliglucerase alfa.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We believe that our existing cash and cash
equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the
next 12 months. We have based this estimate on assumptions that are subject to change and may prove to be wrong, and we may be
required to use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties
associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased
capital outlays and operating expenditures associated with our current and anticipated clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our future capital requirements will depend
on many factors, including the progress of Pfizer's commercialization efforts for taliglucerase alfa in the United States and other
countries, the progress of our commercialization efforts for taliglucerase alfa in Israel<FONT STYLE="color: black"> and, if anticipated
marketing approvals of taliglucerase alfa</FONT> are granted in other jurisdictions, the progress of Pfizer's global commercialization
efforts for taliglucerase alfa, the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review
of our product candidates, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims
and other intellectual property rights, the number and development requirements of other product candidates that we pursue and
the costs of commercialization activities, including product marketing, sales and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We may need to finance our future cash needs
through public or private equity offerings, debt financings, or corporate collaboration and licensing arrangements. We currently
do not have any commitments for future external funding. We may need to raise additional funds more quickly if one or more of our
assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate.
We may also decide to raise additional funds even before we need them if the conditions for raising capital are favorable. Any
sale of additional equity or debt securities will likely result in dilution to our shareholders. The incurrence of indebtedness
would result in increased fixed obligations and could also result in covenants that would restrict our operations. Additional equity
or debt financing, grants or corporate collaboration and licensing arrangements may not be available on acceptable terms, if at
all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate our research and development
programs, reduce our planned commercialization efforts or obtain funds through arrangements with collaborators or others that may
require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effects of Inflation and Currency Fluctuations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations
during the three months ended March 31, 2013 or the three months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Currency fluctuations could affect us through
increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material
effect on our results of operations during the three months ended March 31, 2013 or the three months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We have no off-balance sheet arrangements
as of each of March 31, 2013 and March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&nbsp;3. Quantitative and Qualitative
Disclosures About Market Risk</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Currency Exchange Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The currency of the primary economic environment
in which our operations are conducted is the dollar. We currently have no significant source of revenues; therefore we consider
the currency of the primary economic environment to be the currency in which we expend cash. Approximately 50% of our expenses
and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars.
Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using
the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue
and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency
translation gains or losses are recognized in the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Approximately 35% of our costs, including salaries, expenses
and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S. dollar cost of our operations
in Israel. If the U.S. dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations
in Israel. A revaluation of 1% of the NIS will affect our income before tax by less than 1%. The exchange rate of the U.S. dollar
to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Three months ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center">Year ended </TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">December 31,</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 46%">Average rate for period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">3.708</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">3.771</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; text-align: center">3.856</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rate at period end</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">3.648</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">3.715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">3.733</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not engaged in hedging transactions. In the
future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange
rate of the U.S. dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due
to the impact of inflation in Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Interest Rate Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our exposure to market risk is confined to
our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original
maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible
to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while
maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily
in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest
rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in
the future as a result of changes in the financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Item&nbsp;4. Controls and Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We conducted an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report
on Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of management, including our
Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to
reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly
Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated
and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Based on the controls evaluation, our
Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly
Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required
to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by
the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management,
including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are
being prepared.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inherent Limitations on Effectiveness of Controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our management, including our Chief
Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control
over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated,
can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control
system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns
can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion
of two or more people or by management override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are
subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of
compliance with policies or procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in internal controls</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no changes to our internal controls over financial
reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March 31, 2013
that has materially affected, or that is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PART II &ndash;
OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1. Legal Proceedings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We are not involved in any material legal
proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;1A. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">There have been no material changes to the
risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;2. Unregistered
Sales of Equity Securities and Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><B>Unregistered Sales of Equity
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">There were
no unregistered sales of equity securities during the three months ended March 31, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;3. Defaults
Upon Senior Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;4. Mine Safety
Disclosure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">Not applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;5. Other Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">On May 9,
2013, our Board of Directors resolved that our 2013 Annual Meeting of Shareholders will be held on or around November 7, 2013,
in Tel Aviv, Israel. The final date and location of the meeting will be announced in the proxy statement we will file and distribute
in connection with the meeting.<I> </I>Proposals must be received at our principal executive offices on or prior to July 2, 2013
to be considered timely. Proposals should be directed to the attention of the Secretary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Item&nbsp;6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Incorporated&nbsp;by&nbsp;Reference</B></TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; width: 10%"><B>Exhibit</B><BR>
<B>Number</B></TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; width: 49%"><B>Exhibit&nbsp;Description</B></TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; width: 7%"><B>Form</B></TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; width: 7%"><B>File&nbsp;Number</B></TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; width: 7%"><B>Exhibit</B></TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; width: 7%"><B>Date</B></TD>
    <TD NOWRAP STYLE="text-align: center; padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; width: 7%"><B>Filed</B><BR>
<B>Herewith</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Articles of Incorporation of the Company</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">S-4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">333-48677</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 26, 1998</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated June 9, 2006</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.2</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 13, 2006</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.3</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated December 26, 2006</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.4</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.5</TD>
    <TD>&nbsp;</TD>
    <TD>Article of Amendment to Articles of Incorporation dated February 26, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">8-A</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.5</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">March 9, 2007</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>3.6</TD>
    <TD>&nbsp;</TD>
    <TD>Amended and Restated Bylaws of the Company</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">10-K</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">001-33357</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">3.6</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">February 28, 2013</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>31.1</TD>
    <TD>&nbsp;</TD>
    <TD>Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">31.2</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 7%; text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.1</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>32.2</TD>
    <TD>&nbsp;</TD>
    <TD>18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.INS</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL INSTANCE FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.SCH</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL SHEMA FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.CAL</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL CALCULATION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.DEF</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL DEFINITION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.LAB</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL LABEL FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101.PRE</TD>
    <TD>&nbsp;</TD>
    <TD>XBRL PRESENTATION FILE</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">X</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.9pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">PROTALIX BIOTHERAPEUTICS, INC.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Registrant)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 9, 2013</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ David Aviezer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>David Aviezer, Ph.D.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Date: May 9, 2013</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Yossi Maimon</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer, Treasurer and Secretary</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v343144_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, David Aviezer, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 9, 2013</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ David Aviezer</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">David Aviezer, Ph.D.</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v343144_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">I, Yossi Maimon, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.5pt">1.</TD><TD>I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">4.</TD><TD>The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)<FONT STYLE="font-weight: normal">) </FONT>for the registrant and have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during
the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 24.45pt">5.</TD><TD>The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
(or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
information; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-indent: -24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.45pt"></TD><TD STYLE="width: 24.5pt">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 9, 2013</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Chief Financial Officer, Treasurer </TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v343144_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission
(the &ldquo;Report&rdquo;), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify as of the date
hereof, solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 9, 2013</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ David Aviezer</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">David Aviezer, Ph.D.</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">President and Chief Executive Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v343144_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROTALIX BIOTHERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the quarterly report of Protalix BioTherapeutics,
Inc. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2013 as filed with the Securities and Exchange Commission
(the &ldquo;Report&rdquo;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby certify as of the
date hereof, solely for the purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best of
my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(1) the Report fully complies with the requirements
of Section&nbsp;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">(2) the information contained in the Report fairly
presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">This Certification has not
been, and shall not be deemed, &ldquo;filed&rdquo; with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.2pt; text-indent: -12.25pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">Date: May 9, 2013</TD>
    <TD STYLE="width: 50%; padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-bottom: windowtext 1pt solid">/s/ Yossi Maimon</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Yossi Maimon</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">Vice President and Chief Financial Officer</TD>
    <TD STYLE="padding-left: 12pt; text-indent: -12pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>plx-20130331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-05-08 @ 4:39 PM-->
<xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:plx="http://www.protalix.com/20130331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2012-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2012-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="plx-20130331.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">2013-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">0001006281</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.15982.0.0.0.0.0.0" contextRef="as-of-2013-05-01.15982.0.0.0.0.0.0.0" unitRef="shares" decimals="0">93503268</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory id="EntityFilerCategory.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:TradingSymbol id="TradingSymbol.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">PLX</dei:TradingSymbol>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28000</plx:CashlessExerciseOfStockOptions>
  <plx:CashlessExerciseOfStockOptions id="CashlessExerciseOfStockOptions.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2000</plx:CashlessExerciseOfStockOptions>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.15040.20890.999.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.20890.999.0.0.0.0" unitRef="pure" decimals="1">0.4</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:CollaborativeArrangementProfitSharePercentage id="CollaborativeArrangementProfitSharePercentage.15040.20891.999.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.20891.999.0.0.0.0" unitRef="pure" decimals="1">0.6</plx:CollaborativeArrangementProfitSharePercentage>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">926000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:DepreciationAmortizationAndAssetImpairment id="DepreciationAmortizationAndAssetImpairment.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">930000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2431000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:GrantsAndReimbursementsReceivedOrReceivable id="GrantsAndReimbursementsReceivedOrReceivable.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2003000</plx:GrantsAndReimbursementsReceivedOrReceivable>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">815000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment id="IncreaseInLiabilitiesForPropertyPlantAndEquipment.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">829000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:MilestonePayment id="MilestonePayment.16265.88671.4951.0.0.0.0" contextRef="from-2012-04-01-to-2012-06-30.16265.0.88671.4951.0.0.0.0" unitRef="USD" decimals="-5">25000000</plx:MilestonePayment>
  <plx:MilestonePayment id="MilestonePayment.16267.88672.4951.0.0.0.0" contextRef="from-2012-12-01-to-2012-12-31.16267.0.88672.4951.0.0.0.0" unitRef="USD" decimals="-5">8300000</plx:MilestonePayment>
  <plx:NatureOfOperationsPolicyTextBlock id="NatureOfOperationsPolicyTextBlock.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Operation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive marketing rights. &lt;font style="COLOR: black"&gt;In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In December 2012, Protalix Ltd. entered into a Clinical Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment made, in December 2012.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Liquidity and Financial Resources&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</plx:NatureOfOperationsPolicyTextBlock>
  <plx:NumberOfSubsidiaries id="NumberOfSubsidiaries.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="pure" decimals="0">2</plx:NumberOfSubsidiaries>
  <plx:OtherGainsLosses id="OtherGainsLosses.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">400000</plx:OtherGainsLosses>
  <plx:OtherGainsLosses id="OtherGainsLosses.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-133000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.15042.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses id="ProceedsFromIssuanceOfCommonStockNetOfExpenses.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25538000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5323000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet id="ResearchDevelopmentAndEngineeringExpenseNet.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">6844000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:SupplementalOfferingAndStockIssuanceCosts id="SupplementalOfferingAndStockIssuanceCosts.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">150000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">12055000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableOtherCurrent id="AccountsPayableOtherCurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">11051000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3762000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsPayableTradeCurrent id="AccountsPayableTradeCurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5267000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1698000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1410000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15042.461.4957.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15043.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">347000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">129000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15042.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15043.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-03-31.15043.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15042.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition id="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.15043.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-03-31.15043.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts id="AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1780000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.15042.4381.4617.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.4381.4617.0.0.0.0" unitRef="USD" decimals="-3">870000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.15043.4381.4617.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.4381.4617.0.0.0.0" unitRef="USD" decimals="-3">61000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.15042.2354.4617.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.2354.4617.0.0.0.0" unitRef="USD" decimals="-3">497000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="AllocatedShareBasedCompensationExpense.15043.2354.4617.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.2354.4617.0.0.0.0" unitRef="USD" decimals="-3">68000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="shares" decimals="0">7471571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="shares" decimals="0">7373768</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets id="Assets.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">69942000</us-gaap:Assets>
  <us-gaap:Assets id="Assets.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78727000</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">52894000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">61170000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="BasisOfAccountingPolicyPolicyTextBlock.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;a.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;General&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Operation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&amp;#39;s proprietary ProCellEx&lt;sup&gt;&amp;reg;&lt;/sup&gt; protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&amp;#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&amp;#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&amp;trade; by Pfizer Inc. (&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;), the Company&amp;#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the &lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;Pfizer Agreement&lt;font style="TEXT-TRANSFORM: uppercase"&gt;"&lt;/font&gt;). The Company, through Protalix Ltd., markets ELELYSO in Israel.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive marketing rights. &lt;font style="COLOR: black"&gt;In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold&lt;/font&gt;.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In December 2012, Protalix Ltd. entered into a Clinical Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment made, in December 2012.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&amp;#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&amp;#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.75in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;Liquidity and Financial Resources&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&amp;#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&amp;#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&amp;#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"&gt; Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;b.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,373,768 and 7,471,571 &lt;font style="COLOR: black"&gt;shares of Common Stock underlying outstanding options and restricted shares of Common Stock&lt;/font&gt; for the three months ended March 31, 2012 and 2013, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">41870000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">52035000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.15044.0.0.0.0.0.0" contextRef="as-of-2011-12-31.15044.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">27001000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.15045.0.0.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">45605000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-10165000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">18604000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.15040.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="CommitmentsAndContingencies.15041.0.0.0.0.0.0" xsi:nil="true" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.15045.0.0.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.15045.0.0.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.0.0.0.0.0.0" unitRef="shares" decimals="0">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CostOfRevenue id="CostOfRevenue.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">971000</us-gaap:CostOfRevenue>
  <us-gaap:CostOfRevenue id="CostOfRevenue.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1320000</us-gaap:CostOfRevenue>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8591000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="DeferredRevenueCurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">9437000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">46994000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="DeferredRevenueNoncurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">48888000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1343000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent id="DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1247000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD_per_share" decimals="2">0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock id="EarningsPerSharePolicyTextBlock.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt;&lt;strong&gt;c.&lt;/strong&gt;&lt;/td&gt; &lt;td&gt;&lt;strong&gt;Net loss per share&lt;/strong&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&amp;#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Diluted LPS does not include 7,373,768 and 7,471,571 &lt;font style="COLOR: black"&gt;shares of Common Stock underlying outstanding options and restricted shares of Common Stock&lt;/font&gt; for the three months ended March 31, 2012 and 2013, respectively, because the effect would be anti-dilutive.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">110000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="EffectOfExchangeRateOnCashAndCashEquivalents.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">163000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">108000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax id="ForeignCurrencyTransactionGainLossBeforeTax.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">161000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized id="ForeignCurrencyTransactionGainLossUnrealized.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">114000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2103000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="GeneralAndAdministrativeExpense.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1629000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit id="GrossProfit.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2997000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2408000</us-gaap:GrossProfit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3005000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-242000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">42000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-1270000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2740000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="IncreaseDecreaseInDeferredRevenue.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-2405000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1734000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-16000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:InventoryDisclosureTextBlock id="InventoryDisclosureTextBlock.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 2 - INVENTORIES&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Inventory at March 31, 2013 and December&amp;nbsp;31, 2012 consisted of the following:&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;March 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2013&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 64%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;2,418&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;2,118&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;341&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3,014&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,729&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5,773&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,039&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;font style="COLOR: black"&gt;Prior to the FDA&amp;#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses&lt;/font&gt;. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:InventoryFinishedGoods id="InventoryFinishedGoods.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3014000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryFinishedGoods id="InventoryFinishedGoods.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1729000</us-gaap:InventoryFinishedGoods>
  <us-gaap:InventoryNet id="InventoryNet.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5773000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="InventoryNet.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">4039000</us-gaap:InventoryNet>
  <us-gaap:InventoryRawMaterials id="InventoryRawMaterials.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2418000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryRawMaterials id="InventoryRawMaterials.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2118000</us-gaap:InventoryRawMaterials>
  <us-gaap:InventoryWorkInProcess id="InventoryWorkInProcess.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">341000</us-gaap:InventoryWorkInProcess>
  <us-gaap:InventoryWorkInProcess id="InventoryWorkInProcess.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">192000</us-gaap:InventoryWorkInProcess>
  <us-gaap:Liabilities id="Liabilities.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">76225000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">82084000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">69942000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">78727000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">24408000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25755000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">51817000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent id="LiabilitiesNoncurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">56329000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2700000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent id="LongTermDebtNoncurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5425000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.15042.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25574000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-689000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-852000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-9586000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-6281000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4321000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-5904000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15042.4458.4957.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-4321000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15043.4458.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-5904000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15042.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15043.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-03-31.15043.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15042.461.4957.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.461.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.15043.461.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-03-31.15043.0.461.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-4429000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-6065000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3553000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:OtherReceivablesNetCurrent id="OtherReceivablesNetCurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3686000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">47000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities id="PaymentsForProceedsFromOtherInvestingActivities.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">42000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">642000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="PaymentsToAcquirePropertyPlantAndEquipment.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">810000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2123000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent id="PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">2016000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">19000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions id="PensionAndOtherPostretirementBenefitContributions.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">5000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">60000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense id="PensionAndOtherPostretirementBenefitExpense.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">44000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.16264.0.0.0.0.0.0" contextRef="from-2009-11-30-to-2013-03-31.16264.0.0.0.0.0.0.0" unitRef="USD" decimals="-5">60000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators id="ProceedsFromCollaborators.16266.20882.4951.0.0.0.0" contextRef="from-2009-12-01-to-2009-12-31.16266.0.20882.4951.0.0.0.0" unitRef="USD" decimals="-5">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.15042.0.0.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">36000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="ProceedsFromStockOptionsExercised.15042.21244.3555.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.21244.3555.0.0.0.0" unitRef="USD" decimals="0">28000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">15705000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">16310000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7754000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="ResearchAndDevelopmentExpense.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">8847000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:Revenues id="Revenues.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3568000</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">3861000</us-gaap:Revenues>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock id="ScheduleOfInventoryCurrentTableTextBlock.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; Inventory at March 31, 2013 and December&amp;nbsp;31, 2012 consisted of the following:&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;March 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;December 31,&lt;/td&gt; &lt;td style="FONT-WEIGHT: bold" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2013&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap"&gt;2012&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"&gt; &amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="VERTICAL-ALIGN: bottom"&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap"&gt;(U.S. dollars in thousands)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 64%"&gt;Raw materials&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;2,418&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt; &lt;td style="TEXT-ALIGN: right; WIDTH: 15%"&gt;2,118&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left"&gt;Work in progress&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;341&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="TEXT-ALIGN: right"&gt;192&lt;/td&gt; &lt;td style="TEXT-ALIGN: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Finished goods&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 3,014&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt; &amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt; 1,729&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;Total inventory&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 5,773&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"&gt; $&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"&gt; 4,039&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;nbsp;&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1367000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="ShareBasedCompensation.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">129000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15040.1033.4957.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.1033.4957.0.0.0.0" unitRef="shares" decimals="0">93502230</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15041.1033.4957.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.1033.4957.0.0.0.0" unitRef="shares" decimals="0">93489809</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15044.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.15044.0.1033.4957.0.0.0.0" unitRef="shares" decimals="0">85630157</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15045.1033.4957.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.1033.4957.0.0.0.0" unitRef="shares" decimals="0">90822252</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="shares" decimals="0">93502230</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="shares" decimals="0">93489809</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15044.0.0.0.0.0.0" contextRef="as-of-2011-12-31.15044.0.0.0.0.0.0.0" unitRef="shares" decimals="0">85630157</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding id="SharesOutstanding.15045.0.0.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.0.0.0.0.0.0" unitRef="shares" decimals="0">90822252</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15040.0.0.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-6283000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15041.0.0.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-3357000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15044.0.0.0.0.0.0" contextRef="as-of-2011-12-31.15044.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-26077000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15045.0.0.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">-6457000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15040.1033.4957.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">94000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15041.1033.4957.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">93000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15044.1033.4957.0.0.0.0" contextRef="as-of-2011-12-31.15044.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15045.1033.4957.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">91000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15040.461.4957.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">181539000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15041.461.4957.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">180145000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15044.461.4957.0.0.0.0" contextRef="as-of-2011-12-31.15044.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">145814000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15045.461.4957.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">171333000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15040.4458.4957.0.0.0.0" contextRef="as-of-2013-03-31.15040.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-187916000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15041.4458.4957.0.0.0.0" contextRef="as-of-2012-12-31.15041.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-183595000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15044.4458.4957.0.0.0.0" contextRef="as-of-2011-12-31.15044.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-171977000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.15045.4458.4957.0.0.0.0" contextRef="as-of-2012-03-31.15045.0.4458.4957.0.0.0.0" unitRef="USD" decimals="-3">-177881000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;NOTE 3 - STOCK TRANSACTIONS&lt;/strong&gt;&lt;/p&gt; &lt;p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/p&gt; &lt;p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt; During the three months ended March 31, 2013, the Company issued a total of 12,421 shares of Common Stock in connection with the exercise of a total of 12,421 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $28,000.&lt;/p&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.15043.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.1033.4957.0.0.0.0" unitRef="shares" decimals="0">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="StockIssuedDuringPeriodSharesNewIssues.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="shares" decimals="0">5175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="StockIssuedDuringPeriodSharesShareBasedCompensation.15042.21244.3555.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.21244.3555.0.0.0.0" unitRef="shares" decimals="0">12421</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.15042.1033.4957.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.1033.4957.0.0.0.0" unitRef="shares" decimals="0">12421</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.15043.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.1033.4957.0.0.0.0" unitRef="shares" decimals="0">17095</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="shares" decimals="0">12421</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="shares" decimals="0">17095</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="StockIssuedDuringPeriodSharesStockOptionsExercised.15042.21244.3555.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.21244.3555.0.0.0.0" unitRef="shares" decimals="0">12421</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.15042.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.15042.461.4957.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">1020000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">1020000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices id="StockIssuedDuringPeriodValueIssuedForServices.15042.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.15043.1033.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.15043.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">25383000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">25388000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="StockIssuedDuringPeriodValueNewIssues.15043.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-03-31.15043.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15042.1033.4957.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.1033.4957.0.0.0.0" unitRef="USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15043.1033.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-03-31.15043.0.1033.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15042.461.4957.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15043.461.4957.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.461.4957.0.0.0.0" unitRef="USD" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="USD" decimals="-3">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15042.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2013-01-01-to-2013-03-31.15042.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised id="StockIssuedDuringPeriodValueStockOptionsExercised.15043.4458.4957.0.0.0.0" xsi:nil="true" contextRef="from-2012-01-01-to-2012-03-31.15043.0.4458.4957.0.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.15042.0.0.0.0.0.0" contextRef="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0" unitRef="shares" decimals="0">92184220</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="WeightedAverageNumberOfShareOutstandingBasicAndDiluted.15043.0.0.0.0.0.0" contextRef="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0" unitRef="shares" decimals="0">87821078</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD_per_share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.15042.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.15042.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.15042.0.4381.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.15042.0.2354.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.15042.0.21244.3555.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:EmployeeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.15042.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2013-01-01-to-2013-03-31.15042.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-12-01-to-2012-12-31.16267.0.88672.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-12-01</xbrli:startDate>
      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-04-01-to-2012-06-30.16265.0.88671.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>
      <xbrli:endDate>2012-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-03-31.15043.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-03-31.15043.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-03-31.15043.0.4381.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-03-31.15043.0.2354.4617.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-03-31.15043.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2012-01-01-to-2012-03-31.15043.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>
      <xbrli:endDate>2012-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-12-01-to-2009-12-31.16266.0.20882.4951.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ScenarioTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-12-01</xbrli:startDate>
      <xbrli:endDate>2009-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2009-11-30-to-2013-03-31.16264.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-11-30</xbrli:startDate>
      <xbrli:endDate>2013-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-05-01.15982.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-05-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.15040.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.15040.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.15040.0.20891.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:PfizerIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.15040.0.20890.999.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.15040.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2013-03-31.15040.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.15041.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.15041.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.15041.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-12-31.15041.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-03-31.15045.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-03-31.15045.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-03-31.15045.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2012-03-31.15045.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.15044.0.461.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.15044.0.4458.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.15044.0.1033.4957.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-12-31.15044.0.0.0.0.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>plx-20130331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-05-08 @ 4:39 PM-->
<xsd:schema targetNamespace="http://www.protalix.com/20130331" elementFormDefault="qualified" xmlns:plx="http://www.protalix.com/20130331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="plx-20130331_cal.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="plx-20130331_def.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="plx-20130331_lab.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:linkbaseRef xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="plx-20130331_pre.xml" xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" />
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" id="plx-ccbs" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" id="plx-ccsocf" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" id="plx-ccsocicd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" id="plx-ccsocicdp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" id="plx-ccsoo" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" id="plx-ccsoop" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" id="plx-dein" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/Inventories" id="plx-i1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>102 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" id="plx-isoicd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/InventoriesTables" id="plx-it1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>302 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" id="plx-sap1" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" id="plx-sapd" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" id="plx-sapp" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactions" id="plx-st" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>103 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StockTransactionsDetails" id="plx-std" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>40301 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:labelLink</link:usedOn>
        <link:usedOn>link:referenceLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2012-01-31" schemaLocation="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2012-01-31" schemaLocation="http://xbrl.sec.gov/invest/2012/invest-2012-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2012-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2012/elts/us-types-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2012-01-31" schemaLocation="http://xbrl.sec.gov/country/2012/country-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2012-01-31" schemaLocation="http://xbrl.sec.gov/exch/2012/exch-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:element name="CashlessExerciseOfStockOptions" id="plx_CashlessExerciseOfStockOptions" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="CollaborativeArrangementProfitSharePercentage" id="plx_CollaborativeArrangementProfitSharePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType" />
  <xsd:element name="DepreciationAmortizationAndAssetImpairment" id="plx_DepreciationAmortizationAndAssetImpairment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="EmployeeAndNonemployeeMember" id="plx_EmployeeAndNonemployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="EmployeeMember" id="plx_EmployeeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="GrantsAndReimbursementsReceivedOrReceivable" id="plx_GrantsAndReimbursementsReceivedOrReceivable" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="MilestonePayment" id="plx_MilestonePayment" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" id="plx_NatureOfOperationsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" />
  <xsd:element name="NumberOfSubsidiaries" id="plx_NumberOfSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType" />
  <xsd:element name="OtherGainsLosses" id="plx_OtherGainsLosses" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="PfizerIncorporationMember" id="plx_PfizerIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ProceedsFromIssuanceOfCommonStockNetOfExpenses" id="plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" id="plx_ProtalixBioTherapeuticsIncorporationMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ResearchDevelopmentAndEngineeringExpenseNet" id="plx_ResearchDevelopmentAndEngineeringExpenseNet" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
  <xsd:element name="ScenarioFourMember" id="plx_ScenarioFourMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioOneMember" id="plx_ScenarioOneMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioThreeMember" id="plx_ScenarioThreeMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="ScenarioTwoMember" id="plx_ScenarioTwoMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="plx_SignificantAccountingPoliciesLineItems" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="plx_SignificantAccountingPoliciesTable" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" />
  <xsd:element name="StockOptionsAndRestrictedSharesMember" id="plx_StockOptionsAndRestrictedSharesMember" nillable="true" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType" />
  <xsd:element name="SupplementalOfferingAndStockIssuanceCosts" id="plx_SupplementalOfferingAndStockIssuanceCosts" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>plx-20130331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-05-08 @ 4:39 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20130331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20130331.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20130331.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20130331.xsd#plx-sap1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20130331.xsd#plx-i1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20130331.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20130331.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20130331.xsd#plx-it1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20130331.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20130331.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:href="plx-20130331.xsd#plx-ccsocicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:href="plx-20130331.xsd#plx-ccsocicdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20130331.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20130331.xsd#plx-dein" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20130331.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20130331.xsd#plx-isoicd" xlink:type="simple" />
  <link:calculationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AssetsCurrent.5874.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_AccountsReceivableNetCurrent.5451.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_OtherReceivablesNetCurrent.13172.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryNet.11417.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_AssetsCurrent.5874.14.6" xlink:to="loc_InventoryNet.11417.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Assets.5880.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_AssetsCurrent.5874.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Assets.5880.14.6" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_AccountsPayableTradeCurrent.5457.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_AccountsPayableOtherCurrent.5442.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesCurrent.11668.14.6" xlink:to="loc_DeferredRevenueCurrent.7671.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_DeferredRevenueNoncurrent.7662.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_LongTermDebtNoncurrent.12289.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesNoncurrent.11699.14.6" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_Liabilities.11702.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_Liabilities.11702.14.6" xlink:to="loc_LiabilitiesNoncurrent.11699.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_Liabilities.11702.14.6" xlink:to="loc_LiabilitiesCurrent.11668.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:to="loc_StockholdersEquity.16667.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.14.6" xlink:to="loc_Liabilities.11702.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_GrossProfit.10358.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.15575.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_Revenues.15575.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_OtherGainsLosses.20964.14.6" xlink:href="plx-20130331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_OtherGainsLosses.20964.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_CostOfRevenue.7176.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_GrossProfit.10358.14.6" xlink:to="loc_CostOfRevenue.7176.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.12771.14.6" xlink:to="loc_OperatingIncomeLoss.13080.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetIncomeLoss.12771.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_GrossProfit.10358.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" xlink:href="plx-20130331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_OperatingIncomeLoss.13080.14.6" xlink:to="loc_GeneralAndAdministrativeExpense.10284.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" xlink:to="loc_ResearchAndDevelopmentExpense.15293.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.14.6" xlink:href="plx-20130331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.14.6" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.14.6" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" order="4.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.14.6" order="1.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.14.6" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.14.6" xlink:href="plx-20130331.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.14.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_ShareBasedCompensation.16244.14.6" order="6.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.14.6" xlink:href="plx-20130331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.21078.14.6" order="7.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.13882.14.6" order="8.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.10853.14.6" order="9.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInInventories.10936.14.6" order="10.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.14.6" order="11.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.14.6" order="3.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.13875.14.6" order="4.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.10850.14.6" order="5.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_NetIncomeLoss.12771.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.14.6" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.14.6" order="2.00000" weight="-1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)" xlink:role="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryNet.11417.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterials.11426.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryRawMaterials.11426.14.6" order="1.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryWorkInProcess.11427.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryWorkInProcess.11427.14.6" order="2.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
    <link:loc xlink:label="loc_InventoryFinishedGoods.11405.14.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:calculationArc xlink:from="loc_InventoryNet.11417.14.6" xlink:to="loc_InventoryFinishedGoods.11405.14.6" order="3.00000" weight="1.00" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>plx-20130331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-05-08 @ 4:39 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20130331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20130331.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20130331.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20130331.xsd#plx-sap1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20130331.xsd#plx-i1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20130331.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20130331.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20130331.xsd#plx-it1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20130331.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20130331.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:href="plx-20130331.xsd#plx-ccsocicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:href="plx-20130331.xsd#plx-ccsocicdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20130331.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20130331.xsd#plx-dein" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20130331.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20130331.xsd#plx-isoicd" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.7.6" xlink:href="plx-20130331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.7.6" xlink:to="loc_StockOptionsAndRestrictedSharesMember.26237.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.6.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.8.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.7.6" xlink:href="plx-20130331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.20890.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.7.6" xlink:href="plx-20130331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.7.6" xlink:to="loc_PfizerIncorporationMember.20891.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.6.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.8.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.7.6" xlink:href="plx-20130331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioTwoMember.20882.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioOneMember.20883.7.6" xlink:href="plx-20130331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioOneMember.20883.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioThreeMember.88671.7.6" xlink:href="plx-20130331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioThreeMember.88671.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioFourMember.88672.7.6" xlink:href="plx-20130331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.7.6" xlink:to="loc_ScenarioFourMember.88672.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.6.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementScenarioAxis.4951.8.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:to="loc_StatementScenarioAxis.4951.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.5.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.5.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.5.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.9.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.9.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.9.6" xlink:to="loc_SignificantAccountingPoliciesTable.20885.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.7.6" xlink:href="plx-20130331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_NumberOfSubsidiaries.20893.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_ProceedsFromCollaborators.14370.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_MilestonePayment.20894.7.6" xlink:href="plx-20130331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_MilestonePayment.20894.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.7.6" xlink:href="plx-20130331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.20895.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.7.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.7.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="40301 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.9.6" xlink:to="loc_ScheduleOfStockByClassTable.4702.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ClassOfStockLineItems.966.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.7.6" order="7.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.6.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.8.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.7.6" xlink:href="plx-20130331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:to="loc_EmployeeAndNonemployeeMember.20907.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeMember.21244.7.6" xlink:href="plx-20130331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.7.6" xlink:to="loc_EmployeeMember.21244.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfStockByClassTable.4702.5.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1773.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1033.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_CommonStockMember.1033.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_AdditionalPaidInCapitalMember.461.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EquityComponentDomain.1773.7.6" xlink:to="loc_RetainedEarningsMember.4458.7.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementTable.4950.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementTable.4950.5.6" xlink:to="loc_StatementEquityComponentsAxis.4957.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementTable.4950.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.9.6" xlink:to="loc_StatementTable.4950.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockholdersEquity.16667.7.6" order="2.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_SharesOutstanding.16423.7.6" order="2.75000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.16603.7.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.16628.7.6" order="4.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.7.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.7.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.7.6" order="7.50000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_NetIncomeLoss.12771.7.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.7.6" order="7.75000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementLineItems.4952.7.6" xlink:to="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.7.6" order="7.88000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.4957.6.6" xlink:to="loc_EquityComponentDomain.1773.6.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_StatementEquityComponentsAxis.4957.8.6" xlink:to="loc_EquityComponentDomain.1773.8.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.9.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.9.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.9.6" order="1.00000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.7.6" xlink:to="loc_AllocatedShareBasedCompensationExpense.5724.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.7.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4381.7.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.7.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.7.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2354.7.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.8.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.8.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.8.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.6.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.6.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.6.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.5.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:definitionArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.5.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.5.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>plx-20130331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-05-08 @ 4:39 PM-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/changeLabel2012" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#changeLabel2012" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentDocumentation" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#fragmentDocumentation" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/fragmentLabel" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-roles-2012-01-31.xsd#fragmentLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/deprecatedDateLabel" xlink:href="http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd#deprecatedDateLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.1005">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.11.7" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.138029">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.11.6" xlink:to="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.1010">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.11.6" xlink:to="lab_AntidilutiveSecuritiesNameDomain.1007" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AntidilutiveSecuritiesNameDomain.1007" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AntidilutiveSecuritiesNameDomain.1007">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.11.6" xlink:href="plx-20130331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.20895.11.6" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138005" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138005" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138005">Collaborative Arrangement Profit Share Percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.11.7" xlink:href="plx-20130331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.20895.11.7" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138010" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138010">Pfizer Agreement, future revenues and expense sharing percentage</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.11.12" xlink:href="plx-20130331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementProfitSharePercentage.20895.11.12" xlink:to="lab_CollaborativeArrangementProfitSharePercentage.138007" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementProfitSharePercentage.138007" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementProfitSharePercentage.138007">Collaborative arrangement profit sharing percentage.</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.11.6" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.2624">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.11.6" xlink:to="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.2617">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.7" xlink:to="lab_CommonStockParOrStatedValuePerShare7.134365" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare7.134365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare7.134365">Common stock, par value per share</link:label>
    <link:loc xlink:label="loc_MilestonePayment.20894.11.6" xlink:href="plx-20130331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.20894.11.6" xlink:to="lab_MilestonePayment.138000" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138000">Milestone Payment</link:label>
    <link:loc xlink:label="loc_MilestonePayment.20894.11.7" xlink:href="plx-20130331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.20894.11.7" xlink:to="lab_MilestonePayment.138002" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138002" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138002">Milestone payment triggered</link:label>
    <link:loc xlink:label="loc_MilestonePayment.20894.11.12" xlink:href="plx-20130331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_MilestonePayment.20894.11.12" xlink:to="lab_MilestonePayment.138001" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_MilestonePayment.138001" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_MilestonePayment.138001">Milestone payment.</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.11.6" xlink:href="plx-20130331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.20893.11.6" xlink:to="lab_NumberOfSubsidiaries.137996" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137996">Number Of Subsidiaries</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.11.7" xlink:href="plx-20130331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.20893.11.7" xlink:to="lab_NumberOfSubsidiaries.137998" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137998">Number of Subsidiaries</link:label>
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.11.12" xlink:href="plx-20130331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NumberOfSubsidiaries.20893.11.12" xlink:to="lab_NumberOfSubsidiaries.137997" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NumberOfSubsidiaries.137997" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NumberOfSubsidiaries.137997">Number of subsidiaries.</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.11.6" xlink:href="plx-20130331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.20891.11.6" xlink:to="lab_PfizerIncorporationMember.137992" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137992">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.11.7" xlink:href="plx-20130331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.20891.11.7" xlink:to="lab_PfizerIncorporationMember.137994" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137994">Pfizer Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.11.12" xlink:href="plx-20130331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PfizerIncorporationMember.20891.11.12" xlink:to="lab_PfizerIncorporationMember.137993" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PfizerIncorporationMember.137993" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_PfizerIncorporationMember.137993">Pfizer Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14370.11.6" xlink:to="lab_ProceedsFromCollaborators.14422" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.14422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.14422">Proceeds from Collaborators</link:label>
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromCollaborators.14370.11.7" xlink:to="lab_ProceedsFromCollaborators.137999" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromCollaborators.137999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromCollaborators.137999">Pfizer Agreement, upfront payment received</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.6" xlink:href="plx-20130331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.6" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137989" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137989">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.7" xlink:href="plx-20130331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.7" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137991" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137991">Protalix Bio Therapeutics Incorporation [Member]</link:label>
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.12" xlink:href="plx-20130331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProtalixBioTherapeuticsIncorporationMember.20890.11.12" xlink:to="lab_ProtalixBioTherapeuticsIncorporationMember.137990" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProtalixBioTherapeuticsIncorporationMember.137990" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProtalixBioTherapeuticsIncorporationMember.137990">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.88672.11.6" xlink:href="plx-20130331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.88672.11.6" xlink:to="lab_ScenarioFourMember.501181" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501181">Scenario Four [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.88672.11.7" xlink:href="plx-20130331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.88672.11.7" xlink:to="lab_ScenarioFourMember.501183" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501183">Upon Near Term Clinical Development Milestones [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioFourMember.88672.11.12" xlink:href="plx-20130331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioFourMember.88672.11.12" xlink:to="lab_ScenarioFourMember.501182" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioFourMember.501182" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioFourMember.501182">Scenario Four [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.20883.11.6" xlink:href="plx-20130331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.20883.11.6" xlink:to="lab_ScenarioOneMember.137972" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137972">Scenario One [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.20883.11.7" xlink:href="plx-20130331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.20883.11.7" xlink:to="lab_ScenarioOneMember.137974" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137974">Upon each FDA and European Medicine Agency approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioOneMember.20883.11.12" xlink:href="plx-20130331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioOneMember.20883.11.12" xlink:to="lab_ScenarioOneMember.137973" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioOneMember.137973" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioOneMember.137973">Scenario One [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.88671.11.6" xlink:href="plx-20130331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.88671.11.6" xlink:to="lab_ScenarioThreeMember.501178" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMember.501178" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMember.501178">Scenario Three [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.88671.11.12" xlink:href="plx-20130331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.88671.11.12" xlink:to="lab_ScenarioThreeMember.501179" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMember.501179" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMember.501179">Scenario Three [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioThreeMember.88671.11.7" xlink:href="plx-20130331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioThreeMember.88671.11.7" xlink:to="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioThreeMemberlab_ScenarioThreeMember.501180">Upon FDA Approval [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.11.6" xlink:href="plx-20130331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.20882.11.6" xlink:to="lab_ScenarioTwoMember.137969" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137969">Scenario Two [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.11.7" xlink:href="plx-20130331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.20882.11.7" xlink:to="lab_ScenarioTwoMember.137971" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137971">Upon Filing of Pediatric Investigation Plan to EMA [Member]</link:label>
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.11.12" xlink:href="plx-20130331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioTwoMember.20882.11.12" xlink:to="lab_ScenarioTwoMember.137970" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioTwoMember.137970" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioTwoMember.137970">Scenario Two [Member].</link:label>
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.11.6" xlink:to="lab_ScenarioUnspecifiedDomain.16504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScenarioUnspecifiedDomain.16504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScenarioUnspecifiedDomain.16504">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.11.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.11.6" xlink:to="lab_SignificantAccountingPoliciesLineItems.137995" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesLineItems.137995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesLineItems.137995">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.11.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.11.6" xlink:to="lab_SignificantAccountingPoliciesTable.137976" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137976" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137976">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.11.12" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.11.12" xlink:to="lab_SignificantAccountingPoliciesTable.137977" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SignificantAccountingPoliciesTable.137977" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SignificantAccountingPoliciesTable.137977">Significant Accounting Policies [Table].</link:label>
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementScenarioAxis.4951.11.6" xlink:to="lab_StatementScenarioAxis.17868" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementScenarioAxis.17868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementScenarioAxis.17868">Scenario [Axis]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.11.6" xlink:href="plx-20130331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.26237.11.6" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168199" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168199" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168199">Stock Options And Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.11.7" xlink:href="plx-20130331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.26237.11.7" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168201" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168201">Options and Restricted Shares [Member]</link:label>
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.11.12" xlink:href="plx-20130331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockOptionsAndRestrictedSharesMember.26237.11.12" xlink:to="lab_StockOptionsAndRestrictedSharesMember.168200" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockOptionsAndRestrictedSharesMember.168200" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_StockOptionsAndRestrictedSharesMember.168200">Stock Options And Restricted Shares [Member].</link:label>
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ClassOfStockLineItems.966.11.6" xlink:to="lab_ClassOfStockLineItems.2526" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ClassOfStockLineItems.2526" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ClassOfStockLineItems.2526">Class of Stock [Line Items]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.11.6" xlink:href="plx-20130331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.20907.11.6" xlink:to="lab_EmployeeAndNonemployeeMember.138111" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138111">Employee And Nonemployee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.11.7" xlink:href="plx-20130331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.20907.11.7" xlink:to="lab_EmployeeAndNonemployeeMember.138113" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138113">Certain Employees and Non-employees [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.11.12" xlink:href="plx-20130331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeAndNonemployeeMember.20907.11.12" xlink:to="lab_EmployeeAndNonemployeeMember.138112" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeAndNonemployeeMember.138112" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeAndNonemployeeMember.138112">Employee And Nonemployee [Member].</link:label>
    <link:loc xlink:label="loc_EmployeeMember.21244.11.6" xlink:href="plx-20130331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.21244.11.6" xlink:to="lab_EmployeeMember.140096" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140096">Employee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.21244.11.7" xlink:href="plx-20130331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.21244.11.7" xlink:to="lab_EmployeeMember.140327" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140327">Certain Employee [Member]</link:label>
    <link:loc xlink:label="loc_EmployeeMember.21244.11.12" xlink:href="plx-20130331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeMember.21244.11.12" xlink:to="lab_EmployeeMember.140097" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeMember.140097" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeMember.140097">Employee [Member].</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.11.6" xlink:to="lab_OptionIndexedToIssuersEquityEquityAxis.12418" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityEquityAxis.12418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityEquityAxis.12418">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.11.6" xlink:to="lab_OptionIndexedToIssuersEquityTypeDomain.12421" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OptionIndexedToIssuersEquityTypeDomain.12421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OptionIndexedToIssuersEquityTypeDomain.12421">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.7" xlink:to="lab_ProceedsFromStockOptionsExercised.138107" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.138107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.138107">Cash proceeds from exercise of options</link:label>
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfStockByClassTable.4702.11.6" xlink:to="lab_ScheduleOfStockByClassTable.16952" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfStockByClassTable.16952" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfStockByClassTable.16952">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.17957">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesShareBasedCompensation.162511">Common stock issued in connection with exercise of options</link:label>
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountingPoliciesAbstract.385.11.6" xlink:to="lab_AccountingPoliciesAbstract.137967" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountingPoliciesAbstract.137967" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountingPoliciesAbstract.137967">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.6" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.1457">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.11.7" xlink:to="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.138803">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureAbstract.2789.11.6" xlink:to="lab_InventoryDisclosureAbstract.138059" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureAbstract.138059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureAbstract.138059">INVENTORIES [Abstract]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11399.11.6" xlink:to="lab_InventoryDisclosureTextBlock.9626" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock.9626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock.9626">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryDisclosureTextBlock.11399.11.7" xlink:to="lab_InventoryDisclosureTextBlock7.138804" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryDisclosureTextBlock7.138804" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryDisclosureTextBlock7.138804">INVENTORIES</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.4988.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteAbstract.4988.11.6" xlink:to="lab_StockholdersEquityNoteAbstract.138077" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteAbstract.138077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteAbstract.138077">STOCK TRANSACTIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.6" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.18039" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.18039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.18039">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquityNoteDisclosureTextBlock.16673.11.7" xlink:to="lab_StockholdersEquityNoteDisclosureTextBlock.138805" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquityNoteDisclosureTextBlock.138805" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquityNoteDisclosureTextBlock.138805">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.6" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock.1458" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock.1458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock.1458">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.11.7" xlink:to="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_BasisOfAccountingPolicyPolicyTextBlock7.134441">Basis of Presentation</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.8704.11.6" xlink:to="lab_EarningsPerSharePolicyTextBlock.5427" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.5427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.5427">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerSharePolicyTextBlock.8704.11.7" xlink:to="lab_EarningsPerSharePolicyTextBlock.138811" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerSharePolicyTextBlock.138811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerSharePolicyTextBlock.138811">Net loss per share</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.11.6" xlink:href="plx-20130331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.21035.11.6" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138808" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138808">Nature Of Operations [Policy Text Block]</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.11.7" xlink:href="plx-20130331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.21035.11.7" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138810" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138810">General</link:label>
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.11.12" xlink:href="plx-20130331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NatureOfOperationsPolicyTextBlock.21035.11.12" xlink:to="lab_NatureOfOperationsPolicyTextBlock.138809" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NatureOfOperationsPolicyTextBlock.138809" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_NatureOfOperationsPolicyTextBlock.138809">The accounting policy related to the nature of operations of the entity.</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.6" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock.16610" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock.16610" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock.16610">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.11.7" xlink:to="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfInventoryCurrentTableTextBlock7.138817">Inventory</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.6" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.364">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.11.7" xlink:to="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.138145">Accounts payable and accruals:</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5442.11.6" xlink:to="lab_AccountsPayableOtherCurrent.376" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.376">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableOtherCurrent.5442.11.7" xlink:to="lab_AccountsPayableOtherCurrent.138148" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableOtherCurrent.138148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableOtherCurrent.138148">Other</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5457.11.6" xlink:to="lab_AccountsPayableTradeCurrent.402" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.402">Accounts Payable, Trade, Current</link:label>
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsPayableTradeCurrent.5457.11.7" xlink:to="lab_AccountsPayableTradeCurrent.138147" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsPayableTradeCurrent.138147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsPayableTradeCurrent.138147">Trade</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5451.11.6" xlink:to="lab_AccountsReceivableNetCurrent.390" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.390">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AccountsReceivableNetCurrent.5451.11.7" xlink:to="lab_AccountsReceivableNetCurrent.138137" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AccountsReceivableNetCurrent.138137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AccountsReceivableNetCurrent.138137">Accounts receivable- Trade</link:label>
    <link:loc xlink:label="loc_Assets.5880.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.5880.11.6" xlink:to="lab_Assets.1134" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.1134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Assets.1134">Assets</link:label>
    <link:loc xlink:label="loc_Assets.5880.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Assets.5880.11.9" xlink:to="lab_Assets.138141" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Assets.138141" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Assets.138141">Total assets</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.595.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.595.11.6" xlink:to="lab_AssetsAbstract.1105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.1105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.1105">Assets [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsAbstract.595.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsAbstract.595.11.7" xlink:to="lab_AssetsAbstract.138133" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsAbstract.138133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsAbstract.138133">ASSETS</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.5874.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.5874.11.6" xlink:to="lab_AssetsCurrent.1123" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.1123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.1123">Assets, Current</link:label>
    <link:loc xlink:label="loc_AssetsCurrent.5874.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrent.5874.11.9" xlink:to="lab_AssetsCurrent.138142" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrent.138142" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrent.138142">Total current assets</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.592.11.6" xlink:to="lab_AssetsCurrentAbstract.1099" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.1099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.1099">Assets, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AssetsCurrentAbstract.592.11.7" xlink:to="lab_AssetsCurrentAbstract.138132" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AssetsCurrentAbstract.138132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AssetsCurrentAbstract.138132">CURRENT ASSETS:</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.6" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.2187" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.2187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.2187">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.7" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.138135" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.138135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.138135">Cash and cash equivalents</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.6842.11.6" xlink:to="lab_CommitmentsAndContingencies.2677" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.2677" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.2677">Commitments and Contingencies</link:label>
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommitmentsAndContingencies.6842.11.7" xlink:to="lab_CommitmentsAndContingencies.138162" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommitmentsAndContingencies.138162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommitmentsAndContingencies.138162">COMMITMENTS</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7671.11.6" xlink:to="lab_DeferredRevenueCurrent.3980" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.3980" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.3980">Deferred Revenue, Current</link:label>
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueCurrent.7671.11.7" xlink:to="lab_DeferredRevenueCurrent.138149" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueCurrent.138149" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueCurrent.138149">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7662.11.6" xlink:to="lab_DeferredRevenueNoncurrent.3963" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.3963" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.3963">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DeferredRevenueNoncurrent.7662.11.7" xlink:to="lab_DeferredRevenueNoncurrent.138153" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DeferredRevenueNoncurrent.138153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DeferredRevenueNoncurrent.138153">Deferred revenues</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.6" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.4362">Defined Benefit Plan, Assets for Plan Benefits, Noncurrent</link:label>
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.11.7" xlink:to="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.138140">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.6" xlink:to="lab_InventoryNet.9655" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.9655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.9655">Inventory, Net</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.7" xlink:to="lab_InventoryNet.138139" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138139" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138139">Inventories</link:label>
    <link:loc xlink:label="loc_Liabilities.11702.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.11702.11.6" xlink:to="lab_Liabilities.10148" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.10148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.10148">Liabilities</link:label>
    <link:loc xlink:label="loc_Liabilities.11702.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Liabilities.11702.11.9" xlink:to="lab_Liabilities.138159" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Liabilities.138159" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_Liabilities.138159">Total liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquity.10196" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.10196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.10196">Liabilities and Equity</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquity.11731.11.9" xlink:to="lab_LiabilitiesAndStockholdersEquity.138166" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquity.138166" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquity.138166">Total liabilities net of capital deficiency</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.6" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.10173" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.10173" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.10173">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.11.7" xlink:to="lab_LiabilitiesAndStockholdersEquityAbstract.138143" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesAndStockholdersEquityAbstract.138143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesAndStockholdersEquityAbstract.138143">LIABILITIES NET OF CAPITAL DEFICIENCY</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.11668.11.6" xlink:to="lab_LiabilitiesCurrent.10094" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.10094" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.10094">Liabilities, Current</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrent.11668.11.9" xlink:to="lab_LiabilitiesCurrent.138151" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrent.138151" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrent.138151">Total current liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.11.6" xlink:to="lab_LiabilitiesCurrentAbstract.10147" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.10147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.10147">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.11.7" xlink:to="lab_LiabilitiesCurrentAbstract.138144" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesCurrentAbstract.138144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesCurrentAbstract.138144">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.11699.11.6" xlink:to="lab_LiabilitiesNoncurrent.10143" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.10143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.10143">Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrent.11699.11.9" xlink:to="lab_LiabilitiesNoncurrent.138158" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrent.138158" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrent.138158">Total long term liabilities</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.11.6" xlink:to="lab_LiabilitiesNoncurrentAbstract.10151" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.10151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.10151">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.11.7" xlink:to="lab_LiabilitiesNoncurrentAbstract.138152" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LiabilitiesNoncurrentAbstract.138152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LiabilitiesNoncurrentAbstract.138152">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12289.11.6" xlink:to="lab_LongTermDebtNoncurrent.11025" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.11025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.11025">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_LongTermDebtNoncurrent.12289.11.7" xlink:to="lab_LongTermDebtNoncurrent.138155" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_LongTermDebtNoncurrent.138155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_LongTermDebtNoncurrent.138155">Liability in connection with collaboration operation</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13172.11.6" xlink:to="lab_OtherReceivablesNetCurrent.12515" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.12515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.12515">Other Receivables, Net, Current</link:label>
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherReceivablesNetCurrent.13172.11.7" xlink:to="lab_OtherReceivablesNetCurrent.138138" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherReceivablesNetCurrent.138138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherReceivablesNetCurrent.138138">Other assets</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.6" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13684">Pension and Other Postretirement and Postemployment Benefit Plans, Liabilities, Noncurrent</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.11.7" xlink:to="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.138157">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.11.6" xlink:to="lab_PropertyPlantAndEquipmentNet.14913" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.14913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.14913">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PropertyPlantAndEquipmentNet.14697.11.7" xlink:to="lab_PropertyPlantAndEquipmentNet.134116" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PropertyPlantAndEquipmentNet.134116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PropertyPlantAndEquipmentNet.134116">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.4958.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.11.6" xlink:to="lab_StatementOfFinancialPositionAbstract.138129" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfFinancialPositionAbstract.138129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfFinancialPositionAbstract.138129">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.6" xlink:to="lab_StockholdersEquity.18029" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.18029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.18029">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.7" xlink:to="lab_StockholdersEquity.138164" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138164">CAPITAL DEFICIENCY:</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7176.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7176.11.6" xlink:to="lab_CostOfRevenue.3224" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.3224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.3224">Cost of Revenue</link:label>
    <link:loc xlink:label="loc_CostOfRevenue.7176.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CostOfRevenue.7176.11.42" xlink:to="lab_CostOfRevenue.138492" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CostOfRevenue.138492" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_CostOfRevenue.138492">COST OF REVENUES</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.8698.11.6" xlink:to="lab_EarningsPerShareBasicAndDiluted.5415" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EarningsPerShareBasicAndDiluted.5415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EarningsPerShareBasicAndDiluted.5415">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.7434">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.11.7" xlink:to="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossBeforeTax.138517">FINANCIAL INCOME - NET</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10284.11.6" xlink:to="lab_GeneralAndAdministrativeExpense.7870" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense.7870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense.7870">General and Administrative Expense</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpense.10284.11.42" xlink:to="lab_GeneralAndAdministrativeExpense42.138509" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpense42.138509" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpense42.138509">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.6" xlink:href="plx-20130331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.6" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138496" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138496" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138496">Grants And Reimbursements Received Or Receivable</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.7" xlink:href="plx-20130331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.7" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138500" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138500">Less - grants and reimbursements</link:label>
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.12" xlink:href="plx-20130331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.11.12" xlink:to="lab_GrantsAndReimbursementsReceivedOrReceivable.138498" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrantsAndReimbursementsReceivedOrReceivable.138498" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_GrantsAndReimbursementsReceivedOrReceivable.138498">Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</link:label>
    <link:loc xlink:label="loc_GrossProfit.10358.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10358.11.6" xlink:to="lab_GrossProfit.7981" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.7981" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.7981">Gross Profit</link:label>
    <link:loc xlink:label="loc_GrossProfit.10358.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GrossProfit.10358.11.9" xlink:to="lab_GrossProfit.138487" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GrossProfit.138487" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_GrossProfit.138487">GROSS PROFIT</link:label>
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncomeStatementAbstract.2519.11.6" xlink:to="lab_IncomeStatementAbstract.138470" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncomeStatementAbstract.138470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncomeStatementAbstract.138470">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.9" xlink:to="lab_NetIncomeLoss.138521" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138521" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138521">NET LOSS FOR THE PERIOD</link:label>
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EarningsPerShareBasicAndDiluted.8698.11.7" xlink:to="lab_Netlosspershareofcommonstock-basicanddiluted.167675" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Netlosspershareofcommonstock-basicanddiluted.167675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Netlosspershareofcommonstock-basicanddiluted.167675">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13080.11.6" xlink:to="lab_OperatingIncomeLoss.12364" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.12364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.12364">Operating Income (Loss)</link:label>
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OperatingIncomeLoss.13080.11.9" xlink:to="lab_OperatingIncomeLoss.138511" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OperatingIncomeLoss.138511" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_OperatingIncomeLoss.138511">OPERATING LOSS</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.20964.11.6" xlink:href="plx-20130331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.20964.11.6" xlink:to="lab_OtherGainsLosses.138475" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138475" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138475">Other Gains Losses</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.20964.11.7" xlink:href="plx-20130331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.20964.11.7" xlink:to="lab_OtherGainsLosses.138484" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138484">COMPANY'S SHARE IN COLLABORATION AGREEMENT</link:label>
    <link:loc xlink:label="loc_OtherGainsLosses.20964.11.12" xlink:href="plx-20130331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_OtherGainsLosses.20964.11.12" xlink:to="lab_OtherGainsLosses.138482" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_OtherGainsLosses.138482" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_OtherGainsLosses.138482">The Company's share in collaboration agreement.</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15293.11.6" xlink:to="lab_ResearchAndDevelopmentExpense.15873" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense.15873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense.15873">Research and Development Expense</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpense.15293.11.42" xlink:to="lab_ResearchAndDevelopmentExpense42.140375" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpense42.140375" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpense42.140375">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.6" xlink:href="plx-20130331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.6" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138504">Research Development And Engineering Expense Net</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.45" xlink:href="plx-20130331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.45" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.140370">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.12" xlink:href="plx-20130331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.11.12" xlink:to="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ResearchDevelopmentAndEngineeringExpenseNet.138505">Research and development expenses, net.</link:label>
    <link:loc xlink:label="loc_Revenues.15575.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.15575.11.6" xlink:to="lab_Revenues.16307" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.16307" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.16307">Revenues</link:label>
    <link:loc xlink:label="loc_Revenues.15575.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_Revenues.15575.11.7" xlink:to="lab_Revenues.134146" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_Revenues.134146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_Revenues.134146">REVENUES</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.6" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.19243">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:labelArc xlink:from="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.11.7" xlink:to="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.167681">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</link:label>
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdditionalPaidInCapitalMember.461.11.6" xlink:to="lab_AdditionalPaidInCapitalMember.681" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdditionalPaidInCapitalMember.681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdditionalPaidInCapitalMember.681">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.747">Adjustments to Additional Paid in Capital, Share-based Compensation, Employee Stock Purchase Program, Requisite Service Period Recognition</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.138695">Share-based compensation related to stock options</link:label>
    <link:loc xlink:label="loc_CommonStockMember.1033.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockMember.1033.11.6" xlink:to="lab_CommonStockMember.2694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockMember.2694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockMember.2694">Common Stock [Member]</link:label>
    <link:loc xlink:label="loc_EquityComponentDomain.1773.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EquityComponentDomain.1773.11.6" xlink:to="lab_EquityComponentDomain.5824" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EquityComponentDomain.5824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EquityComponentDomain.5824">Equity Component [Domain]</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.8" xlink:to="lab_NetIncomeLoss.138697" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138697" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138697">Net Loss for the period</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4458.11.6" xlink:to="lab_RetainedEarningsMember.16154" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.16154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.16154">Retained Earnings [Member]</link:label>
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_RetainedEarningsMember.4458.11.7" xlink:to="lab_RetainedEarningsMember.138685" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_RetainedEarningsMember.138685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_RetainedEarningsMember.138685">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.6" xlink:to="lab_SharesOutstanding.17653" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.17653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.17653">Shares, Outstanding</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.10" xlink:to="lab_SharesOutstanding.138690" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138690" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138690">Beginning Balance (in shares)</link:label>
    <link:loc xlink:label="loc_SharesOutstanding.16423.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SharesOutstanding.16423.11.11" xlink:to="lab_SharesOutstanding.138702" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SharesOutstanding.138702" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_SharesOutstanding.138702">Ending Balance (in shares)</link:label>
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementEquityComponentsAxis.4957.11.6" xlink:to="lab_StatementEquityComponentsAxis.17875" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementEquityComponentsAxis.17875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementEquityComponentsAxis.17875">Equity Components [Axis]</link:label>
    <link:loc xlink:label="loc_StatementLineItems.4952.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementLineItems.4952.11.6" xlink:to="lab_StatementLineItems.17869" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementLineItems.17869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementLineItems.17869">Statement [Line Items]</link:label>
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.11.6" xlink:to="lab_StatementOfStockholdersEquityAbstract.138674" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfStockholdersEquityAbstract.138674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfStockholdersEquityAbstract.138674">CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</link:label>
    <link:loc xlink:label="loc_StatementTable.4950.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementTable.4950.11.6" xlink:to="lab_StatementTable.17867" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementTable.17867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementTable.17867">Statement [Table]</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.10" xlink:to="lab_StockholdersEquity.138688" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138688" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138688">Beginning Balance</link:label>
    <link:loc xlink:label="loc_StockholdersEquity.16667.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockholdersEquity.16667.11.11" xlink:to="lab_StockholdersEquity.138700" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockholdersEquity.138700" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockholdersEquity.138700">Ending Balance</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesIssuedForServices.17920">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesIssuedForServices.145599">Share-based compensation related to restricted stock award (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.17977" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.17977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.17977">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesNewIssues.16628.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesNewIssues.138692" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesNewIssues.138692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesNewIssues.138692">Common stock issued for cash (net of issuance costs) (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.6" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.17984">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.11.7" xlink:to="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodSharesStockOptionsExercised.138106">Exercise of options granted to employees and non-employees (in shares)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.6" xlink:to="lab_StockIssuedDuringPeriodValueIssuedForServices.17948" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueIssuedForServices.17948" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueIssuedForServices.17948">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.11.7" xlink:to="lab_StockIssuedDuringPeriodValueIssuedForServices.145592" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueIssuedForServices.145592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueIssuedForServices.145592">Share-based compensation related to restricted stock award</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.6" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.17939" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.17939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.17939">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueNewIssues.16603.11.7" xlink:to="lab_StockIssuedDuringPeriodValueNewIssues.138694" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueNewIssues.138694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueNewIssues.138694">Common stock issued for cash (net of issuance costs)</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.6" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.17935">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.11.7" xlink:to="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_StockIssuedDuringPeriodValueStockOptionsExercised.138696">Exercise of options granted to employees and non-employees</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.6" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.735">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.11.7" xlink:to="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts7.138770">Common stock issued for cash, issuance costs</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.6" xlink:to="lab_CommonStockParOrStatedValuePerShare.2741" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.2741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.2741">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockParOrStatedValuePerShare.6878.11.8" xlink:to="lab_CommonStockParOrStatedValuePerShare.138774" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockParOrStatedValuePerShare.138774" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockParOrStatedValuePerShare.138774">Common Stock, par value</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.6879.11.6" xlink:to="lab_CommonStockSharesAuthorized.2742" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.2742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.2742">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CommonStockSharesAuthorized.6879.11.8" xlink:to="lab_CommonStockSharesAuthorized.138777" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CommonStockSharesAuthorized.138777" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CommonStockSharesAuthorized.138777">Common Stock, Authorized</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.6" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.726">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.11.7" xlink:to="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.139020">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.10" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139058" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139058" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139058">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsAtCarryingValue.6556.11.11" xlink:to="lab_CashAndCashEquivalentsAtCarryingValue.139059" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsAtCarryingValue.139059" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsAtCarryingValue.139059">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.6" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.2245">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.11.9" xlink:to="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashAndCashEquivalentsPeriodIncreaseDecrease.139056">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.11.6" xlink:href="plx-20130331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.22141.11.6" xlink:to="lab_CashlessExerciseOfStockOptions.145608" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145608" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145608">Cashless Exercise Of Stock Options</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.11.7" xlink:href="plx-20130331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.22141.11.7" xlink:to="lab_CashlessExerciseOfStockOptions.145611" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145611">Exercise of options granted to employees</link:label>
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.11.12" xlink:href="plx-20130331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CashlessExerciseOfStockOptions.22141.11.12" xlink:to="lab_CashlessExerciseOfStockOptions.145610" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CashlessExerciseOfStockOptions.145610" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_CashlessExerciseOfStockOptions.145610">Cashless exercise of stock options.</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.11.6" xlink:href="plx-20130331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.21078.11.6" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139023" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139023" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139023">Depreciation Amortization And Asset Impairment</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.11.7" xlink:href="plx-20130331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.21078.11.7" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139027" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139027">Depreciation and write down of fixed assets</link:label>
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.11.12" xlink:href="plx-20130331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DepreciationAmortizationAndAssetImpairment.21078.11.12" xlink:to="lab_DepreciationAmortizationAndAssetImpairment.139026" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DepreciationAmortizationAndAssetImpairment.139026" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_DepreciationAmortizationAndAssetImpairment.139026">The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.6" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.5445">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.11.7" xlink:to="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_EffectOfExchangeRateOnCashAndCashEquivalents.139055">EFFECT OF EXCHANGE RATE CHANGES ON CASH</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.6" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.7370" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.7370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.7370">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.11.42" xlink:to="lab_ForeignCurrencyTransactionGainLossUnrealized.139028" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ForeignCurrencyTransactionGainLossUnrealized.139028" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_ForeignCurrencyTransactionGainLossUnrealized.139028">Financial income, net (mainly exchange differences)</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.6" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment.7730" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment.7730" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment.7730">Gain (Loss) on Sale of Property Plant Equipment</link:label>
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.11.42" xlink:to="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_GainLossOnSaleOfPropertyPlantEquipment42.168198">Loss on sale of fixed assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.6" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.8810">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.11.7" xlink:to="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.139038">Decrease in accounts payable and accruals (including long term )</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.10853.11.6" xlink:to="lab_IncreaseDecreaseInAccountsReceivable.8785" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable.8785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable.8785">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInAccountsReceivable.10853.11.42" xlink:to="lab_IncreaseDecreaseInAccountsReceivable42.139035" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInAccountsReceivable42.139035" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInAccountsReceivable42.139035">Decrease (increase) in accounts receivable and other assets</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.10850.11.6" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.8782" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.8782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.8782">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInDeferredRevenue.10850.11.7" xlink:to="lab_IncreaseDecreaseInDeferredRevenue.139034" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInDeferredRevenue.139034" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInDeferredRevenue.139034">Decrease in deferred revenues (including non-current portion)</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.10936.11.6" xlink:to="lab_IncreaseDecreaseInInventories.8903" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories.8903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories.8903">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInInventories.10936.11.42" xlink:to="lab_IncreaseDecreaseInInventories42.139036" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInInventories42.139036" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInInventories42.139036">Decrease (increase) in inventories</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.6" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.8850">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.11.7" xlink:to="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseDecreaseInOperatingCapitalAbstract.139033">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.6" xlink:href="plx-20130331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.6" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139065">Increase In Liabilities For Property Plant And Equipment</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.7" xlink:href="plx-20130331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.7" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139070">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.12" xlink:href="plx-20130331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.11.12" xlink:to="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_IncreaseInLiabilitiesForPropertyPlantAndEquipment.139067">Increase in liabilities for property, plant and equipment.</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.11796" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.11796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.11796">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivities.12740.11.9" xlink:to="lab_NetCashProvidedByUsedInFinancingActivities.139054" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivities.139054" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivities.139054">Net cash provided by financing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.6" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.11763">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.11.7" xlink:to="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInFinancingActivitiesAbstract.139046">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.11776" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.11776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.11776">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivities.12731.11.9" xlink:to="lab_NetCashProvidedByUsedInInvestingActivities.139044" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivities.139044" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivities.139044">Net cash used in investing activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.6" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.11840">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.11.7" xlink:to="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInInvestingActivitiesAbstract.139040">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.11871" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.11871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.11871">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivities.12778.11.9" xlink:to="lab_NetCashProvidedByUsedInOperatingActivities.139039" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivities.139039" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivities.139039">Net cash used in operating activities</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.6" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract.11842">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.11.7" xlink:to="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetCashProvidedByUsedInOperatingActivitiesAbstract7.138996">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.6" xlink:to="lab_NetIncomeLoss.11860" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.11860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.11860">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:label="loc_NetIncomeLoss.12771.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:labelArc xlink:from="loc_NetIncomeLoss.12771.11.7" xlink:to="lab_NetIncomeLoss.138997" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_NetIncomeLoss.138997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_NetIncomeLoss.138997">Net loss</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.6" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.13356" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.13356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.13356">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.11.42" xlink:to="lab_PaymentsForProceedsFromOtherInvestingActivities.139042" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsForProceedsFromOtherInvestingActivities.139042" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsForProceedsFromOtherInvestingActivities.139042">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.6" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment.13519">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.11.42" xlink:to="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PaymentsToAcquirePropertyPlantAndEquipment42.139041">Purchase of property and equipment</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.13663" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.13663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.13663">Pension and Other Postretirement Benefit Contributions</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitContributions.13875.11.42" xlink:to="lab_PensionAndOtherPostretirementBenefitContributions.139032" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitContributions.139032" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitContributions.139032">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.6" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.13676" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.13676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.13676">Pension and Other Postretirement Benefit Expense</link:label>
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_PensionAndOtherPostretirementBenefitExpense.13882.11.7" xlink:to="lab_PensionAndOtherPostretirementBenefitExpense.139030" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_PensionAndOtherPostretirementBenefitExpense.139030" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_PensionAndOtherPostretirementBenefitExpense.139030">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.6" xlink:href="plx-20130331.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.6" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139047">Proceeds From Issuance Of Common Stock Net Of Expenses</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.7" xlink:href="plx-20130331.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.7" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139050">Issuance of shares, net of issuance cost</link:label>
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.12" xlink:href="plx-20130331.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.11.12" xlink:to="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromIssuanceOfCommonStockNetOfExpenses.139048">Proceeds from issuance of common stock net of expenses.</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.6" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.14631">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.11.7" xlink:to="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromSaleOfPropertyPlantAndEquipment.145607">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.6" xlink:to="lab_ProceedsFromStockOptionsExercised.14691" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.14691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.14691">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.11.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ProceedsFromStockOptionsExercised.14555.11.8" xlink:to="lab_ProceedsFromStockOptionsExercised.139052" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ProceedsFromStockOptionsExercised.139052" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ProceedsFromStockOptionsExercised.139052">Exercise of options</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16244.11.6" xlink:to="lab_ShareBasedCompensation.17402" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation.17402" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation.17402">Share-based Compensation</link:label>
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ShareBasedCompensation.16244.11.7" xlink:to="lab_ShareBasedCompensation7.138110" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ShareBasedCompensation7.138110" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_ShareBasedCompensation7.138110">Share based compensation</link:label>
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.11.6" xlink:to="lab_StatementOfCashFlowsAbstract.138995" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_StatementOfCashFlowsAbstract.138995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_StatementOfCashFlowsAbstract.138995">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5043.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5043.11.6" xlink:to="lab_SupplementalCashFlowInformationAbstract.519401" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.519401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.519401">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS: [Abstract]</link:label>
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5043.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5043.11.7" xlink:to="lab_SupplementalCashFlowInformationAbstract.522041" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalCashFlowInformationAbstract.522041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalCashFlowInformationAbstract.522041">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.6" xlink:href="plx-20130331.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.6" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139071" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139071">Supplemental Offering And Stock Issuance Costs</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.7" xlink:href="plx-20130331.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.7" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139074" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139074">Issuance cost not yet paid</link:label>
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.12" xlink:href="plx-20130331.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:labelArc xlink:from="loc_SupplementalOfferingAndStockIssuanceCosts.21083.11.12" xlink:to="lab_SupplementalOfferingAndStockIssuanceCosts.139073" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_SupplementalOfferingAndStockIssuanceCosts.139073" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" id="lab_SupplementalOfferingAndStockIssuanceCosts.139073">Supplemental offering and stock issuance costs.</link:label>
    <link:loc xlink:label="loc_AmendmentFlag.144.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AmendmentFlag.144.11.6" xlink:to="lab_AmendmentFlag.8" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AmendmentFlag.8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AmendmentFlag.8">Amendment Flag</link:label>
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_CurrentFiscalYearEndDate.155.11.6" xlink:to="lab_CurrentFiscalYearEndDate.20" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_CurrentFiscalYearEndDate.20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_CurrentFiscalYearEndDate.20">Current Fiscal Year End Date</link:label>
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.20908.11.6" xlink:href="plx-20130331.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.11.6" xlink:to="lab_DocumentAndEntityInformationAbstract.138116" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentAndEntityInformationAbstract.138116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentAndEntityInformationAbstract.138116">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.208.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalPeriodFocus.208.11.6" xlink:to="lab_DocumentFiscalPeriodFocus.123" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalPeriodFocus.123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalPeriodFocus.123">Document Fiscal Period Focus</link:label>
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.207.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentFiscalYearFocus.207.11.6" xlink:to="lab_DocumentFiscalYearFocus.122" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentFiscalYearFocus.122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentFiscalYearFocus.122">Document Fiscal Year Focus</link:label>
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentPeriodEndDate.161.11.6" xlink:to="lab_DocumentPeriodEndDate.30" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentPeriodEndDate.30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentPeriodEndDate.30">Document Period End Date</link:label>
    <link:loc xlink:label="loc_DocumentType.212.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:labelArc xlink:from="loc_DocumentType.212.11.6" xlink:to="lab_DocumentType.32" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_DocumentType.32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_DocumentType.32">Document Type</link:label>
    <link:loc xlink:label="loc_EntityCentralIndexKey.188.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCentralIndexKey.188.11.6" xlink:to="lab_EntityCentralIndexKey.101" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCentralIndexKey.101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCentralIndexKey.101">Entity Central Index Key</link:label>
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.192.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityCommonStockSharesOutstanding.192.11.6" xlink:to="lab_EntityCommonStockSharesOutstanding.105" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityCommonStockSharesOutstanding.105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityCommonStockSharesOutstanding.105">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:label="loc_EntityFilerCategory.185.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityFilerCategory.185.11.6" xlink:to="lab_EntityFilerCategory.98" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityFilerCategory.98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityFilerCategory.98">Entity Filer Category</link:label>
    <link:loc xlink:label="loc_EntityRegistrantName.187.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EntityRegistrantName.187.11.6" xlink:to="lab_EntityRegistrantName.100" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EntityRegistrantName.100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EntityRegistrantName.100">Entity Registrant Name</link:label>
    <link:loc xlink:label="loc_TradingSymbol.177.11.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:labelArc xlink:from="loc_TradingSymbol.177.11.6" xlink:to="lab_TradingSymbol.60" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_TradingSymbol.60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_TradingSymbol.60">Trading Symbol</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5724.11.6" xlink:to="lab_AllocatedShareBasedCompensationExpense.852" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense.852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense.852">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:labelArc xlink:from="loc_AllocatedShareBasedCompensationExpense.5724.11.7" xlink:to="lab_AllocatedShareBasedCompensationExpense7.138668" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_AllocatedShareBasedCompensationExpense7.138668" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_AllocatedShareBasedCompensationExpense7.138668">Share-based compensation</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.5595">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:labelArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.11.6" xlink:to="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.5604" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.5604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.5604">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_GeneralAndAdministrativeExpenseMember.2354.11.6" xlink:to="lab_GeneralAndAdministrativeExpenseMember.7876" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_GeneralAndAdministrativeExpenseMember.7876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_GeneralAndAdministrativeExpenseMember.7876">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ResearchAndDevelopmentExpenseMember.4381.11.6" xlink:to="lab_ResearchAndDevelopmentExpenseMember.15885" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ResearchAndDevelopmentExpenseMember.15885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ResearchAndDevelopmentExpenseMember.15885">Research and Development Expense [Member]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.16736" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.16736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.16736">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:labelArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.11.6" xlink:to="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.16738">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoods.11405.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoods.11405.11.6" xlink:to="lab_InventoryFinishedGoods.9634" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoods.9634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoods.9634">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:label="loc_InventoryFinishedGoods.11405.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryFinishedGoods.11405.11.7" xlink:to="lab_InventoryFinishedGoods.135792" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryFinishedGoods.135792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryFinishedGoods.135792">Finished goods</link:label>
    <link:loc xlink:label="loc_InventoryNet.11417.11.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryNet.11417.11.9" xlink:to="lab_InventoryNet.138062" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryNet.138062" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryNet.138062">Total inventory</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterials.11426.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterials.11426.11.6" xlink:to="lab_InventoryRawMaterials.9669" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterials.9669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterials.9669">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:label="loc_InventoryRawMaterials.11426.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryRawMaterials.11426.11.7" xlink:to="lab_InventoryRawMaterials.135790" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryRawMaterials.135790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryRawMaterials.135790">Raw materials</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcess.11427.11.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcess.11427.11.6" xlink:to="lab_InventoryWorkInProcess.9671" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcess.9671" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcess.9671">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:label="loc_InventoryWorkInProcess.11427.11.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:labelArc xlink:from="loc_InventoryWorkInProcess.11427.11.7" xlink:to="lab_InventoryWorkInProcess.135791" order="1" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:type="arc" />
    <link:label xlink:label="lab_InventoryWorkInProcess.135791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US" id="lab_InventoryWorkInProcess.135791">Work in process</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>plx-20130331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Created by Vintage Filings ("VF")-->
<!--produced on 2013-05-08 @ 4:39 PM-->
<link:linkbase xmlns:plx="http://www.protalix.com/20130331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase">
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:href="plx-20130331.xsd#plx-sapd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactionsDetails" xlink:href="plx-20130331.xsd#plx-std" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:href="plx-20130331.xsd#plx-sap1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/Inventories" xlink:href="plx-20130331.xsd#plx-i1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/StockTransactions" xlink:href="plx-20130331.xsd#plx-st" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:href="plx-20130331.xsd#plx-sapp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesTables" xlink:href="plx-20130331.xsd#plx-it1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:href="plx-20130331.xsd#plx-ccbs" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="plx-20130331.xsd#plx-ccsoo" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:href="plx-20130331.xsd#plx-ccsocicd" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:href="plx-20130331.xsd#plx-ccsocicdp" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="plx-20130331.xsd#plx-ccsocf" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:href="plx-20130331.xsd#plx-dein" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:href="plx-20130331.xsd#plx-ccsoop" xlink:type="simple" />
  <link:roleRef roleURI="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:href="plx-20130331.xsd#plx-isoicd" xlink:type="simple" />
  <link:presentationLink xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.6" xlink:to="loc_SignificantAccountingPoliciesTable.20885.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_StockOptionsAndRestrictedSharesMember.26237.12.7" xlink:href="plx-20130331.xsd#plx_StockOptionsAndRestrictedSharesMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesNameDomain.559.12.7" xlink:to="loc_StockOptionsAndRestrictedSharesMember.26237.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesNameDomain.559.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" xlink:to="loc_AntidilutiveSecuritiesNameDomain.559.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:loc xlink:label="loc_ProtalixBioTherapeuticsIncorporationMember.20890.12.7" xlink:href="plx-20130331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_ProtalixBioTherapeuticsIncorporationMember.20890.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PfizerIncorporationMember.20891.12.7" xlink:href="plx-20130331.xsd#plx_PfizerIncorporationMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.7" xlink:to="loc_PfizerIncorporationMember.20891.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsMember.994.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioTwoMember.20882.12.7" xlink:href="plx-20130331.xsd#plx_ScenarioTwoMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioTwoMember.20882.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioOneMember.20883.12.7" xlink:href="plx-20130331.xsd#plx_ScenarioOneMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioOneMember.20883.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioThreeMember.88671.12.7" xlink:href="plx-20130331.xsd#plx_ScenarioThreeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioThreeMember.88671.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScenarioFourMember.88672.12.7" xlink:href="plx-20130331.xsd#plx_ScenarioFourMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScenarioUnspecifiedDomain.4553.12.7" xlink:to="loc_ScenarioFourMember.88672.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementScenarioAxis.4951.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_ScenarioUnspecifiedDomain.4553.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementScenarioAxis.4951.12.6" xlink:to="loc_ScenarioUnspecifiedDomain.4553.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_StatementScenarioAxis.4951.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis.560.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxis.999.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.12.6" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesTable.20885.12.6" xlink:to="loc_SignificantAccountingPoliciesLineItems.20892.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:href="plx-20130331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NumberOfSubsidiaries.20893.12.7" xlink:href="plx-20130331.xsd#plx_NumberOfSubsidiaries" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_NumberOfSubsidiaries.20893.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromCollaborators.14370.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_ProceedsFromCollaborators.14370.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_MilestonePayment.20894.12.7" xlink:href="plx-20130331.xsd#plx_MilestonePayment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_MilestonePayment.20894.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CollaborativeArrangementProfitSharePercentage.20895.12.7" xlink:href="plx-20130331.xsd#plx_CollaborativeArrangementProfitSharePercentage" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_CollaborativeArrangementProfitSharePercentage.20895.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SignificantAccountingPoliciesLineItems.20892.12.7" xlink:to="loc_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount.5816.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40301 - Disclosure - STOCK TRANSACTIONS (Details)" xlink:role="http://www.protalix.com/role/StockTransactionsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ClassOfStockLineItems.966.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesShareBasedCompensation.16615.12.7" order="7.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="locator" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" xlink:to="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_EmployeeAndNonemployeeMember.20907.12.7" xlink:href="plx-20130331.xsd#plx_EmployeeAndNonemployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:to="loc_EmployeeAndNonemployeeMember.20907.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeMember.21244.12.7" xlink:href="plx-20130331.xsd#plx_EmployeeMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_OptionIndexedToIssuersEquityTypeDomain.3556.12.7" xlink:to="loc_EmployeeMember.21244.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:to="loc_OptionIndexedToIssuersEquityEquityAxis.3555.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ClassOfStockLineItems.966.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfStockByClassTable.4702.12.6" xlink:to="loc_ClassOfStockLineItems.966.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.4988.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.4988.12.6" xlink:to="loc_ScheduleOfStockByClassTable.4702.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES" xlink:role="http://www.protalix.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock.6085.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="102 - Disclosure - INVENTORIES" xlink:role="http://www.protalix.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryDisclosureTextBlock.11399.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryDisclosureTextBlock.11399.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="103 - Disclosure - STOCK TRANSACTIONS" xlink:role="http://www.protalix.com/role/StockTransactions" xlink:type="extended">
    <link:loc xlink:label="loc_StockholdersEquityNoteAbstract.4988.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquityNoteDisclosureTextBlock.16673.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StockholdersEquityNoteAbstract.4988.12.7" xlink:to="loc_StockholdersEquityNoteDisclosureTextBlock.16673.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)" xlink:role="http://www.protalix.com/role/SignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:label="loc_AccountingPoliciesAbstract.385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NatureOfOperationsPolicyTextBlock.21035.12.7" xlink:href="plx-20130331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_NatureOfOperationsPolicyTextBlock.21035.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_BasisOfAccountingPolicyPolicyTextBlock.6086.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EarningsPerSharePolicyTextBlock.8704.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountingPoliciesAbstract.385.12.7" xlink:to="loc_EarningsPerSharePolicyTextBlock.8704.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="302 - Disclosure - INVENTORIES (Tables)" xlink:role="http://www.protalix.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_ScheduleOfInventoryCurrentTableTextBlock.15772.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:label="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AccountsPayableTradeCurrent.5457.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:to="loc_AccountsPayableTradeCurrent.5457.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsPayableOtherCurrent.5442.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" xlink:to="loc_AccountsPayableOtherCurrent.5442.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsCurrentAbstract.592.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AccountsReceivableNetCurrent.5451.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_AccountsReceivableNetCurrent.5451.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherReceivablesNetCurrent.13172.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_OtherReceivablesNetCurrent.13172.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryNet.11417.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsCurrentAbstract.592.12.7" xlink:to="loc_InventoryNet.11417.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.595.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_AssetsCurrentAbstract.592.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent.7957.12.7" order="2.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PropertyPlantAndEquipmentNet.14697.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.7" xlink:to="loc_PropertyPlantAndEquipmentNet.14697.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AssetsAbstract.595.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Assets.5880.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.9" xlink:to="loc_Assets.5880.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_AssetsCurrent.5874.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AssetsAbstract.595.12.9" xlink:to="loc_AssetsCurrent.5874.12.9" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:to="loc_AccountsPayableAndAccruedLiabilitiesCurrentAbstract.394.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DeferredRevenueCurrent.7671.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.7" xlink:to="loc_DeferredRevenueCurrent.7671.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesCurrentAbstract.2935.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesCurrent.11668.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesCurrentAbstract.2935.12.9" xlink:to="loc_LiabilitiesCurrent.11668.12.9" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DeferredRevenueNoncurrent.7662.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_DeferredRevenueNoncurrent.7662.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LongTermDebtNoncurrent.12289.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_LongTermDebtNoncurrent.12289.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesNoncurrentAbstract.2937.12.7" xlink:to="loc_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent.13885.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_LiabilitiesCurrentAbstract.2935.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_LiabilitiesNoncurrentAbstract.2937.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_LiabilitiesNoncurrent.11699.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_LiabilitiesNoncurrent.11699.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_Liabilities.11702.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_Liabilities.11702.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_CommitmentsAndContingencies.6842.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_CommitmentsAndContingencies.6842.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" xlink:to="loc_StockholdersEquity.16667.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_LiabilitiesAndStockholdersEquity.11731.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.9" xlink:to="loc_LiabilitiesAndStockholdersEquity.11731.12.9" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:to="loc_AssetsAbstract.595.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfFinancialPositionAbstract.4958.12.7" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract.2940.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_Revenues.15575.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Revenues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_Revenues.15575.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_OtherGainsLosses.20964.12.7" xlink:href="plx-20130331.xsd#plx_OtherGainsLosses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_OtherGainsLosses.20964.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CostOfRevenue.7176.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CostOfRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_CostOfRevenue.7176.12.42" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_GrossProfit.10358.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GrossProfit" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_GrossProfit.10358.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpense.15293.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_ResearchAndDevelopmentExpense.15293.12.42" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.12.7" xlink:href="plx-20130331.xsd#plx_GrantsAndReimbursementsReceivedOrReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_GrantsAndReimbursementsReceivedOrReceivable.20968.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.45" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.12.45" xlink:href="plx-20130331.xsd#plx_ResearchDevelopmentAndEngineeringExpenseNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.45" xlink:to="loc_ResearchDevelopmentAndEngineeringExpenseNet.20971.12.45" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpense.10284.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.42" xlink:to="loc_GeneralAndAdministrativeExpense.10284.12.42" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_OperatingIncomeLoss.13080.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_OperatingIncomeLoss.13080.12.9" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_ForeignCurrencyTransactionGainLossBeforeTax.10004.12.7" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.9" xlink:to="loc_NetIncomeLoss.12771.12.9" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_EarningsPerShareBasicAndDiluted.8698.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_EarningsPerShareBasicAndDiluted.8698.12.7" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.7" xlink:to="loc_WeightedAverageNumberOfShareOutstandingBasicAndDiluted.17395.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency" xlink:type="extended">
    <link:loc xlink:label="loc_EquityComponentDomain.1773.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockMember.1033.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.6" xlink:to="loc_CommonStockMember.1033.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AdditionalPaidInCapitalMember.461.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.6" xlink:to="loc_AdditionalPaidInCapitalMember.461.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EquityComponentDomain.1773.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_RetainedEarningsMember.4458.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EquityComponentDomain.1773.12.7" xlink:to="loc_RetainedEarningsMember.4458.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementTable.4950.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" />
    <link:loc xlink:label="loc_StatementEquityComponentsAxis.4957.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_StatementEquityComponentsAxis.4957.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementTable.4950.12.6" xlink:to="loc_StatementLineItems.4952.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.10" xlink:to="loc_StockholdersEquity.16667.12.10" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.10" xlink:to="loc_SharesOutstanding.16423.12.10" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesNewIssues.16628.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesNewIssues.16628.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueNewIssues.16603.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueNewIssues.16603.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition.5661.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesStockOptionsExercised.16634.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueStockOptionsExercised.16599.12.7" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.8" xlink:to="loc_NetIncomeLoss.12771.12.8" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_StatementLineItems.4952.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_StockholdersEquity.16667.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.11" xlink:to="loc_StockholdersEquity.16667.12.11" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_SharesOutstanding.16423.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.11" xlink:to="loc_SharesOutstanding.16423.12.11" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodValueIssuedForServices.16607.12.7" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementLineItems.4952.12.7" xlink:to="loc_StockIssuedDuringPeriodSharesIssuedForServices.16587.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.6" xlink:to="loc_StatementTable.4950.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_StatementEquityComponentsAxis.4957.12.6" xlink:to="loc_EquityComponentDomain.1773.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.7" xlink:to="loc_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts.5652.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfStockholdersEquityAbstract.4954.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CommonStockParOrStatedValuePerShare.6878.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.8" xlink:to="loc_CommonStockParOrStatedValuePerShare.6878.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_CommonStockSharesAuthorized.6879.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfStockholdersEquityAbstract.4954.12.8" xlink:to="loc_CommonStockSharesAuthorized.6879.12.8" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ShareBasedCompensation.16244.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_ShareBasedCompensation.16244.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_DepreciationAmortizationAndAssetImpairment.21078.12.7" xlink:href="plx-20130331.xsd#plx_DepreciationAmortizationAndAssetImpairment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_DepreciationAmortizationAndAssetImpairment.21078.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_ForeignCurrencyTransactionGainLossUnrealized.9966.12.42" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitExpense.13882.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" xlink:to="loc_PensionAndOtherPostretirementBenefitExpense.13882.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_PensionAndOtherPostretirementBenefitContributions.13875.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_PensionAndOtherPostretirementBenefitContributions.13875.12.42" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.42" xlink:to="loc_GainLossOnSaleOfPropertyPlantEquipment.10196.12.42" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInDeferredRevenue.10850.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:to="loc_IncreaseDecreaseInDeferredRevenue.10850.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsReceivable.10853.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:to="loc_IncreaseDecreaseInAccountsReceivable.10853.12.42" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInInventories.10936.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.42" xlink:to="loc_IncreaseDecreaseInInventories.10936.12.42" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" xlink:to="loc_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.10871.12.7" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.12.7" xlink:href="plx-20130331.xsd#plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" xlink:to="loc_ProceedsFromIssuanceOfCommonStockNetOfExpenses.21079.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromStockOptionsExercised.14555.12.8" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.8" xlink:to="loc_ProceedsFromStockOptionsExercised.14555.12.8" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment.13779.12.42" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.12.42" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.42" xlink:to="loc_PaymentsForProceedsFromOtherInvestingActivities.13667.12.42" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" xlink:to="loc_ProceedsFromSaleOfPropertyPlantAndEquipment.14507.12.7" order="1.50000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetIncomeLoss.12771.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" xlink:to="loc_NetIncomeLoss.12771.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract.3386.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract.480.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract.2616.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInOperatingActivities.12778.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities.12778.12.9" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract.3385.12.7" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInInvestingActivities.12731.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities.12731.12.9" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract.3365.12.7" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_NetCashProvidedByUsedInFinancingActivities.12740.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities.12740.12.9" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_EffectOfExchangeRateOnCashAndCashEquivalents.8714.12.7" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.9" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease.6589.12.9" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.10" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.10" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.10" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:label="loc_StatementOfCashFlowsAbstract.4955.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.11" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.11" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue.6556.12.11" order="12.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:label="loc_SupplementalCashFlowInformationAbstract.5043.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_StatementOfCashFlowsAbstract.4955.12.7" xlink:to="loc_SupplementalCashFlowInformationAbstract.5043.12.7" order="13.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.12.7" xlink:href="plx-20130331.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5043.12.7" xlink:to="loc_IncreaseInLiabilitiesForPropertyPlantAndEquipment.21082.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_SupplementalOfferingAndStockIssuanceCosts.21083.12.7" xlink:href="plx-20130331.xsd#plx_SupplementalOfferingAndStockIssuanceCosts" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5043.12.7" xlink:to="loc_SupplementalOfferingAndStockIssuanceCosts.21083.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_CashlessExerciseOfStockOptions.22141.12.7" xlink:href="plx-20130331.xsd#plx_CashlessExerciseOfStockOptions" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_SupplementalCashFlowInformationAbstract.5043.12.7" xlink:to="loc_CashlessExerciseOfStockOptions.22141.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:title="001 - Document - Document and Entity Information" xlink:role="http://www.protalix.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:label="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:href="plx-20130331.xsd#plx_DocumentAndEntityInformationAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_DocumentType.212.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentType" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentType.212.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_AmendmentFlag.144.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_AmendmentFlag.144.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentPeriodEndDate.161.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentPeriodEndDate.161.12.6" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalYearFocus.207.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentFiscalYearFocus.207.12.6" order="4.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_DocumentFiscalPeriodFocus.208.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_DocumentFiscalPeriodFocus.208.12.6" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_TradingSymbol.177.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_TradingSymbol" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_TradingSymbol.177.12.6" order="6.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityRegistrantName.187.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityRegistrantName.187.12.6" order="7.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCentralIndexKey.188.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityCentralIndexKey.188.12.6" order="8.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_CurrentFiscalYearEndDate.155.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_CurrentFiscalYearEndDate.155.12.6" order="9.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityFilerCategory.185.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityFilerCategory.185.12.6" order="10.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EntityCommonStockSharesOutstanding.192.12.6" xlink:href="http://xbrl.sec.gov/dei/2012/dei-2012-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_DocumentAndEntityInformationAbstract.20908.12.6" xlink:to="loc_EntityCommonStockSharesOutstanding.192.12.6" order="11.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)" xlink:role="http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended">
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:loc xlink:label="loc_AllocatedShareBasedCompensationExpense.5724.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.12.7" xlink:to="loc_AllocatedShareBasedCompensationExpense.5724.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain" xlink:type="locator" />
    <link:loc xlink:label="loc_ResearchAndDevelopmentExpenseMember.4381.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" xlink:to="loc_ResearchAndDevelopmentExpenseMember.4381.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_GeneralAndAdministrativeExpenseMember.2354.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" xlink:to="loc_GeneralAndAdministrativeExpenseMember.2354.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_IncomeStatementAbstract.2519.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_IncomeStatementAbstract.2519.12.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.12.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsReportLineDomain.1715.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" xlink:to="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsByReportLineAxis.4617.12.6" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
    <link:loc xlink:label="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.12.6" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable.4618.12.6" xlink:to="loc_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems.1710.12.6" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:title="40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)" xlink:role="http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails" xlink:type="extended">
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryRawMaterials.11426.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryRawMaterials.11426.12.7" order="1.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryWorkInProcess.11427.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryWorkInProcess.11427.12.7" order="2.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryFinishedGoods.11405.12.7" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.7" xlink:to="loc_InventoryFinishedGoods.11405.12.7" order="3.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:label="loc_InventoryDisclosureAbstract.2789.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:type="locator" />
    <link:loc xlink:label="loc_InventoryNet.11417.12.9" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_InventoryNet" xlink:type="locator" />
    <link:presentationArc xlink:from="loc_InventoryDisclosureAbstract.2789.12.9" xlink:to="loc_InventoryNet.11417.12.9" order="5.00000" priority="0" use="optional" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 2 - INVENTORIES</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Inventory at March 31, 2013 and December&nbsp;31, 2012 consisted of the following:</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">March 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2013</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 64%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">2,418</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">2,118</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">341</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">192</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,014</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,729</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,773</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,039</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <font style="COLOR: black">Prior to the FDA&#39;s approval of taliglucerase alfa, manufacturing costs related to taliglucerase alfa were not capitalized; rather, such costs were expensed as research and development expenses</font>. Effective as of the FDA approval of taliglucerase alfa on May 1, 2012, the Company capitalizes all manufacturing costs associated with taliglucerase alfa.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section A<br><br> -Paragraph 9<br><br> -Chapter 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\V9CDU-3)E,%]D9#$Q7S0X-6-?.6)E95\Q-C$U
M,F0R83,T8C@B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/
M3E-/3$E$051%1%]"04Q!3D-%/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]35$%414U%/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$
M7T-/3E-/3$E$051%1%]35$%414U%,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-/3D1%3E-%1%]#3TY33TQ)1$%4141?4U1!5$5-
M13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#3TY$
M14Y3141?0T].4T],241!5$5$7U-4051%344S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^0T].1$5.4T5$7T-/3E-/3$E$051%1%]3
M5$%414U%-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-)1TY)1DE#04Y47T%#0T]53E1)3D=?4$],24-)13PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]22453/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4U1/0TM?5%)!3E-!0U1)
M3TY3/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4TE'
M3DE&24-!3E1?04-#3U5.5$E.1U]03TQ)0TE%,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DE.5D5.5$]224537U1A8FQE<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-)1TY)1DE#04Y4
M7T%#0T]53E1)3D=?4$],24-)13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y)3E9%3E1/4DE%4U]38VAE9'5L95]O9E]);G9E;G0\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y35$]#2U]4
M4D%.4T%#5$E/3E-?1&5T86EL<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^
M#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC
M<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@
M/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E
M/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W
M<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*
M/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@
M;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S9F.34U
M,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R9#)A,S1B.`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\V9CDU-3)E,%]D9#$Q7S0X-6-?.6)E95\Q-C$U
M,F0R83,T8C@O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4$-!
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y
M($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%Y(#`Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#,Q+`T*"0DR
M,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;V-U;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^,C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO
M9"!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^43$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R
M861I;F<@4WEM8F]L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y0
M3%@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/E!23U1!3$E8($))3U1(15)!4$555$E#4RP@24Y#+CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XP,#`Q,#`V,C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N
M9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/D%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T
M;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDS+#4P,RPR-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R
M9#)A,S1B.`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V9CDU-3)E
M,%]D9#$Q7S0X-6-?.6)E95\Q-C$U,F0R83,T8C@O5V]R:W-H965T<R]3:&5E
M=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%4#%!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY#3TY$14Y3140@0T].4T],241!5$5$($)!3$%.0T4@4TA%1513("A54T0@
M)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#55)214Y4($%34T544SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T,2PX-S`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4R+#`S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L92T@5')A9&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-CDX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU-3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8X-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YV96YT;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-S<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PP,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3(L.#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L,3<P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&54Y$4R!)3B!215-0
M14-4($]&($5-4$Q/645%(%))1TA44R!54$].(%)%5$E214U%3E0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S0S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!23U!%4E19
M($%.1"!%455)4$U%3E0L($Y%5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34L-S`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,38L,S$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV.2PY-#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW."PW,C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C
M;W5N=',@<&%Y86)L92!A;F0@86-C<G5A;',Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#<V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,C8W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,#4U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,#4Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M979E;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PU.3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M+#0S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(T+#0P.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#<U-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,3TY'
M(%1%4DT@3$E!0DE,251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-BPY.30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT."PX.#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!I
M;B!C;VYN96-T:6]N('=I=&@@8V]L;&%B;W)A=&EO;B!O<&5R871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT,C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I
M;&ET>2!F;W(@96UP;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`Q-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&QO;F<@=&5R;2!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3$L.#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-38L,S(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+#(R-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R+#`X-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]-
M34E4345.5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0T%0251!3"!$149)0TE%3D-9.CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPR.#,I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPS-3<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@;&EA8FEL:71I97,@;F5T(&]F(&-A<&ET86P@9&5F:6-I96YC>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.2PY-#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<X+#<R-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-F8Y-34R
M93!?9&0Q,5\T.#5C7SEB965?,38Q-3)D,F$S-&(X#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R
M9#)A,S1B."]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4S24%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4
M140@4U1!5$5-14Y44R!/1B!/4$52051)3TY3("A54T0@)"D\8G(^26X@5&AO
M=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S
M<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0T].1$5.4T5$($-/3E-/3$E$051%1"!35$%414U%3E13($]&
M($]015)!5$E/3E,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y2159%3E5%4SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S+#4V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPX-C$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/35!!3EDG4R!32$%2
M12!)3B!#3TQ,04)/4D%424].($%'4D5%345.5#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0T]35"!/1B!2159%3E5%4SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.3<Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,S(P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=23U-3
M(%!23T9)5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY.3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#0P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4D5314%20T@@04Y$($1%5D5,3U!-14Y4($584$5.4T53/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#<U-"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#@T-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@
M+2!G<F%N=',@86YD(')E:6UB=7)S96UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#0S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,#`S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4D5314%20T@@04Y$($1%5D5,
M3U!-14Y4($584$5.4T53+"!.150\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#4L,S(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#8L.#0T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1T5.15)!3"!!3D0@041-24Y)4U12051)
M5D4@15A014Y315,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L
M,3`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-C(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]015)!5$E.1R!,3U-3/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@T+#0R.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V+#`V-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9)3D%.0TE!3"!)3D-/344@
M+2!.150\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DY%5"!,3U-3($9/4B!42$4@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#0L,S(Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H-2PY,#0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.150@3$]34R!015(@4TA!
M4D4@3T8@0T]-34].(%-43T-+("T@0D%324,@04Y$($1)3%54140\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5T5)1TA4
M140@059%4D%'12!.54U"15(@3T8@4TA!4D53($]&($-/34U/3B!35$]#2R!5
M4T5$($E.($-/35!55$E.1R!,3U-3(%!%4B!32$%212U"05-)0R!!3D0@1$E,
M551%1#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3(L,3@T+#(R
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@W+#@R,2PP-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R9#)A,S1B.`T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V9CDU-3)E,%]D9#$Q7S0X
M-6-?.6)E95\Q-C$U,F0R83,T8C@O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%,4Y!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#3TY$14Y3
M140@0T].4T],241!5$5$(%-4051%345.5%,@3T8@3U!%4D%424].4R`H4&%R
M96YT:&5T:6-A;"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O
M=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@17AP96YS92!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N
M+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@.#<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@061M:6YI
M<W1R871I=F4@17AP96YS92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA<F4M
M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ960@
M4&5R:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#DW/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-F8Y-34R
M93!?9&0Q,5\T.#5C7SEB965?,38Q-3)D,F$S-&(X#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R
M9#)A,S1B."]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T1D)'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4
M140@4U1!5$5-14Y4($]&($-(04Y'15,@24X@0T%0251!3"!$149)0TE%3D-9
M("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,L,S4W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C8L,#<W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G
M:6YN:6YG($)A;&%N8V4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDS+#0X.2PX,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-2PV,S`L,34W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@:7-S=65D(&9O<B!C87-H("AN970@;V8@:7-S=6%N8V4@8V]S=',I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PS.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:R!I<W-U960@9F]R(&-A<V@@*&YE="!O9B!I<W-U86YC92!C;W-T<RD@
M*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M,3<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@=&\@
M<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T;R!R
M97-T<FEC=&5D('-T;V-K(&%W87)D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O
M(&5M<&QO>65E<R!A;F0@;F]N+65M<&QO>65E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!O<'1I;VYS(&=R86YT
M960@=&\@96UP;&]Y965S(&%N9"!N;VXM96UP;&]Y965S("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPT,C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!,;W-S(&9O<B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@T+#,R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@U+#DP-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"86QA;F-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#(X,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#0U-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!"86QA;F-E("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY,RPU,#(L,C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.3`L.#(R+#(U,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN
M;FEN9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"96=I;FYI;F<@0F%L86YC92`H:6X@<VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3,L-#@Y+#@P.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U+#8S,"PQ-3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:R!I<W-U960@9F]R(&-A<V@@*&YE="!O9B!I<W-U86YC92!C
M;W-T<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:R!I<W-U960@9F]R(&-A<V@@*&YE="!O9B!I<W-U86YC92!C;W-T
M<RD@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,3<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N(')E;&%T960@
M=&\@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!C;VUP
M96YS871I;VX@<F5L871E9"!T;R!R97-T<FEC=&5D('-T;V-K(&%W87)D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@86YD(&YO
M;BUE;7!L;WEE97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F(&]P=&EO;G,@9W)A;G1E9"!T;R!E
M;7!L;WEE97,@86YD(&YO;BUE;7!L;WEE97,@*&EN('-H87)E<RD\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#0R,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W+#`Y-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO
M<W,@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!"
M86QA;F-E("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XY,RPU,#(L,C,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.3`L.#(R+#(U,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!086ED+6EN
M($-A<&ET86P@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0F5G:6YN:6YG($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X,"PQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-#4L.#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D
M(&9O<B!C87-H("AN970@;V8@:7-S=6%N8V4@8V]S=',I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR-2PS.#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E+6)A<V5D(&-O;7!E
M;G-A=&EO;B!R96QA=&5D('1O('-T;V-K(&]P=&EO;G,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,T-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N
M<V%T:6]N(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!A=V%R9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP,C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F
M(&]P=&EO;G,@9W)A;G1E9"!T;R!E;7!L;WEE97,@86YD(&YO;BUE;7!L;WEE
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO
M<W,@9F]R('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD:6YG($)A;&%N8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,2PU,SD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S$L,S,S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-U;75L871E9"!$969I8VET(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D)E9VEN;FEN9R!"86QA;F-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.#,L-3DU*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W,2PY-S<I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM
M;VX@<W1O8VL@:7-S=65D(&9O<B!C87-H("AN970@;V8@:7-S=6%N8V4@8V]S
M=',I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O('-T;V-K
M(&]P=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M<&5N<V%T:6]N
M(')E;&%T960@=&\@<F5S=')I8W1E9"!S=&]C:R!A=V%R9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O
M9B!O<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S(&%N9"!N;VXM96UP;&]Y
M965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S(&9O<B!T:&4@<&5R:6]D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#,R,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#DP-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!"86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$X
M-RPY,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q-S<L.#@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-F8Y-34R93!?9&0Q,5\T.#5C7SEB965?,38Q-3)D,F$S
M-&(X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S9F.34U,F4P7V1D
M,3%?-#@U8U\Y8F5E7S$V,34R9#)A,S1B."]7;W)K<VAE971S+U-H965T,#8N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5.14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-/
M3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y4($]&($-(04Y'15,@24X@
M0T%0251!3"!$149)0TE%3D-9("A087)E;G1H971I8V%L*2`H55-$("0I/&)R
M/DEN(%1H;W5S86YD<RP@97AC97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-/3D1%3E-%1"!#3TY33TQ)1$%4140@4U1!5$5-14Y4
M($]&($-(04Y'15,@24X@0T%0251!3"!$149)0TE%3D-9(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K(&ES<W5E9"!F;W(@8V%S:"P@:7-S=6%N8V4@8V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PW.#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3
M=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K+"!!=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14%(04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0T].1$5.4T5$($-/
M3E-/3$E$051%1"!35$%414U%3E13($]&($-!4T@@1DQ/5U,@*%531"`D*3QB
M<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!
M4T@@1DQ/5U,@1E)/32!/4$52051)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-"PS,C$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@U+#DP-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^061J=7-T;65N=',@<F5Q=6ER960@=&\@<F5C;VYC:6QE(&YE
M="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PS-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@=W)I=&4@
M9&]W;B!O9B!F:7AE9"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDS,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1FEN86YC:6%L(&EN8V]M92P@;F5T("AM86EN;'D@
M97AC:&%N9V4@9&EF9F5R96YC97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V5S(&EN(&%C8W)U960@;&EA8FEL:71Y
M(&9O<B!E;7!L;WEE92!R:6=H=',@=7!O;B!R971I<F5M96YT/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN(&]N(&%M;W5N=',@
M9G5N9&5D(&EN(')E<W!E8W0@;V8@96UP;&]Y964@<FEG:'1S('5P;VX@<F5T
M:7)E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3DI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L:6%B
M:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5C<F5A<V4@:6X@9&5F97)R960@<F5V96YU97,@*&EN8VQU9&EN
M9R!N;VXM8W5R<F5N="!P;W)T:6]N*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,BPW-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPT,#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96-R96%S92`H:6YC<F5A<V4I(&EN
M(&%C8V]U;G1S(')E8V5I=F%B;&4@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8W)E87-E("AI
M;F-R96%S92D@:6X@:6YV96YT;W)I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$L-S,T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$96-R96%S92!I;B!A8V-O=6YT<R!P87EA
M8FQE(&%N9"!A8V-R=6%L<R`H:6YC;'5D:6YG(&QO;F<@=&5R;2`I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#`P-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-#(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A
M<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.2PU.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPR.#$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-!4T@@
M1DQ/5U,@1E)/32!)3E9%4U1)3D<@04-4259)5$E%4SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O
M<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C0R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#@Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W5N=',@9G5N9&5D(&EN(')E<W!E8W0@;V8@
M96UP;&]Y964@<FEG:'1S('5P;VX@<F5T:7)E;65N="P@;F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!U<V5D
M(&EN(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@V.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.#4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@
M1DE.04Y#24Y'($%#5$E6251)15,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('-H87)E<RP@;F5T(&]F
M(&ES<W5A;F-E(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(U+#4S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@8V%S:"!P<F]V:61E9"!B>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-3<T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%1D9%0U0@3T8@15A#2$%.1T4@4D%412!#2$%.1T53($].($-!4T@\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!)3D-2
M14%312`H1$5#4D5!4T4I($E.($-!4T@@04Y$($-!4T@@15%5259!3$5.5%,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#$V-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PV,#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)!3$%.0T4@3T8@0T%32"!!3D0@0T%32"!%455)5D%,14Y44R!!5"!"14=)
M3DY)3D<@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,BPP,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-RPP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)!3$%.0T4@3T8@0T%32"!!3D0@0T%32"!%455)
M5D%,14Y44R!!5"!%3D0@3T8@4$5224]$/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,2PX-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-2PV,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%2
M62!)3D9/4DU!5$E/3B!/3B!)3E9%4U1)3D<@04Y$($9)3D%.0TE.1R!!0U1)
M5DE42453($Y/5"!)3E9/3%9)3D<@0T%32"!&3$]74SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<')O
M<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!C;W-T(&YO="!Y970@<&%I9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!O9B!O
M<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY324=.249)0T%.
M5"!!0T-/54Y424Y'(%!/3$E#2453(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TE'3DE&24-!3E0@04-#
M3U5.5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,
M(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O
M>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^/&1I=CX@
M/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`\<W1R;VYG/DY/5$4@,2`M(%-)1TY)1DE#04Y4($%#0T]53E1)
M3D<@4$],24-)15,\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@
M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^(#QS=')O;F<^)FYB<W`[/"]S=')O;F<^/"]P/B`\=&%B;&4@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@
M<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=7
M24142#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@
M,"XR-6EN)SX\<W1R;VYG/F$N/"]S=')O;F<^/"]T9#X@/'1D/CQS=')O;F<^
M1V5N97)A;#PO<W1R;VYG/CPO=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,"XU:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@/'-T<F]N9SXF;F)S<#L\+W-T<F]N9SX\+W`^(#QT86)L92!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U143TTZ(#!P="<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^(#QT<B!S='EL
M93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@/'1D('-T>6QE/3-$)U=)1%1(
M.B`P+C<U:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=724142#H@,"XR
M-6EN)SX\<W1R;VYG/C$N/"]S=')O;F<^/"]T9#X@/'1D/CQS=')O;F<^3W!E
M<F%T:6]N/"]S=')O;F<^/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@/'-T<F]N9SXF;F)S<#L\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
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M("@B4')O0V5L;$5X(BDN($EN(%-E<'1E;6)E<B`R,#`Y+"!0<F]T86QI>"!,
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M(")3=6)S:61I87)I97,N(CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@3VX@36%Y(#$L(#(P,3(L('1H92!5+E,N($9O;V0@86YD
M($1R=6<@061M:6YI<W1R871I;VX@*")&1$$B*2!A<'!R;W9E9"!T86QI9VQU
M8V5R87-E(&%L9F$@9F]R(&EN:F5C=&EO;BP@=&AE($-O;7!A;GDF(S,Y.W,@
M9FER<W0@87!P<F]V960@9')U9R!P<F]D=6-T+"!A<R!A;B!E;GIY;64@<F5P
M;&%C96UE;G0@=&AE<F%P>2`H15)4*2!F;W(@=&AE(&QO;F<M=&5R;2!T<F5A
M=&UE;G0@;V8@861U;'0@<&%T:65N=',@=VET:"!A(&-O;F9I<FUE9"!D:6%G
M;F]S:7,@;V8@='EP92`Q($=A=6-H97(@9&ES96%S92X@5&%L:6=L=6-E<F%S
M92!A;&9A(&ES(&$@<')O<')I971A<GDL(')E8V]M8FEN86YT(&9O<FT@;V8@
M9VQU8V]C97)E8G)O<VED87-E("A'0T0I('1H870@=&AE($-O;7!A;GD@9&5V
M96QO<&5D('5S:6YG(%!R;T-E;&Q%>"X@5&%L:6=L=6-E<F%S92!A;&9A('=A
M<R!A;'-O(&%P<')O=F5D(&)Y('1H92!)<W)A96QI($UI;FES=')Y(&]F($AE
M86QT:"`H=&AE("))<W)A96QI($U/2"(I(&EN(%-E<'1E;6)E<B`R,#$R+"!B
M>2!T:&4@0G)A>FEL:6%N($UI;FES=')Y(&]F($AE86QT:"!I;B!-87)C:"`R
M,#$S(&%N9"!B>2!T:&4@87!P;&EC86)L92!R96=U;&%T;W)Y(&%U=&AO<FET
M:65S(&]F(&-E<G1A:6X@;W1H97(@8V]U;G1R:65S+B!486QI9VQU8V5R87-E
M(&%L9F$@:7,@=&AE(&9I<G-T('!L86YT(&-E;&PM8F%S960@<F5C;VUB:6YA
M;G0@=&AE<F%P975T:6,@<')O=&5I;B!A<'!R;W9E9"!B>2!E86-H(&]F('1H
M92!&1$$@86YD('1H92!)<W)A96QI($U/2"X\+W`^(#QP('-T>6QE/3-$)TU!
M4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-
M05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^(%1A;&EG;'5C97)A<V4@86QF82!I<R!B
M96EN9R!M87)K971E9"!I;B!T:&4@56YI=&5D(%-T871E<R!U;F1E<B!T:&4@
M8G)A;F0@;F%M92!%3$5,65-/)G1R861E.R!B>2!09FEZ97(@26YC+B`H/&9O
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M<F]T86QI>"!,=&0N(&%N9"!09FEZ97(@*'1H92`\9F]N="!S='EL93TS1"=4
M15A4+51204Y31D]233H@=7!P97)C87-E)SXB/"]F;VYT/E!F:7IE<B!!9W)E
M96UE;G0\9F]N="!S='EL93TS1"=415A4+51204Y31D]233H@=7!P97)C87-E
M)SXB/"]F;VYT/BDN(%1H92!#;VUP86YY+"!T:')O=6=H(%!R;W1A;&EX($QT
M9"XL(&UA<FME=',@14Q%3%E33R!I;B!)<W)A96PN/"]P/B`\<"!S='EL93TS
M1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@
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M+C`@;6EL;&EO;B!C;&EN:6-A;"!D979E;&]P;65N="UR96QA=&5D(&UI;&5S
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M<F%S92!A;&9A(&]N(&$@-#`E(&%N9"`V,"4@8F%S:7,L(')E<W!E8W1I=F5L
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M=',@;V8@9V]O9',@<V]L9#PO9F]N=#XN/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B!);B!$96-E;6)E<B`R,#$R+"!0<F]T86QI
M>"!,=&0N(&5N=&5R960@:6YT;R!A($-L:6YI8V%L($1E=F5L;W!M96YT($%G
M<F5E;65N="!W:71H(%!F:7IE<B!U;F1E<B!W:&EC:"!0<F]T86QI>"!,=&0N
M('=I;&P@8V]N=&EN=64@=&\@;6%N86=E+"!A9&UI;FES=&5R(&%N9"!S<&]N
M<V]R(&-U<G)E;G0L(&]N9V]I;F<@8VQI;FEC86P@=')I86QS(')E;&%T:6YG
M('1O('1A;&EG;'5C97)A<V4@86QF82X@06-C;W)D:6YG('1O('1H92!T97)M
M<R!O9B!T:&4@86=R965M96YT+"!0<F]T86QI>"!,=&0N('=A<R!E;&EG:6)L
M92!T;R!R96-E:79E(&$@<&%Y;65N="!O9B`D."XS(&UI;&QI;VX@=7!O;B!T
M:&4@86-H:65V96UE;G0@;V8@8V5R=&%I;B!N96%R+71E<FT@8VQI;FEC86P@
M9&5V96QO<&UE;G0@9V]A;',N(%1H92!G;V%L<R!W97)E(&%C:&EE=F5D+"!A
M;F0@=&AE('!A>6UE;G0@;6%D92P@:6X@1&5C96UB97(@,C`Q,BX\+W`^(#QP
M('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T
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M9FEL960@:6X@82!N=6UB97(@;V8@8V]U;G1R:65S+CPO<#X@/'`@<W1Y;&4]
M,T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE
M/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
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M97,@;V8@87!P<F]V960@=')E871M96YT<RX@3VX@2G5L>2`Q,RP@,C`Q,"P@
M=&AE($-O;7!A;GD@86YN;W5N8V5D('1H870@=&AE($9R96YC:"!R96=U;&%T
M;W)Y(&%U=&AO<FET>2!H860@9W)A;G1E9"!A;B!!=71O<FES871I;VX@5&5M
M<&]R86ER92!D)B,S.3M5=&EL:7-A=&EO;B`H0515*2P@;W(@5&5M<&]R87)Y
M($%U=&AO<FEZ871I;VX@9F]R(%5S92P@9F]R('1A;&EG;'5C97)A<V4@86QF
M82!F;W(@=&AE('1R96%T;65N="!O9B!'875C:&5R(&1I<V5A<V4N($%N($%4
M52!I<R!T:&4@<F5G=6QA=&]R>2!M96-H86YI<VT@=7-E9"!B>2!T:&4@1G)E
M;F-H($AE86QT:"!0<F]D=6-T<R!A;F0@4V%F971Y($%G96YC>2!T;R!M86ME
M(&YO;BUA<'!R;W9E9"!D<G5G<R!A=F%I;&%B;&4@=&\@<&%T:65N=',@:6X@
M1G)A;F-E('=H96X@82!G96YU:6YE('!U8FQI8R!H96%L=&@@;F5E9"!E>&ES
M=',N(%1H:7,@0515(&%L;&]W<R!'875C:&5R('!A=&EE;G1S(&EN($9R86YC
M92!T;R!R96-E:79E('1R96%T;65N="!W:71H('1A;&EG;'5C97)A<V4@86QF
M82!B969O<F4@;6%R:V5T:6YG(&%U=&AO<FEZ871I;VX@9F]R('1H92!P<F]D
M=6-T(&ES(&=R86YT960@:6X@=&AE($5U<F]P96%N(%5N:6]N+B!087EM96YT
M(&9O<B!T86QI9VQU8V5R87-E(&%L9F$@:&%S(&)E96X@<V5C=7)E9"!T:')O
M=6=H(&=O=F5R;FUE;G0@86QL;V-A=&EO;G,@=&\@:&]S<&ET86QS+B!);B!A
M9&1I=&EO;BP@=&%L:6=L=6-E<F%S92!A;&9A(&ES(&-U<G)E;G1L>2!B96EN
M9R!P<F]V:61E9"!T;R!'875C:&5R('!A=&EE;G1S('5N9&5R('-P96-I86P@
M86-C97-S(&%G<F5E;65N=',@;W(@;F%M960@<&%T:65N="!P<F]V:7-I;VYS
M(&EN($)R87II;"!A;F0@:6X@;W1H97(@8V]U;G1R:65S+CPO<#X@/'`@<W1Y
M;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T
M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@26X@861D:71I;VX@=&\@
M=&%L:6=L=6-E<F%S92!A;&9A+"!T:&4@0V]M<&%N>2!I<R!W;W)K:6YG(&]N
M('1H92!D979E;&]P;65N="!O9B!C97)T86EN(&]T:&5R('!R;V1U8W1S('5S
M:6YG(%!R;T-E;&Q%>"X\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!-05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#
M04PM04Q)1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XW-6EN)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/'-T<F]N
M9SXR+CPO<W1R;VYG/CPO=&0^(#QT9#Y,:7%U:61I='D@86YD($9I;F%N8VEA
M;"!297-O=7)C97,\+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3`N,C5I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[
M($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F
M;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@
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M;65N="P@=&AE($-O;7!A;GD@<F5C96EV960@82`D,C4N,"!M:6QL:6]N(&UI
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M92!D979E;&]P;65N=&%L('!E<FEO9',N/"]P/B`\<"!S='EL93TS1"=-05)'
M24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
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M97-E(&%C=&EV:71I97,N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
M<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM
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M8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/33H@,'!T
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\=&0@<W1Y
M;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5TE$5$@Z(#`N,C5I;B<^/'-T<F]N9SYB+CPO<W1R;VYG/CPO=&0^(#QT9#X\
M<W1R;VYG/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO<W1R;VYG/CPO=&0^(#PO
M='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,"XR-6EN
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^)FYB<W`[/"]S
M=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
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M;"!Y96%R+CPO<#X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$
M)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@5&AE<V4@=6YA=61I=&5D(&-O
M;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@<VAO
M=6QD(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@875D:71E9"!C
M;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@:6X@=&AE($%N;G5A
M;"!297!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E
M;6)E<B`S,2P@,C`Q,BP@9FEL960@8GD@=&AE($-O;7!A;GD@=VET:"!T:&4@
M4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;BX@5&AE(&-O;7!A
M<F%T:79E(&)A;&%N8V4@<VAE970@870@1&5C96UB97(@,S$L(#(P,3(@:&%S
M(&)E96X@9&5R:79E9"!F<F]M('1H92!A=61I=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(&%T('1H870@9&%T92X\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`P:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P
M/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-
M.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT
M9"!S='EL93TS1"=724142#H@,"XU:6XG/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=724142#H@,"XR-6EN)SX\<W1R;VYG/F,N/"]S=')O;F<^/"]T9#X@
M/'1D/CQS=')O;F<^3F5T(&QO<W,@<&5R('-H87)E/"]S=')O;F<^/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/B9N8G-P.SPO<W1R
M;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE.
M.B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B!"87-I8R!A;F0@9&EL=71E9"!L;W-S('!E
M<B!S:&%R92`H(DQ04R(I(&%R92!C;VUP=71E9"!B>2!D:79I9&EN9R!N970@
M;&]S<R!B>2!T:&4@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@<VAA<F5S
M(&]F('1H92!#;VUP86YY)B,S.3MS($-O;6UO;B!3=&]C:RP@<&%R('9A;'5E
M("0P+C`P,2!P97(@<VAA<F4@*'1H92`B0V]M;6]N(%-T;V-K(BD@;W5T<W1A
M;F1I;F<@9F]R(&5A8V@@<&5R:6]D+CPO<#X@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&
M3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@1&EL
M=71E9"!,4%,@9&]E<R!N;W0@:6YC;'5D92`W+#,W,RPW-C@@86YD(#<L-#<Q
M+#4W,2`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/G-H87)E<R!O9B!#
M;VUM;VX@4W1O8VL@=6YD97)L>6EN9R!O=71S=&%N9&EN9R!O<'1I;VYS(&%N
M9"!R97-T<FEC=&5D('-H87)E<R!O9B!#;VUM;VX@4W1O8VL\+V9O;G0^(&9O
M<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R
M,#$S+"!R97-P96-T:79E;'DL(&)E8V%U<V4@=&AE(&5F9F5C="!W;W5L9"!B
M92!A;G1I+61I;'5T:79E+CPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-F8Y-34R93!?9&0Q,5\T.#5C7SEB965?,38Q-3)D,F$S-&(X#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S9F.34U,F4P7V1D,3%?-#@U8U\Y
M8F5E7S$V,34R9#)A,S1B."]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY)3E9%3E1/4DE%4SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DE.5D5.5$]22453(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^24Y614Y43U))15,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@4%5"3$E#("(M
M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%3B(@(FAT='`Z
M+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R86YS:71I;VYA
M;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE;G0M+3X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SY.3U1%(#(@+2!)3E9%
M3E1/4DE%4SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M(#!I;CL@34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/B9N8G-P
M.SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@
M34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B!);G9E;G1O<GD@870@36%R8V@@
M,S$L(#(P,3,@86YD($1E8V5M8F5R)FYB<W`[,S$L(#(P,3(@8V]N<VES=&5D
M(&]F('1H92!F;VQL;W=I;F<Z/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)U=)
M1%1(.B`X,"4[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494
M.B`P+C<U:6XG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT
M<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D(&YO=W)A
M<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'
M2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y
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M,B!N;W=R87`],T1N;W=R87`^1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[
M/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P
M/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P
M/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,7!T('-O;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4
M.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,SPO=&0^
M(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G
M(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N
M=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$
M;F]W<F%P/C(P,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB
M<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W
M<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,7!T)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^
M*%4N4RX@9&]L;&%R<R!I;B!T:&]U<V%N9',I/"]T9#X@/'1D('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\
M+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B
M*#(P-"PR-34L,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@-C0E)SY287<@;6%T
M97)I86QS/"]T9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^
M)#PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z
M(#$U)2<^,BPT,3@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@5TE$5$@Z(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
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M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/C,T,3PO=&0^(#QT9"!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[
M/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3DR/"]T9#X@
M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO
M='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U
M-2PR,#0I.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/D9I;FES
M:&5D(&=O;V1S/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q
M<'0G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`Q<'0@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<^(#,L,#$T/"]T9#X@/'1D('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T
M('-O;&ED.R!415A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!
M3$E'3CH@<FEG:'0G/B`Q+#<R.3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\
M+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SY4;W1A;"!I;G9E;G1O
M<GD\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX@-2PW-S,\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX@-"PP,SD\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@
M,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@
M,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B`\9F]N="!S='EL93TS1"=#3TQ/4CH@8FQA8VLG/E!R
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M/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-43T-+(%1204Y304-424].4SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-43T-+(%1204Y3
M04-424].4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-43T-+(%1204Y304-424].4SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\
M<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/DY/5$4@,R`M(%-4
M3T-+(%1204Y304-424].4SPO<W1R;VYG/CPO<#X@/'`@<W1Y;&4],T0G34%2
M1TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`\<W1R;VYG/B9N8G-P.SPO<W1R;VYG
M/CPO<#X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P
M<'0@,'!X(#!P="`P+C5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^($1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H(#,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!I<W-U960@82!T;W1A;"!O
M9B`Q,BPT,C$@<VAA<F5S(&]F($-O;6UO;B!3=&]C:R!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE(&5X97)C:7-E(&]F(&$@=&]T86P@;V8@,3(L-#(Q(&]P=&EO
M;G,@8GD@8V5R=&%I;B!E;7!L;WEE97,@;V8@=&AE($-O;7!A;GDN(%1H92!A
M9V=R96=A=&4@<')O8V5E9',@:6X@8V]N;F5C=&EO;B!W:71H('-U8V@@97AE
M<F-I<V5S('1O=&%L960@87!P<F]X:6UA=&5L>2`D,C@L,#`P+CPO<#X@/"$M
M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-F8Y-34R93!?9&0Q,5\T.#5C7SEB
M965?,38Q-3)D,F$S-&(X#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R9#)A,S1B."]7;W)K<VAE
M971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+2#X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453("A0;VQI
M8WDI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4TE'3DE&24-!3E0@04-#3U5.5$E.1R!03TQ)0TE%4R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=E;F5R86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$
M3T-465!%(&AT;6P@4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A
M;G-I=&EO;F%L+R]%3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$
M5$0O>&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M
M+5-T87)T1G)A9VUE;G0M+3X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#!P=#L@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@34%21TE.+4)/5%1/33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,
M+4%,24=..B!T;W`G/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-6EN)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/'-T<F]N9SYA
M+CPO<W1R;VYG/CPO=&0^(#QT9#X\<W1R;VYG/D=E;F5R86P\+W-T<F]N9SX\
M+W1D/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3`N-6EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^)FYB<W`[
M/"]S=')O;F<^/"]P/B`\=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-
M05)'24XM0D]45$]-.B`P<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)
M1TXZ('1O<"<^(#QT9"!S='EL93TS1"=724142#H@,"XW-6EN)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#`N,C5I;B<^/'-T<F]N9SXQ+CPO
M<W1R;VYG/CPO=&0^(#QT9#X\<W1R;VYG/D]P97)A=&EO;CPO<W1R;VYG/CPO
M=&0^(#PO='(^(#PO=&%B;&4^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,"XR-6EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^)FYB<W`[
M/"]S=')O;F<^/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^(%!R;W1A;&EX($)I;U1H97)A<&5U=&EC<RP@26YC+B`H8V]L;&5C=&EV
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M86YY)B,S.3MS('!R;W!R:65T87)Y(%!R;T-E;&Q%>#QS=7`^)G)E9SL\+W-U
M<#X@<')O=&5I;B!E>'!R97-S:6]N('-Y<W1E;2`H(E!R;T-E;&Q%>"(I+B!)
M;B!397!T96UB97(@,C`P.2P@4')O=&%L:7@@3'1D+B!F;W)M960@86YO=&AE
M<B!W:&]L;'DM;W=N960@<W5B<VED:6%R>2!U;F1E<B!T:&4@;&%W<R!O9B!T
M:&4@3F5T:&5R;&%N9',L(%!R;W1A;&EX($(N5BXL(&EN(&-O;FYE8W1I;VX@
M=VET:"!T:&4@175R;W!E86X@365D:6-I;F5S($%G96YC>2`H(D5-02(I(&%P
M<&QI8V%T:6]N('!R;V-E<W,@:6X@=&AE($5U<F]P96%N(%5N:6]N+B!4:&4@
M0V]M<&%N>28C,SD[<R!T=V\@<W5B<VED:6%R:65S(&%R92!R969E<G)E9"!T
M;R!C;VQL96-T:79E;'D@:&5R96EN(&%S('1H92`B4W5B<VED:6%R:65S+B(\
M+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[
M/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^($]N($UA
M>2`Q+"`R,#$R+"!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T
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M92`H1T-$*2!T:&%T('1H92!#;VUP86YY(&1E=F5L;W!E9"!U<VEN9R!0<F]#
M96QL17@N(%1A;&EG;'5C97)A<V4@86QF82!W87,@86QS;R!A<'!R;W9E9"!B
M>2!T:&4@27-R865L:2!-:6YI<W1R>2!O9B!(96%L=&@@*'1H92`B27-R865L
M:2!-3T@B*2!I;B!397!T96UB97(@,C`Q,BP@8GD@=&AE($)R87II;&EA;B!-
M:6YI<W1R>2!O9B!(96%L=&@@:6X@36%R8V@@,C`Q,R!A;F0@8GD@=&AE(&%P
M<&QI8V%B;&4@<F5G=6QA=&]R>2!A=71H;W)I=&EE<R!O9B!C97)T86EN(&]T
M:&5R(&-O=6YT<FEE<RX@5&%L:6=L=6-E<F%S92!A;&9A(&ES('1H92!F:7)S
M="!P;&%N="!C96QL+6)A<V5D(')E8V]M8FEN86YT('1H97)A<&5U=&EC('!R
M;W1E:6X@87!P<F]V960@8GD@96%C:"!O9B!T:&4@1D1!(&%N9"!T:&4@27-R
M865L:2!-3T@N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^("9N8G-P.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P
M="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
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M4T\@:6X@27-R865L+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X
M(#!P="`Q:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@4')O=&%L:7@@3'1D+B!G<F%N=&5D(%!F:7IE<B!A;B!E>&-L
M=7-I=F4L('=O<FQD=VED92!L:6-E;G-E('1O(&1E=F5L;W`@86YD(&-O;6UE
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M;65N="!O9B`D-C`N,"!M:6QL:6]N(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@
M97AE8W5T:6]N(&]F('1H92!09FEZ97(@06=R965M96YT(&%N9"!S:&]R=&QY
M('1H97)E869T97(@86X@861D:71I;VYA;"`D-2XP(&UI;&QI;VX@8VQI;FEC
M86P@9&5V96QO<&UE;G0M<F5L871E9"!M:6QE<W1O;F4@<&%Y;65N="X@5&AE
M($-O;7!A;GD@<F5C96EV960@86X@861D:71I;VYA;"`D,C4N,"!M:6QL:6]N
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M)2!A;F0@-C`E(&)A<VES+"!R97-P96-T:79E;'DL(&5X8V5P="!W:71H(')E
M<W!E8W0@=&\@=&AE('!R;V9I=',@;W(@;&]S<V5S(')E;&%T960@=&\@8V]M
M;65R8VEA;&EZ871I;VX@969F;W)T<R!I;B!)<W)A96PL('=H97)E('1H92!#
M;VUP86YY(')E=&%I;F5D(&5X8VQU<VEV92!M87)K971I;F<@<FEG:'1S+B`\
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M+V9O;G0^+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SX@26X@1&5C96UB97(@,C`Q,BP@4')O=&%L:7@@3'1D+B!E;G1E<F5D(&EN
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M9&4L(&EN($1E8V5M8F5R(#(P,3(N/"]P/B`\<"!S='EL93TS1"=-05)'24XZ
M(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL
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M(&]F(&-O=6YT<FEE<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P
M>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P
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M96%T;65N=',N($]N($IU;'D@,3,L(#(P,3`L('1H92!#;VUP86YY(&%N;F]U
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M(&]T:&5R(&-O=6YT<FEE<RX\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T
M(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P
M="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^($EN(&%D9&ET:6]N('1O('1A;&EG;'5C97)A<V4@86QF
M82P@=&AE($-O;7!A;GD@:7,@=V]R:VEN9R!O;B!T:&4@9&5V96QO<&UE;G0@
M;V8@8V5R=&%I;B!O=&AE<B!P<F]D=6-T<R!U<VEN9R!0<F]#96QL17@N/"]P
M/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO
M<#X@/'1A8FQE('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@34%21TE.+4)/5%1/
M33H@,'!T)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H
M/3-$,3`P)3X@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/B`\
M=&0@<W1Y;&4],T0G5TE$5$@Z(#`N-S5I;B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`P+C(U:6XG/CQS=')O;F<^,BX\+W-T<F]N9SX\+W1D
M/B`\=&0^3&EQ=6ED:71Y(&%N9"!&:6YA;F-I86P@4F5S;W5R8V5S/"]T9#X@
M/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TP+C(U
M:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@)FYB<W`[/"]P/B`\<"!S='EL
M93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#%I;CL@1D].5#H@,3!P="!4:6UE
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M(')E8V5I=F5D(&$@)#(U+C`@;6EL;&EO;B!M:6QE<W1O;F4@<&%Y;65N="!I
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M97)I;V1S+CPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q
M:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B`F;F)S<#L\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>"`P<'0@
M,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
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M<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`Q:6X[($9/3E0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B`F;F)S<#L\
M+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P:6X[($U!4D=)3CH@,'!T
M(#!P>"`P<'0@,6EN.R!&3TY4.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
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M('1H92!N97AT(#$R(&UO;G1H<RX\+W`^(#PA+2U%;F1&<F%G;65N="TM/CPO
M9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@
M(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T
M<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO
M;F%L+F1T9"(@+2T^/&1I=CX@/&1I=CX\(2TM4W1A<G1&<F%G;65N="TM/B`\
M=&%B;&4@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&3TY4.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!-05)'24XM0D]45$]-.B`P
M<'0G(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/B`\='(@<W1Y;&4],T0G5D525$E#04PM04Q)1TXZ('1O<"<^(#QT9"!S
M='EL93TS1"=724142#H@,"XR-6EN)SX\<W1R;VYG/F(N/"]S=')O;F<^/"]T
M9#X@/'1D/CQS=')O;F<^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]S=')O;F<^
M/"]T9#X@/"]T<CX@/"]T86)L93X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TP+C(U:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX@/'-T<F]N9SXF
M;F)S<#L\+W-T<F]N9SX\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`P
M:6X[($U!4D=)3CH@,'!T(#!P>"`P<'0@,"XW-6EN.R!&3TY4.B`Q,'!T(%1I
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M(&%L;"!A9&IU<W1M96YT<R`H;V8@82!N;W)M86P@<F5C=7)R:6YG(&YA='5R
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M('1H92!F=6QL('EE87(N/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P.SPO<#X@/'`@
M<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P
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M9&5D($1E8V5M8F5R(#,Q+"`R,#$R+"!F:6QE9"!B>2!T:&4@0V]M<&%N>2!W
M:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S:6]N+B!4
M:&4@8V]M<&%R871I=F4@8F%L86YC92!S:&5E="!A="!$96-E;6)E<B`S,2P@
M,C`Q,B!H87,@8F5E;B!D97)I=F5D(&9R;VT@=&AE(&%U9&ET960@9FEN86YC
M:6%L('-T871E;65N=',@870@=&AA="!D871E+CPO<#X@/"$M+45N9$9R86=M
M96YT+2T^/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@<&5R('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5
M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB
M(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N
M<VET:6]N86PN9'1D(B`M+3X\9&EV/B`\9&EV/CPA+2U3=&%R=$9R86=M96YT
M+2T^(#QT86)L92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU"3U14
M3TTZ(#!P="<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#$P,"4^(#QT<B!S='EL93TS1"=615)424-!3"U!3$E'3CH@=&]P)SX@
M/'1D('-T>6QE/3-$)U=)1%1(.B`P+C5I;B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U=)1%1(.B`P+C(U:6XG/CQS=')O;F<^8RX\+W-T<F]N9SX\+W1D
M/B`\=&0^/'-T<F]N9SY.970@;&]S<R!P97(@<VAA<F4\+W-T<F]N9SX\+W1D
M/B`\+W1R/B`\+W1A8FQE/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN
M.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^(#QS=')O;F<^)FYB<W`[/"]S
M=')O;F<^/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@,&EN.R!-05)'
M24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^($)A<VEC(&%N9"!D:6QU=&5D(&QO<W,@
M<&5R('-H87)E("@B3%!3(BD@87)E(&-O;7!U=&5D(&)Y(&1I=FED:6YG(&YE
M="!L;W-S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!S:&%R
M97,@;V8@=&AE($-O;7!A;GDF(S,Y.W,@0V]M;6]N(%-T;V-K+"!P87(@=F%L
M=64@)#`N,#`Q('!E<B!S:&%R92`H=&AE(")#;VUM;VX@4W1O8VLB*2!O=71S
M=&%N9&EN9R!F;W(@96%C:"!P97)I;V0N/"]P/B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@,&EN.R!-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I;CL@1D].
M5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^("9N8G-P
M.SPO<#X@/'`@<W1Y;&4],T0G34%21TE..B`P<'0@,'!X(#!P="`P+C<U:6X[
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M(&)E(&%N=&DM9&EL=71I=F4N/"]P/B`\(2TM16YD1G)A9VUE;G0M+3X\+V1I
M=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DE.5D5.5$]22453
M("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^24Y614Y43U))15,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<GD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CPA+2U$3T-465!%(&AT;6P@
M4%5"3$E#("(M+R]7,T,O+T141"!82%1-3"`Q+C`@5')A;G-I=&EO;F%L+R]%
M3B(@(FAT='`Z+R]W=W<N=S,N;W)G+U12+WAH=&UL,2]$5$0O>&AT;6PQ+71R
M86YS:71I;VYA;"YD=&0B("TM/CQD:78^(#QD:78^/"$M+5-T87)T1G)A9VUE
M;G0M+3X@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z(#!I;CL@34%21TE..B`P
M<'0@,'!X(#!P="`P+C<U:6X[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B!);G9E;G1O<GD@870@36%R8V@@,S$L(#(P,3,@
M86YD($1E8V5M8F5R)FYB<W`[,S$L(#(P,3(@8V]N<VES=&5D(&]F('1H92!F
M;VQL;W=I;F<Z/"]P/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T
M(#`N-S5I;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^("9N8G-P.SPO<#X@/'1A8FQE('-T>6QE/3-$)U=)1%1(.B`X,"4[
M($)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[($U!4D=)3BU,1494.B`P+C<U:6XG
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^(#QT<B!S='EL93TS
M1"=615)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D(&YO=W)A<#TS1&YO=W)A
M<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U714E'2%0Z(&)O;&0G
M(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS
M1#(@;F]W<F%P/3-$;F]W<F%P/DUA<F-H(#,Q+#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$
M;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!C
M96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C;VQS<&%N/3-$,B!N;W=R87`]
M,T1N;W=R87`^1&5C96UB97(@,S$L/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M5T5)1TA4.B!B;VQD)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W<F%P
M/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T
M.R!&3TY4+5=%24=(5#H@8F]L9"<@;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O
M;&ED.R!415A4+4%,24=..B!C96YT97([($9/3E0M5T5)1TA4.B!B;VQD)R!C
M;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`^,C`Q,SPO=&0^(#QT9"!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,7!T.R!&3TY4+5=%24=(5#H@8F]L9"<@
M;F]W<F%P/3-$;F]W<F%P/B`F;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G4$%$
M1$E.1RU"3U143TTZ(#%P=#L@1D].5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS
M1&YO=W)A<#X@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4
M+5=%24=(5#H@8F]L9"<@8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P/C(P
M,3(\+W1D/B`\=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P=#L@1D].
M5"U714E'2%0Z(&)O;&0G(&YO=W)A<#TS1&YO=W)A<#X@)FYB<W`[/"]T9#X@
M/"]T<CX@/'1R('-T>6QE/3-$)U9%4E1)0T%,+4%,24=..B!B;W1T;VTG/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#%P="<@;F]W<F%P/3-$;F]W
M<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,7!T)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@
M8V5N=&5R)R!C;VQS<&%N/3-$-B!N;W=R87`],T1N;W=R87`^*%4N4RX@9&]L
M;&%R<R!I;B!T:&]U<V%N9',I/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`Q<'0G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@<F=B*#(P-"PR-34L
M,C`T*3L@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^(#QT9"!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!724142#H@-C0E)SY287<@;6%T97)I86QS/"]T
M9#X@/'1D('-T>6QE/3-$)U=)1%1(.B`Q)2<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)#PO=&0^(#QT
M9"!S='EL93TS1"=415A4+4%,24=..B!R:6=H=#L@5TE$5$@Z(#$U)2<^,BPT
M,3@\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
M(#$E)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$E)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@5TE$5$@Z
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M1"=415A4+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/C,T,3PO=&0^(#QT9"!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SXF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^,3DR/"]T9#X@/'1D('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B!R9V(H,C`T+#(U-2PR,#0I.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/D9I;FES:&5D(&=O;V1S
M/"]T9#X@/'1D('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P
M.SPO=&0^(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`Q<'0@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/B`F;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!415A4+4%,
M24=..B!R:6=H="<^(#,L,#$T/"]T9#X@/'1D('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`Q<'0G/B9N8G-P.SPO=&0^(#QT
M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,7!T('-O;&ED.R!4
M15A4+4%,24=..B!L969T)SX@)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U!3$E'3CH@<FEG
M:'0G/B`Q+#<R.3PO=&0^(#QT9"!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@=VAI=&4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VTG/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#(N-7!T)SY4;W1A;"!I;G9E;G1O<GD\+W1D/B`\
M=&0@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U
M8FQE.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(')I9VAT)SX@-2PW-S,\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\=&0@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,BXU<'0@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)SX@)#PO=&0^(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R+C5P="!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX@-"PP,SD\+W1D/B`\=&0@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#(N-7!T)SXF;F)S<#L\+W1D/B`\+W1R/B`\
M+W1A8FQE/B`\<"!S='EL93TS1"=-05)'24XZ(#!P="`P<'@@,'!T(#`N-S5I
M;CL@1D].5#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M("9N8G-P.SPO<#X@/"$M+45N9$9R86=M96YT+2T^/"]D:78^(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-F8Y-34R
M93!?9&0Q,5\T.#5C7SEB965?,38Q-3)D,F$S-&(X#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R
M9#)A,S1B."]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.,T%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-)1TY)1DE#04Y4($%#0T]53E1)
M3D<@4$],24-)15,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@36EL;&EO;G,L
M(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE
M9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^-#`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3,\8G(^4')O=&%L:7@@0FEO(%1H97)A<&5U=&EC<R!);F-O<G!O<F%T:6]N
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^4&9I>F5R($EN8V]R<&]R871I;VX@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`P
M.3QB<CY5<&]N($9I;&EN9R!O9B!0961I871R:6,@26YV97-T:6=A=&EO;B!0
M;&%N('1O($5-02!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$R/&)R/E5P;VX@1D1!($%P<')O=F%L(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^57!O;B!.96%R(%1E<FT@0VQI;FEC86P@1&5V96QO<&UE
M;G0@36EL97-T;VYE<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O=6YT:6YG
M(%!O;&EC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@4W5B<VED:6%R:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y09FEZ97(@06=R965M
M96YT+"!U<&9R;VYT('!A>6UE;G0@<F5C96EV960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!P87EM96YT('1R
M:6=G97)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M."XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y09FEZ97(@06=R965M96YT+"!F=71U<F4@<F5V96YU97,@86YD(&5X
M<&5N<V4@<VAA<FEN9R!P97)C96YT86=E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A
M;'5E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS('1O('!U<F-H87-E(&-O
M;6UO;B!S=&]C:R!N;W0@:6YC;'5D960@:6X@9&EL=71E9"!,4%,@8F5C875S
M92!T:&4@969F96-T('=O=6QD(&)E(&%N=&DM9&EL=71I=F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L-#<Q+#4W,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,S<S+#<V.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-F8Y-34R93!?
M9&0Q,5\T.#5C7SEB965?,38Q-3)D,F$S-&(X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R9#)A
M,S1B."]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V14%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DE.5D5.5$]22453("A38VAE9'5L92!O
M9B!);G9E;G1O<GD@0V]M<&]N96YT<RD@*$1E=&%I;',I("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY)3E9%3E1/4DE%4R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A=R!M871E<FEA;',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPT,3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,3$X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7;W)K
M(&EN('!R;V-E<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1FEN:7-H960@9V]O9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PW,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!I;G9E;G1O<GD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PW-S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L,#,Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-#044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4U1/0TL@5%)!3E-!0U1)3TY3("A$971A:6QS
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V4@;V8@;W!T:6]N<R!G<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N+65M
M<&QO>65E<R`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3(L-#(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<L,#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R;V-E961S(&9R;VT@97AE<F-I
M<V4@;V8@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-E<G1A:6X@16UP;&]Y964@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@;V8@;W!T:6]N<R!G
M<F%N=&5D('1O(&5M<&QO>65E<R!A;F0@;F]N+65M<&QO>65E<R`H:6X@<VAA
M<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L-#(Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H('!R;V-E961S(&9R;VT@97AE<F-I<V4@;V8@;W!T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R."PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&5X97)C:7-E(&]F(&]P=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#0R,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-F8Y-34R93!?
M9&0Q,5\T.#5C7SEB965?,38Q-3)D,F$S-&(X#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S9F.34U,F4P7V1D,3%?-#@U8U\Y8F5E7S$V,34R9#)A
M,S1B."]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\]
M,T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-
M"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$U+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\V9CDU-3)E
A,%]D9#$Q7S0X-6-?.6)E95\Q-C$U,F0R83,T8C@M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES</strong></p> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>a.</strong></td> <td><strong>General</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>1.</strong></td> <td><strong>Operation</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. (<font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer<font style="TEXT-TRANSFORM: uppercase">"</font>), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the <font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer Agreement<font style="TEXT-TRANSFORM: uppercase">"</font>). The Company, through Protalix Ltd., markets ELELYSO in Israel.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive marketing rights. <font style="COLOR: black">In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</font>.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In December 2012, Protalix Ltd. entered into a Clinical Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment made, in December 2012.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>2.</strong></td> <td>Liquidity and Financial Resources</td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>b.</strong></td> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>c.</strong></td> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Diluted LPS does not include 7,373,768 and 7,471,571 <font style="COLOR: black">shares of Common Stock underlying outstanding options and restricted shares of Common Stock</font> for the three months ended March 31, 2012 and 2013, respectively, because the effect would be anti-dilutive.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EP1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 41,870<span></span></td>
        <td class="nump">$ 52,035<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable- Trade</a></td>
        <td class="nump">1,698<span></span></td>
        <td class="nump">1,410<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other assets</a></td>
        <td class="nump">3,553<span></span></td>
        <td class="nump">3,686<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump">5,773<span></span></td>
        <td class="nump">4,039<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">52,894<span></span></td>
        <td class="nump">61,170<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</a></td>
        <td class="nump">1,343<span></span></td>
        <td class="nump">1,247<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
        <td class="nump">15,705<span></span></td>
        <td class="nump">16,310<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">69,942<span></span></td>
        <td class="nump">78,727<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
        <td class="nump">3,762<span></span></td>
        <td class="nump">5,267<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
        <td class="nump">12,055<span></span></td>
        <td class="nump">11,051<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
        <td class="nump">8,591<span></span></td>
        <td class="nump">9,437<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">24,408<span></span></td>
        <td class="nump">25,755<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
        <td class="nump">46,994<span></span></td>
        <td class="nump">48,888<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Liability in connection with collaboration operation</a></td>
        <td class="nump">2,700<span></span></td>
        <td class="nump">5,425<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
        <td class="nump">2,123<span></span></td>
        <td class="nump">2,016<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
        <td class="nump">51,817<span></span></td>
        <td class="nump">56,329<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">76,225<span></span></td>
        <td class="nump">82,084<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">CAPITAL DEFICIENCY:</a></td>
        <td class="num">(6,283)<span></span></td>
        <td class="num">(3,357)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities net of capital deficiency</a></td>
        <td class="nump">$ 69,942<span></span></td>
        <td class="nump">$ 78,727<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableOtherCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableTradeCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for overfunded plans recognized in the balance sheet as a noncurrent asset associated with a defined benefit pension plan or other postretirement defined benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This represents the noncurrent liability recognized in the balance sheet that is associated with the defined benefit pension plans and other postretirement and postemployment benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e1928-114920<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915240&amp;loc=d3e1703-114919<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e2417-114920<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=21915506&amp;loc=d3e2410-114920<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 132R<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ENEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Common stock issued for cash, issuance costs</a></td>
        <td class="nump">$ 1,780<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Authorized</a></td>
        <td class="nump">150,000,000<span></span></td>
        <td class="nump">150,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Direct costs (e.g., legal and accounting fees) associated with issuing stock that is deducted from additional paid in capital. Also includes any direct costs associated with stock issues under a shelf registration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Technical Practice Aid (TPA)<br><br> -Number 4110<br><br> -Paragraph 1, 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (4,321)<span></span></td>
        <td class="num">$ (5,904)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="nump">1,367<span></span></td>
        <td class="nump">129<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DepreciationAmortizationAndAssetImpairment', window );">Depreciation and write down of fixed assets</a></td>
        <td class="nump">926<span></span></td>
        <td class="nump">930<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
        <td class="num">(78)<span></span></td>
        <td class="num">(114)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
        <td class="nump">60<span></span></td>
        <td class="nump">44<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
        <td class="num">(19)<span></span></td>
        <td class="num">(5)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Decrease in deferred revenues (including non-current portion)</a></td>
        <td class="num">(2,740)<span></span></td>
        <td class="num">(2,405)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable and other assets</a></td>
        <td class="num">(42)<span></span></td>
        <td class="nump">1,270<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
        <td class="num">(1,734)<span></span></td>
        <td class="nump">16<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accruals (including long term )</a></td>
        <td class="num">(3,005)<span></span></td>
        <td class="num">(242)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(9,586)<span></span></td>
        <td class="num">(6,281)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(642)<span></span></td>
        <td class="num">(810)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
        <td class="num">(47)<span></span></td>
        <td class="num">(42)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(689)<span></span></td>
        <td class="num">(852)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses', window );">Issuance of shares, net of issuance cost</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">25,538<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">36<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">25,574<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH</a></td>
        <td class="nump">110<span></span></td>
        <td class="nump">163<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num">(10,165)<span></span></td>
        <td class="nump">18,604<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
        <td class="nump">52,035<span></span></td>
        <td class="nump">27,001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
        <td class="nump">41,870<span></span></td>
        <td class="nump">45,605<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">815<span></span></td>
        <td class="nump">829<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SupplementalOfferingAndStockIssuanceCosts', window );">Issuance cost not yet paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CashlessExerciseOfStockOptions', window );">Exercise of options granted to employees</a></td>
        <td class="nump">$ 28<span></span></td>
        <td class="nump">$ 2<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CashlessExerciseOfStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cashless exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CashlessExerciseOfStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DepreciationAmortizationAndAssetImpairment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets and intangible assets to periods that benefit from use of the assets. Also includes the charge against earnings resulting from the write down of assets from their carrying value to their fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DepreciationAmortizationAndAssetImpairment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in liabilities for property, plant and equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of common stock net of expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ProceedsFromIssuanceOfCommonStockNetOfExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalOfferingAndStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Supplemental offering and stock issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SupplementalOfferingAndStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The effect of exchange rate changes on cash balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 25<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate unrealized foreign currency transaction gain (loss) (pretax) included in determining net income for the reporting period. Represents the aggregate of gains (losses) on transactions that are unsettled as of the balance sheet date, which is therefore an adjustment to reconcile income (loss) from continuing operations to net cash provided by or used in continuing operations. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting entity's financial statements. For certain entities, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossUnrealized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3095-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3098-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForProceedsFromOtherInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitContributions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 70<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414718&amp;loc=d3e28014-114942<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 11<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>20
<FILENAME>0001144204-13-027499-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-13-027499-xbrl.zip
M4$L#!!0````(`/.)J4+\LAN-_B@``+:_`0`0`!P`<&QX+3(P,3,P,S,Q+GAM
M;%54"0`#^A&,4?H1C%%U>`L``00E#@``!#D!``#L/6M7VTB6W_><_0_5WID^
MR3G86+;!0#HSZX!)V"&8`=/3_;$LE>WJR))&)0'N7[_WWBJ];!G,PPZ;U4EW
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M2MB-B7^["P\0Y%:]:=4SH&-5GW`>I%/&7(UH9?.@9(I4?J=E=1_"5(\P$]8A
M";")L5\0CR-E3\6,7XDQ([R.HGD`XJ'D+'"1=/3=-!3CCS7@3CUA0N->.36V
MJ]<!5(]Z,^$Y\']TZO()D\['6N&;AK77[+0:S>Q/C=F^%XG[Z`K7'H?^K*Y%
MRL+_(M_\U`9*+$^&Z7\;<U>)7W:77I[!=!R'(7XIE<W=WP4/^YYS`J).X*UZ
MN`%(ZW7@:=O2L*YZ;P;VB6_'LW3(I0BE[YS"=XK@7OET`X#_T\"\\IVK@$:\
M5H&</ML`P/B\#.3TG<L`:VSRDE'Z9$/`ZN=%D`OO709X"`I:@!._V`!X5K/^
MSR)@^*(,GKX7R6A^#-^'W#WS'''_#S$GP$J?;`#"9K-I-9O[K0-#P-+W+@'L
MSV:^=QWY]K?K*0^%&L01.49P>'GH'Q@&T!P>/(`*5W5_7$\=I+4\'F?$GM3#
M%:U?8XZPY0R,VL<:X';8WFNV6_L'!<P>@&D13?#@(CP&`9KX89XKA>\WP).>
M;0MX`P44]*X\`H67+T)\)292`>>\Z(+/1`[DXH,-P'QY-1CVSL]^8Y_.!L,O
M_:O>9?]F>'9\O</.+HX;>02*H&08#$..3+B>ST:^2Z`7OMD$S.>_:<`*+](0
M@:,^.N9JZ@JE^O<BM*42@S')S2"(($;49OGA(:\/<R;Q-]<G>7&OM\$8'H`V
M_[+[..BOC6+[<11;!11;.13;3T+QZ1CZKLM'/FB3O!6]$.1N(LA#A/Y81F0#
MP%G80@?MA/!39A`*S4:K>7#8;$!D^[@U2Q''<27S4O2#.!1Y_"VPUHV.P?XI
M,'X/8EC/)(;U%&+LOX@8)R((83V.`M.;^6$D_]2?/:>GE(C.9@&7(2ZD0X6U
MAV]9[0];^ZE6K`_DMNBP/=MPV&Z^B`Z?T2<I&'$EY&P4AXJ$2%T)6X!<.8-0
M?^(C5ZO&$\9OVQ%TVE9*BB>`N3U:;-5CM%]&BS//#@57XLP[EWPD71E)H4[]
M$,Q+(,)H?NG"HK!F_]^Q#%(U>?*L+<O(`<Q(R/)D6+\/<;8G-`>MP]<@SE>(
MU57D>^*2SU/<%[]L6/NM_;W&P<%^UVIT#O>L1S'L%##<K[>;9HUFZ2HK$=T#
M[4`A2%%=!.TYF'0)AM9:F&AV)9A0@<>LT2Q=Y2%,#MIK(7+!(X@D!N-!@`D6
MAHJ7OBOM^1"@^^1"`$F8/3IJ`]G(SV[TX:=Z_61P//S]LL^PELHN;SZ=GQVS
M6GUW]U_MX]W=D^$)^^W+\.LY`ZHP2%L\)1$\[N[N]B]JK*3<.KS2=5D+)YN/
M]2@WL^%$3HW5ZS]/H@\(@R-O\2/+?3:@74<\C$Y#/D&2Z@DT*B(WH**Y*T`H
M>E>?SR[JP\'E$6L&,.)T<#$\8A9\9D,Y$XI=B#MVY<^XMZ._V&'7(I3C#\Q,
M_308#@=?:3805;BN"KA-9?BF_CG@CI/\?">=:`KA8+/YUUH&4)A`\VO_"K+0
MWGD=<M//%T<L\H/<,"<9]J^SD^$7>&-C3WKT_&<^"SYX(Q40[KN1\]"D5CH+
MGD-JZWL3_(DW:&[VQ?)2RY,^"P]$SGUDYFX4YCXC^=,?@P2\8?^W8?WLXJ2/
MY*\3:@F)B;;P_SW]:^&#=;F442\'79%8"V`'/Z*<=%]34*SG"$IJFC8@*JWO
M+RM!44Y>#,6EV09CGZ0_G`+I`A%'TH9!X-\;[)T-.:2P,8%TYR`LT93)2#$5
MCY1T)`\E+A=-!8.$&%(';UY[O\.XY]"HNRE,GM?].T\XV93Y3O;2\\AIP/A0
ML)'T`TA(9]RF]W,7W`8N""]@8ZRNZYU!?)4C`!A?!TWX*A@XPUH'K*B3&>:/
M&60Y_FPD/8A!<%*"%\-M/R$]Q7!O,%W2`$],^*_VX0>%XP+`#BS[',$]!K7I
MWQ/+XB#E5R@FAEWZRV1U)NXAS5*X9<K47$5BQM[5TE5J[QM`7&!"``]&(F00
MBA\N$`5PABS,`?Q\A'X5*<'S._`447#YG4+$\?.%P$D0?SDJM^ZGQJ]`;(`.
M'+*'/`7HB*,XI1]CV,8]]E4X$JP%D+TW$9X]!\C[7WNU]XP'`;AZ36#`TP;\
M<+'"Y!L/GC;8L)2DT9U?$!SB>RC&(@P!J<AG!5D#!)"27&GQNLY-;-0VK!0+
MRKBY%PV`WGS.K!W<\FYI3;II7#?8J>\[)-PG83QA/6<F/2H.$_7?U4Y/#$="
M_Q9I!_R=N+$-8JX$X^Z8H_P`=_[0;-Y9(>1C&:HH6\;!=^E]^&@'*0\<%=Z?
M$"D"FP(75)-T3JL3"`;XAO?T(I(_L%?U2(0S%N&>/XT$<>1.[$8L`,`QH=3R
MQE$"QY($'%@Z\7PEM>SB]I/%/O/81J%WI,($`^1I&3^8P/-*NE/0>-0>7!`G
M@:2&8A3".QR<_>[S\<E[@)A'>:(D1@4@BA7NUJ3:6OKV.R2.J_R,=J,Y+7>F
M0BY<R;YJ?LT1B"^"NX#U.Y+C=,#@"W!0%LT`BH!9Z%/(_X2<"A5R>2F)8A/:
M4SHH06)B9AD=Q7`";%/L\@AW:'@<3?V0\C-<!!")."RA+8OMQUY$6K6"S+BN
M%I0`,SJ*(.K:>CYB9`O4$1S@-?8)Q)>@+E!L\*7QHZAU.2%'`@5KQL-O`G>P
MC.T$DXD_00X1P;*9/1^%2"$/MZOZY_WSWZ\'!#[8`$=\0()>CN6?,%:[:<1B
M#'E6(7(97O4NKD\'5Q`+Q@&$138>AT$`M?W$\?B37N@E*[Q?96"677,`J1)$
M\F1>4#BDDY%"W-LN:-\M&!-I"P])YZ&W`Z$&(9Z$0ML?P)U$7D1W0G@+?A.?
M&,J0PKV<,.`'S9M?1**"5T1ZA7X\F2Z&0EHZ5,)RI(Q6D!]&-XKLFF#A4:0L
M0X>3",$.N_-#UX$$)9,'"!*,H5Z*_$29%\S4:9&78&CC"`P86D+TH%,?YH1R
M,HU4CNAYGK$I&GV<3\$*9RH0MAR#N>.NZYO`Z%&A!+/,0SH/@%!!D!CXGI))
M^2SUIE@SD5Z,#C(7[8HQ/(_,J"5L`5H@#YB1@C82V*$IY"*!XV`<HA`'IF(%
M-ODO^\U&D\VDZR(.*R)$<2_L.`FORTBJM14\3>22-X(P8!QIIF+"J:LJ["][
MN5?9+C@W#/9S6-9#X=(6_RPI5B6@%MF1QRF_?BO_@J4U5F$'+BEGM[3C@M40
MU1)C7F*Z05RG$EP<A@8V\A0D3TO*2*"P0/P:@:RC=<N`0D8&<1B`\"F=M=P*
MX#HYUHDG=>P&9(6_;-LGN7'!>-QIEL(7B+Y*ISEQF$A60`=]$%(-%GZ7O9?B
M%WLJ89ZCJ9J95V.5U7*,1(=)-,D,[_&I)VC.&#,^0,?U%0*D60C8KYVQE=`9
M'G#6:?Z5)NW#OQ!V2+5#:I,D"CMH,2"&TG"9)\F+%^`2!<B6H4CT*S4`R%1@
M8X$*J<W(W)6VVDAZ;4$:2V[G>'`^N#IB(PBBOY$=A`00Y-[&$"UA60DA"Q$!
MSVP7:1?E3TDP9PQ3#.8$K.6,UM!2RF<8X1EVSB#;&"%#,,:'\5B/!2.,/%/<
M-08H61.R6+2ZRO!,122C$TA-8+3O.@4']\,X*.#,"9B67$A>-.;``-)LZ9$7
M.$Y,V$E.R#.;F-<6S4JMC\4U[\!<I38?91-@XQ,PY-QD?F1&P;JBMT`.Z8.>
M.\#CB8_RDQI2".4A,=%B3H+EEWJ*7F).$DW!S"VM'^0D;0%.L!L0K$\D9A@P
MT]A@3,5RWN2@T4X-,`DDK:G-33(HD3%/\%"GC66^`(0-L-$6BCZR.Q)\8[IV
MTBPB>?T,HF.J<118N&G9S+LEB>;?UT5((&_!6OK,'Q'6F<%(/4VY3T=4<LXM
M3=8(\3_`W"M'VOK`$3.G?]$DYM;7N9\Q<+D:CH+``#@WPFAE#(Z!?`5G7DQ4
M0PZEB>&/HMDY`J4%":H]4F(6F:L*.B18X8PRGZ%]47D6A\Q)(LBSC($/OG;B
M^B,().=I9K`BHUI0='Q5XM-4%#M4D*72*94?\=QQK,@10J@]@V<4M<)\""BP
M@I>J.CS"9--)8-1Q@"))P9?H:D&R#BBIDA-/.U)P$C$Y28P7DN*/QI'?<NER
M8RV2NDY*!8F^"ARF*=CB6RE^!--'MB@K<*6K-K!F]C\QT,EJ4]6L68QVN>>!
MW-H4TIOPY128;D_+"B(8'#MI#@)Q9"^&YU)I91F*6>"'7`(:3LJ!FPA"=3/@
M76]X`ZDO**X9"DOW"OJ&2GVCP"*MT.XDW"^4S);*7ST`;'B3U&)R>,R$/>7@
M'F:,ZN.F"&3P-;6B2UW/TTR\YF,!6)O*+OF9;Q!X^%Z]4`141;[E^74:XB4/
M#(M0'6"=6&)P'8_`KK"I?J4G*#H"MT6F&^!&\#%+NE.E0F`6S3F4C""KU'$D
M@'ABI:5+*&O*F4B\A,\KBM;)#OX*5F$:1<9201I$D;W1TPF0+?1T;)LF@@J1
M@9PRD!$YL((5*#/S*O'I[MP8AK0Z4J8Y.I18J<LHDRNU&?#7U46]4;-<"/Q1
M['V.Z.5Q4-%T``_N_/`;TKYDIVFI<!HDBK58,/Y>Y*NVD<NWD5OK;2.?RW_'
MTD&G@&IQBE5M4JXKH?PX!`5[>SO(WTN1]$[#0Q42-**9:2ZOER0IMC9&.^PK
MN`S;SP4;J46"J"4F$S>.];ZP*_*%J.4H*:^X:<B2;$MGAWP0&<\/9XA&>J()
M[8`C(/-U<#;E+SIJ3_)T]#L0^Q0""D,-3+Q`BDSA1X&2T!M34R$Q=_2XCN;=
MN?8+E(IIKYI4HW0VIM-N3Q->K2J[[2Q4)Y*JV'>KA$'`DI6[T#M1`8(6`,FB
M$@1&IXD'+T1O.K'#O3T769BKB<%W#M`6`UHD;1Q`P!41=3/60>8'02/YX30S
M3)?&[3JL:"`?8`7I@<,MP$GE#B`V>'>UBC@E/$\WPU'FDUVN'->9C;>H'$H,
ML@*=#'-5K+R\XH)4N_MQ_/`@59^2O'>Q;(>\6J(<Z22HE8WA4::<*T]OZ/.H
M%.'29>-DWQI"4V05!NHY3JI(!$7--6DZ6)UI!NG*5*]T+S4G>C8F);C9P!7H
M_<A%!/&4A0;)CR,P:<*H-RH6R@1M!WQ_"2CXK^8K^JY/R?$;U!03^@*A%,F"
M]K=IJ5A&)D'-Z_-(N-I4R$B7S[#,;A*6&<=>`[*X..Y>>PL;*AFI4WL!QECO
MRE!U++5"!>.`F@YFQ@6&)F)U#U1HL9GO15,`%-,@2@X\$&@%V3&9=Y`#A'("
M&N_I]#2!'<6#LJ9<K6<,,3X:$>F'VN)A%1_H"$YCG"L`QYXV:I38Z!/99+TF
M^L`DX<5SYT=N15;7]<D("3I*@.,*>TUF4)'J:+P]D;@W\:T`L`Z9@&JY?8@B
M918%^J=ZO>\YQ:.S-"1_V#;Y01]A?O0(<NY,,]6R!N/\V2%]C+GDP2:O&2Q>
MTL(+V@:;$D@R!`;(YL\@R.I<;P8@\(M?;OE^1"=WG'P1E.=`OKW+"W6KW5X#
M]$MTY\)1I_#V,]!=5-W!.'<_^D)$@W$_T2%$[&E3RAAVK^21)]V/M2B,Q2OS
MS_0=4;*LZTBKV;1V?_MZ?DVM.NI98Y/=;5-DBU>?]O;:V97@IX&:4>7*6,[<
MO@_>=O$F$@PDVC\S!:8329XP?LLJO==N98KQ!#"W1XOMR<;^0:?S,EI<XWDE
MH4/YP7A,XV`6B5(B7\>TF8J46'OTENE`M^`,&=:&41/!M!LZPCU&W'F^Y',,
MS,CBFBT8W<1G]?/TZO,*9%=>E5X?OU9S3U_T6P/<U\7+6@.O]-;7XOA'\;*:
M>]:KX(7-'\0#>.6?;YY?[>Y^ZR&T\M"\+EH;9==>:[_[,K2RF[E@A<KP*ANP
M!?W:/SPH1:P,G-?&;+,:UK&:S\7,^2-6.ID=^KTT<[KDTCGSCCEM%E%;!LJ.
M,><"[T))3G\6N/Y<"+*YEY`>3V'$I:YL7F'A0LE(0'I]*VVA>SQ=94?(--&^
MS[M---+9I]NWW9?$,\MK/&@P.@N*]7WPKP1`AQ[K"<##P<O3!,`R=]4K`7@#
M`K"]9*;2^S?$]BWF*Y6VOQVV@[_O[!TLV.H7E[A*UGS%0M?_=YZUG\FS1UQV
MQ;.-ZIG5;+=?6\]*UJQX]HIZ]CR>/:QG;XAG2550.,O5SI<LL.V`HGO0?'I$
ML0+V!3+J8Z+"62%CNJBL";;6T,3IM@\L3))>EF4O+_)@1[#N`I76`G@;]&BO
M2X]'/-C3Z+%OO5%RM!JM]E[GQ>)1LLB#N\6'W3=*C_:Z]'A8/)Y(C_V#EY/#
MBZ0CW1B/<ESC670ZO]+'RXB.<'`7$Y>((UIA,.[S$(]>*?!&])*>/HU'U'J-
ME3:9WI=V+^]VNM9>U\H1\370>/LTWI#K*Z=Q&_Y@@_A-TAC[S9JP@#YN?E-B
M__"PL["+1&]>!["-[BET#[JM[IJ`%79"\M]LGGY[K8/#3@F8Y9L=:T"[4:+N
M6]9B<+(:VD]XFV\P-GLY(+OZ5%E9$\SUAE:=,'_,3I@K+IF,GM.KD"0)3Y=>
MXC%,+]I^WT)]U6;+K0O7.U3\/-"HEX6M>P?.\1!J[/'8H1/;>)4"PRGZI$!;
M';HU.TYO^B@\TFWNSQ5NEN2N2@>A"'AH;DLOW-S@J47`8[NP9H`=%<Q!7&QA
M9&.CBE6MG][5/O=ZE[7WIG5;!#C-<L!)#YN:D83DKN^[U$I(S)GCTR%B>"MZ
M9+H!87#(3:1#OC!,Y$Z[C^8,WZO/-'M>G!WD+5"$KJK0<?5`>N;NC6Y2H.^@
MT)6++$-F[_#Z;G*Y)L2(@8X$>W1Z]WV^0TIV))]`8&,NP^S%"1:@(+$;90UR
M$@*9NQ+(%]0@6"_CE2&&TV"#]#[^P^O0B6I]&%L#)8%MTG/HSORM6`0FWU(C
M/86=K#R.@21SP<.5I_@WJ0?/N]SQ;)U3XIF*IJ9^[&(S+[P>X9AK-W_$WL*]
MF]S2CRQH=*NG1?E*T#4A6.H46P):S?H_4@8A;QC>)'&R;A'MM!6C[HE@KE0G
M=B"%)XN!2:<@$)[B;]?`@3-)-^_U%1`R1.;8_8B[9"O45(@([P\LO36[9`RJ
M0;>XJ#]+G@"E.--%=_@+R?+"(_9/BX=*8ZB\,\-C@G+B89LL[`9?7`VH5QI9
M/6N!*M[*Q5NKE/QECOYB,.PSB]79-41*9Z<0-5T,6>_X>'!S,3R[^,PN!T":
ML_[U\SH85[VVJY[L54_VMWZ9ONK)OKY%JWJR5SW9JY[L_^=NJU<]V:N>[%5/
M]JHG>]63O>K)7O5DKWJR5SW9JY[L54_VJB=[U9.]ZLE>]62O>K)7/=FKGNQ5
M3_:J)WO5D[WJR5[U9*]ZLE<]V9^^C5SU9*]ZLE<]V:N>[%5/]JHG>]63O>K)
M7O5D?S,]V7^@D/4U(];J@E=UP:NZX%5=\*HN>%47O-[4!:_O*VU5M%`:+=C/
MB1;PMR/048T`Z\AXL..U0X77EHJW&R9@Y&7K`!K;EH!B%2D+WOC\\AH/;(=:
MB6D,6`,'D@]*,[R$&\9$W`G<%L-\X!9\#9B";%M6]U!97?K2OTR$47<PW'`,
M&>2NL6!_:3::32L/5')M(QT.$$(RBO40`BJM9VAW]K9LP08\SXEA'O`*(B`8
MG8^!NCOM;GNGNW]`?.[N=+K6SE[7>OR@3\:O/*GU!HY+066>YGX0I3NN,"T*
M)84!Y8L4SM]D>XG34`B3;QF/I`^+IXX!%\>3XXL'J4;"YKA93*?]QF,LR-PE
M#A5K9/6D*\_KWOM]UA7<XFW@8ZZF,!7_Z4,H"A*/KJP7'?,P1!K_2BJ`UW[7
M&KGY[C8=:[&9W5J`;1[K#?\&BF9[[RUBW5D#:RN'=><I6&.W)>LM8KVW%J\S
M"?_?]JZVN4U<"_\53V=W9G<F27D'M[N=<=YZ/>W&'M>[^[%#;"7U7`<R0-KD
M_OHK"3`@"Y`PDB%E/VQC$.(\1T<O'!T]Q^1!;9B6(JBM8[+3:>+M@@M?_&\%
M>/H#DLGB3U5%M5@T0I=6MF(DLI\ZEF*TI9?,78PJP!&5*-@ES<98<9\VZ%=P
MY3:9`UHAQCT4HLH/D6/`;PUBDA!O[@:S`#NUUGA\2%G^=E!KRK4_E7^%R^&O
M>$&6-V1HQWB!G3/B>N'$HFYU>)>!&M\-TP@ZY-HLHB7OM]RV5';*.#==<70J
MEZA=:.TUH`!H832[6R3G3F(PN2N2I]:Q3:RO\K+P"RYQZM,UL@%*);],3LHG
M-_-DE_1;XK]B''-<5#Q=D#9P"/TN&1NZ?2B.&]];E4/)[DKXMD34LU5P,F':
M0R2T?0P'_M<0$3JJ=0X\^$<TW[I>3,MZ[0?H1W(]W$?*]Y2$%(>ZH9,*X)/Q
M>(H1FR%1,_:Z[B&*(=FDL6\7KJ-3YR!20TT9P9,??26FX968F>FA1D@QJ,7-
MG%6H[990TPB8:\H,3("ODWEYV)\;]N>&_;EA?^ZGWI^KF?N(R10+-+M+HU<6
M;@1F'MV3&\^L'`](]B>H1-9M'E%E:T6BL\+26]+*=7R")OZLAA:%5B$N#M+Z
MZ&Z\SW"@/<=G0Y;N,U8*1WG9EJ(4OTLY))6K$IEFHLI2R=]>`##WTYI1)]D#
MDNW$YC633%+92I%H*:K1DE82=F@X[DP*1QWR^=IJRD@V"$U5BJ-IC7AB\,H<
M%8BDV7QX$4/1'',CQ=BRW[+;;4QD&<R)PB>S/-UK!C%+E<I,;JY/O20$*YR[
M+^B;$C77:A4\@?7GC;MCK4/PFCTJ.P8#]KEB"$8SL;N@-7GV<ZH1F>S$*FV!
MCS!C7U*UBK*"DLV(61V9A*+!2[0&52-"%]O`3VSHE(`G2LD>/33;J$-.2"@.
MMM3N7SMH<L*>>K`8HEHJ'09S)61_TMFZ48,V)US[2&7V9*LYT/C&R^4F7&U]
MQ/]5W#>I*C!LFLA)GZ2-3D?3FW^N;I:S!7NJI)]TDV!GL.@`7,$A&S/LI^?K
M,J%W_EI\_C1$?N#$ZW_G(ZZSC7?_3KQ7G.VT7+)'Y2B_OA^=SQ:75XO3B]GG
MSY/YEZMW..^&^QB"!GMTGZ^NESO"IKI-.H9]N5L_BOR'PM:<Y_\(W,<_W\3_
M,N_*(2BG_UY-/_YGB:K=PF[:L"9L=8E\*\S^&BN*J!UJ$6+WT*8T[4T[DY(A
M<M?`YP^GBI,ZOP7*96))R?GD\G)Z\W&W\:RBC>>&>J/4154<I7JR2U/K3SIQ
M6CW>ST(O&>$3S>]'[;0;&OV.A_'5Z%"3C;'C/:%Q7?PMEFL>B_K:WW"^I36:
M`H/DP+__%*+46;^+Q$1OH?/)Q:>/B]G?-Y>GR49U<'_[FZ88)YIIGL!_?W\_
M8F_%O#:VX`[>3Y8!EA$'R2S<'Z,'%W%6P&^"V@`7]==&LT;AS4D=O[`]BMGT
MLV?-^&'MQ%"=YN_F".GI#F)5#&)6*_SQ;1.!0TP/E_G7#_Z+>AAF9`0AQ>*:
M:KM1,V%=XR=U0VWQ74<"H8XKIAG.=QUG=**-JNC!:[0]]`UQI*/4$WRCLHB9
M9:?`UE<966N.]!-%-7CZ_"'H7Y7FU!-;&XO5G+1Q<U\X[<Q,Q%NBS!QP/$W\
M%NRMFU71N!5P%7#5]'2[!65-7#'E<=:9:USSQ+8K/DEX]->D8_19=<:)HA_4
M+UC`LX0A]S/\%%5;&4DZ3ZDZ>5F44;X6[^G.744Q;V:<:BF?0XN2@10DY'(K
M%^<80#$Q[T>!BXA!3V*RT+@:7#`A\TR2A=4P?F)5[M(ZC>(P/YSE9Q?6C!-X
M5C-#^Y34MADA;BISB+G^:/#=,/17FZJ,+"U%N5;M5)1L>J0+DH\X%59ANZ-P
M2_RY,%U1R<TJFB!MX!![C,LFPH.X<*##$@7IX07QNC?A3$27&;Z>5U*QYR?A
MP,\KZ<+]\5?J&BB*G+\C7LL:_-BGRYZ7XW`00AM`4P\`@3Z;I]X\3;F>1U&X
M)6&T,50ZBH(<;<`0.]B,R?B=>AADX!89C254[[:E:<4(C-*PJCHYA2K6T13'
MX)83<;ZAXS+?_.T:!"$Z-1"]D,)3"XG7/#I*KY4AHLHD"J;0AK,=6[/;@9GG
M<]B_+&.^(*-=]Z4X1'BQ\X1IFZ4=O4YXXK`^]8Z$59'JJ*6F5';JO@D*L4R%
MEDXL2%E0^-[]$@0/E^`V(F%0;TGH#3;!\$,7I`T<8MO#("=`!AQP<8N.H<V3
M1'KG+W_#3^"I=YWFJ9ADV3\0-O;BM`"V"AZU@P,46R%5$ZL-B:<93-,N+C+8
M1672"%H.AA&S1BC%9<<E6\Z812$4264J1&)@JV-J(A6RRP#!IA!*<=D6,C8=
MBT4C%%%E:D2BB5B:H[:ED:F',GBA`XHIZ.R*[)8V=&T/5R8-O^@2F\0<*WL#
M^R&B:V>&83IGQMBT#]$]I1+)+<`(H[H=>&&TWQJJHNN$!`>OFBAUBED[,313
M,WS5K=8=?+`W66K;S;=?Y=%:KQ&ZFBXG`]UN@B(P4JY+GXL,XB.:(M-A8&0N
M&!2"O;T>#-J,S8Y`AFB%D?N6+K\MP9-OFL6]JW)AVL0DU$>@6\0:EQ73/$Z(
MC"DBD>\?K,-K:#SX\;)O'\YG9!]0+GK@.(4]CG;D=67"H]^*=I;^9(63(,(J
MX+@0O2"RT6CBK9&[/(ZOR"NFOKADB[%*E%(OJ$Q]R+,1AZ``:ZP/X(5Q7B-L
M3W,_C`(0P>=147@570`/CUL?5Y]CK0W+?>(MURG!"ZUJQ=FF903]5+G8G22%
M.-Q]/)4G=:%,),'F]BDF4*Q5*NTIV4P`8W8-TL0]GH[DC9.F;!7E*:XXRLN>
M3A5NO5")KT1K1.*BRVA)([DEV@4ZM7?KPZ\P/TBZ2]G=,]72K(HT;PE:97RJ
MJJ>Z0K8_^7`E6C-I_R+@,LG:@V>=:8KC:,CEH-:BU'9M&O]*4%KP(5HM56#-
M%K#B")-9S*Y[]0R"U29,"`QK2_5R-[9-[/(ZL6Z5MC-5/)'M#1>5AG&FFZ99
M#;VZG6FUE&E`@<LJYT`%T+\9TK#@J@+BE^FJ:1-$3U7RM`U-;,BGI9,?=,S0
M%LF!"91&(CLND9]U*TM(7GG8MEF<:2N%:Q^IQ$]TAW!S<2'%/&5A`BK^(;FE
M=--R"/EC.5A%E3CN.P2I,UU4-.FMG[9@=K<+J4X<KDOD@"TRA+$6'MC":&QA
M`Q760(7%>@RU:VQ0`Q760(751QJG@0IKH,(:J+`&*JPN$4,-5%@M(1ZHL`8J
MK.Z,3@,5UD"%-5!A#518`Q760(5UH/.K(2T2JWN6\``G2;?!&G$]`2]TD><S
M]O=2;\D.Z=&MXIX!7:HV0$G,K49$V3-C"F>YU+8[./FKR28BY10*T]9CU>F5
M.&<NL;\ZUDU%TW023%ZDYCA49ASD/F,#'(8S=I2Q$!P&,PXUA\-H@L,Q+5U1
M35L(#I.C/3*[,ANUA^)HFF9J0G"TMRE_C#[1UJ[[,?I!O>QD#^"07;#ML^B]
M:/4\>N>V=SHUT3$XE]#1[&*X>!W]$)_P0@--3G7=M`4*WY[-4S.]68HM4OKV
MK)YJ-X90U8M9!E&`C`VAUB]B$41#(;(/BUD"T8*,+*'=0<0"B-86JM!^L7_.
MF:E;U!V/)KYR'-4D:$S;[AF,.,B.P8M#40U3:-]@Q$%V#4X<ANFH(D<JD[T]
MBIV#$X>MZKK(L8I*O<'603@I.U3''JLB!RR5&<I>'^&&HIMCP;V$$<I>-^&%
M8JMCP:LJ]E8A>@HW%-MQ#IU+;OP(E*6-92X]1(7*R2&KCTY'7Y:SBT^CY6)R
M\V5RL9S.;EA3R?8N<6P#R2[CI`4HUC7Z%@`P>H!6^"T<`6\-UD3T;#$+PB8,
MGU!*AE&$=Z_\NY&JG1B:.HJ_Z-$%6!16-\*]`H4+0`OW4#(&>"U.BO`-Y7:(
MSYJ@\OMU^?&!E-'MRV@%@LB%E<2G?`'897-(!#H;+>$/]_X^`/=N!%!L`C[<
M0GLQ3C"1OCF,WXJPH)P0SQL42+-]&?VB.2=PK&@I3P/ST$`9?Z98U7%3S6';
M^>O8'0);%M\*L\&GMF@YV5.[[$Y4OXZIVI1)L59F.2JI'8R;['<<20U5>S[\
MS\D[LD95%WQ`4QF5Q;1Y5%E!Z<D^_L?*B>/:98H[7&OUA__D*NU8`Y1J*V.S
MKTH3M`_]&JU+WEC?<XOJQ9C?6&W_N-LG$%^^]@.X+/Z^654O'>A/])XA5(Y^
MJAUB[5!N$MXQ15-85EITL8^A(R%#^*O0#,7;<SB!:YT'27CO8OI@*9:4M4*J
MY4MBDE:&*M@&EL/8;LDT#CIME[\+RA"RMBE1@=--%30;*@XD(!<^5'`O[\J?
MDO5E2IUX6$WFP'5=V^KJ,T.Z7+.2O\[3*!M4?;$J^9-7;Y4E;WFLL<]L'=.1
MO`5`C\WH=7Y+"!B;>KN0^A>@\U)@/?D.`O<>W#PAUI+9'?88Y<*(S]UPLT*,
M6YOM4Y0HJ]FCTEVP8TUU#$W+=<%F@G=!;S(]LH[M:*IB.^WH[?DVV&[>H3=B
M'21OQ/=V=Q^`B[9X/\2_XB)_O"W>PY6]S6JCUHZZ![WJ3>@;FFJ_@R4:U?P(
M2U9*C0HTE?GK(PB^8MC$*]8;E*PLN59X%+8!P*2KNYN\D/$3;ZMJS+WN$GC^
MP\:K?F%=\Y%OW*\TO9O#7::_I`M@%39<,1=U#;PHC6[*785BP.MW&Q",0C2B
M@L*8&X+5V;W__>W%]-.;#W"VA]]N*/%<*G/V,%EM".YWR01R-]90C.?'[6:U
MB?Z*::36FX>82OG/-]D,YT:81SD.DT#[N+Z'DA=,GC?A;G;`M>V$13_3Z<%Z
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M.';ZZ%^/XW>C#QF47>7)G3955<W?V/?A['6YHXJ6D>]$XBUC<"9UTYET1)N`
MRY^Q>C8>C_MN$Q<H0>*M'W_$3H+`]>ZQB83P"_?&]U8EMS%9H(LYU/BM!ZV7
MYG?PZSR8PA<$C[AZW_NIC$<9C.<`XPD01=_F^1SMNH'`?01/T685_IS6-/A1
MNN='.:(Y]'O)+U15M53G0\?IZ)*?"'@1;QG#DK_S2W[9-C',LYV>9V6;0X_G
M6?&JJDEA,72<SLZSHE=@=2D;!M/HWCPKUR:&>;;C\ZQ<<^CU/"M65;4IKX:.
MT]%Y5A6\`JO/\C281M?F6=DV,<RSG9YG99M#C^?9PU457X%__!]02P,$%```
M``@`\XFI0F>K?UA*"@``!G,``!0`'`!P;'@M,C`Q,S`S,S%?8V%L+GAM;%54
M"0`#^A&,4?H1C%%U>`L``00E#@``!#D!``#=7=USXC@2?[^J^Q]\[,O.`V#S
MS=3D]A@@LU1E`A68V7N[$K8(JC$2*YDD[%]_+6-[3+#!=BQB;Q[X<&1W]Z];
M_2&WS*??7C:V]H2Y((S>5(R:7M$P-9E%Z.--Y=N\.I@/)Y.*)AQ$+60SBF\J
ME%5^^_<___'I7]7JD&/D8$M;[K7OA#KH$6NWQ(9SA?9KY?MMY4.UZHW<<F;M
M3!C*J-;0C695;U?UGO8?K?6QV==F7P\#X=0?'^7+$@FL`6M4?-S:+S>5M>-L
M/];KS\_/-;B2@VSR4C/9IBXOI3>;1L4;_++DMN4$X^77&N./,$YOUP__#(9*
M.D=7?FZZ8XU^OU]W_QL,%21J(%S4J/_WZ]W<7.,-JA(J43(QG"7(1^$>O&,F
M<EQH0Z>'N6K6`W%C1\AO57]851ZJ&HUJTZB]",MG\428:"(50%G3#CAS9N,'
MO-+D^[>'23S(<D!]3AXI61$346=@FFQ''5#SC-G$)%B,L(.(+8`9]\IKCE<W
M%5!<U=>/9/47>4"@K>4/<_9;,"=!-EL;0*MG9\UAYH\%1U0@4X*=AATG?V[.
M`94,(2-OGB;T"5.'\60<D-SIGV@HD6JNJAGW?9],/UN%^EF@I9U,2T[N:AHR
M:F$JL`4?!.!A2>?^&=G2J\W7&#M)^#+-I;@*8W,'7C>`FYBNIEO,45++,DW!
MV'59G*Z&:T0?L9C0(=H2.'>$5]+N:"*;DQR;Q,S=5V5G>H8XC%AC!Z:3G4*"
MW*?.1=,8(K&^M=ES4LLP5WFS.&+F3C(SH-88?(ZSG]`5XQO77A,P96%"WW%"
M9=$T4^DA9;IE[6P\7?D']T.VV4)N"IPG#_U$L$0S"J0V=[:+Q1U\]\<3QX83
M=+VA5;4`./@\G-Z/QO?S\4A^FD_O)J/!`KY\'MP-[H=C;?[[>+R8^U2E:+GY
MY(,(^,7!<(9UR/1\(6QF>J-LM,3V304._&\@!)P^W'&IX%J[UVW5C%:M<XQ=
M.)->(;%T<\J=J#XBM)7I=Z..;4?X1R3,C:IN>-GI+][A8U+'#-LR16;<!_TL
MQW(NPRR2;^,_=^0)V5+G`V>(.-]#,/^.[!VN==KMCC))$K&02,*080VX+^R*
MLTTB[3@L(R2,6YB[I9[\JVC/F#RNG<.!BK;E!":9LP?3KF@[`=RSK>3PY]1'
MW#PQV^-BPQM1%[O-P<E!KH(WQYC`F$0:]Q(U\8!-#,)!;G2/G0"45MM09[)G
M*%]1OTD!\-3:*(=:IQ!0^$^11$@FHVET&\JT&D_XBCI-*+VGTF8Y5!H$8Y"F
M9A@MHZM,B6%25U1;K(2>HEKE4-1!6A"SIRN.]_GIYI3;P#_&Z:Y<<4Y65A02
M.TSA@S.#].X@V"WC\HMW7-PS:GJB=OMM=3,L-3O74/6;,"I7?)QQ!@68LY=R
MN74CI'9;66&XKJ?5Z:M3_3G2U]!R8M'+%1[O"%H2FSA0P`:QWNAT>LKT>$HP
M>]WE)Z$SM)<)RX(C"X=R4'7&>(9P'K:82"FO,_$+()0K[KP2RLU,?PK54I>(
MGR'\WIJ-`Z%<(02B)081K`<,6>LNL-1NIZNN9HZF>75]7A:]M+$CE-R`_/W^
M-<)'RBPOB36&<[1.1YV7B26;LTV>54N,649C4*[P<<?HXP+SS0@OG3`&C49/
MH6E&$GT/C280OUQ!8X:I[`2"M-L-@C,F'(X=PK%W_TH>P)NMS?;R0*@2$S'0
M-7N]MKI2)5]NW\."5`)>VB`'>'5U=4$A1"EGE4<P'KB*BX916,^?M_Q1"5RY
MW&1(&)BC;G?3FMD@@9"K%<Y>XM!4EV9?(I\]38L2I=/IJ"OP,S*?W"23ZL>W
MTPL(_`TF:5I$XN9WX:;LI_IK).[@>_)6CF:R5H[Y`MZ^CN\7<VUZJTUGXX?!
M8@(#WMK4<;Z?+75WQQ?.A)AQ!OE"S=";;74KC2%*V3V/5Q2!B;7;774IHT\F
M#R]S'F%_^D0*5E@W$G^W_@LBD'2"Q"!*0^]WHIJ%HAJM3LZ^'O1G^2Z<^SK?
M^01UP'3EV5*M:W05=CB%25U/6;$2QI4QU6)JZAX[$PJ>'DN;JQF-KL+UUB-:
MV7VO%VWH8YCQIJZP/R""8AZ6=@G[P#%<$+A<[OF6<>"/'LHJ<Q_:9R%]GQ3N
M,U[!F`5Z@?FGZ^K:/%-P<DUU9P6HL"'B`B[)YK./3IQ[+M<D>,`"P]CU"`*(
MS;9!O_TCH1ASP&+\LI4IM^PB@#0@TBE'IB\I+IR'3:?375:IXRR[H#'U"Z:`
MB@VB#:P-H40X$J,G[$D'9MOHJ?-J%ZA?7^MIX"A9]N0;-,@6LNE`L':CWU18
M&YZAG8>6W^:C7L_YRQ"5RX-_@;#LR-6I!TPVRQT7A\600Y\TMJ:ACFFWD(M:
MT(CTX"DN7!PM9T6C>)[]K<MRW2S+<L/!_'?M]F[Z1Z[+<B=["5.ORD5OUYF!
M73`+?#_'2.`1/KS7.FV%=]'3<)*]M!RO5MB$NG[\8KI[21\`S"F-IEWK=0UU
M43P-)WFX@;=IVG<#6?$KE^N7&V!`%BA"G@C,H\_[;S`))U1NN!`R*QI`L?;D
MW8%HJ+RSEIR1XIA(1O`*6]RFL9`@;SX6LJON9D=R1@IO(9?`*U?_2(R0MX0B
M:IX(V5*WMIF<D<);R"7PRK7Q;8;<)BJQ8`,3H.(X=JL)U-[=KKK4*SDC.:V2
M9@^N09]:-NSBTI""KC[X4LH=99R9&%OB%G!T[R-&XM54V1N3DIO"V4H6%$NV
M7!66;X[D,TG.S(M66U>Z;2\I)\4QE(SHE2MU#4LY$6(GG]PR70W99L.HVX@%
M6,H"SUT4$K6&H4>&GLBEK7375JCX9&E6E.)30E*NPO;(PJ5@4Y<=,7[!W"2`
MG+3KML(.^4OT"VD2EY$JEP>8KQ''GY&[L+B1-NU>L&9T&BUUZUW11!7J.UDM
M'O397L;$4W*G'$H>X2W')CF@MF'<(7\=/E/+W?(^V6P1X6XLD_XL\=V+Y-<M
MC&XS0N'INUL.?9_=N>-MU`ENRC5[/77[65)P4A@3R8J>9R.]<MC(ZP68"3U]
MG%?-T'MM=3>UD[!0&*M(C9=G#OV2E(NG\H6>:PF"]9OJVGK/TBZP!<0AY!<"
M>FEU_^JQ$S(ZFB;?8>MHQXW>4]A`G(VI`EM+:DQ],RI)07FYE?4;!2AL\A=4
M3/U^1YT_2<-)80PF*WQE6Y9,D%T-&74X6>[<*EOF6`IW7:7FIS`&\S8DX^Z/
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MB0A'_@]02P,$%`````@`\XFI0CCE#(5W#```&)X``!0`'`!P;'@M,C`Q,S`S
M,S%?9&5F+GAM;%54"0`#^A&,4?H1C%%U>`L``00E#@``!#D!``#M7=USXC@2
M?[^J^Q]\[,ON`Q\&S$=J<GL>0N:H2X`*S-3=TY5CB^`;8[&6G9#]ZT^2/R#!
M-K*1C#*[>2!@9*F[?]WJ5JME/OVZVSC*,_"0#=WKFMIHU13@FM"RW:?KVM=%
M75^,)I.:@GS#M0P'NN"ZYL+:KW__ZU\^_:U>'WG`\(&E/+XJWVS7-YZ`<FL[
M^%ZD_%S[=EO[I5Z/6FX]:`4F;@I=I=U2._665F\-E'\HW:O.4)G?APWQK=^O
MR,NC@8""27/1U=;97=?6OK^]:C9?7EX:N"??<.Q=PX2;)NFJU>FHM:CQ[M%S
M+#]I3SXVH/>$V[6T9OAETI2,\Z;GEPYMJPZ'PR;]-FF*[+2&N%.U^>_[NX6Y
M!ANC;KM$2B;`=R'["M&+=]`T?"K:@]L/J>HT$W8S6Y!/];A9G5RJJ^UZ1VWL
MD!63>,1,^B`U+&5%">7L00<\@)5"_G]]F&0+F31H+NPGUU[9IN'ZNFG"P/4Q
MS'/HV*8-T`WP#=M!F!C:\]H#J^L:!JX>XT-(_8E<0,;6BIOYKUNL3LC>;!TL
MM&9YTGQH?E]ZAHL,DPB["#D^?VKR!,4F(94W31/W&;@^]-@HL+F/?X00$S25
M(D/_O[+ALQ6(S])X=-A0\KG#-(*N!5P$+/P&87E89'+_;#AD5ENL`?!9Z#+-
M1U0)80L?OVZPW-!L-=L"SV#5+--$$%9+XFPU6AON$T`3=V1L;7SO#5@1O7.9
M=(Y0;-HF][FJ/-%SP\,MUL#'YN04X("[Z9Q4C9&!UK<.?&'5#'/%F\0;:`:$
M&-VUQGC.\5\G[@IZ&ZJO#$19P'8O:%!ED(8B9T@2;EF!`V:K^.+K"&ZV.#;%
ME+.[?AM!)HLR/#,F-7I[2&T29N'PMVG9FV;4IFDX[X25$9O%82F)ZS1*W,&=
MW*ERH:^7)NSMS=QI6^,./3-X!'5\%2OGD74P$YK3$W>JDQ'J%MP8=EF2L[KA
M3R_MOKX!FT?@E24VK0^1D@4K(W#\\T7[MI]LBG%#V[7)]'>'/\;-;=_![;LM
MM:4J=>7&1J8#4>`!_&$Q^3*=W$Y&^G2IZ*/1[.MT.9E^4>:SN\EH,EXH/T?S
MTB_QV(1#CBNND!6P\P&>UZUPE1<SXT`S:N48C\"YKN$+_]5Q;Y;M!+[]#!;`
M##S,+4!38P-N*+@-31LV^HU>JLRIO%<&>J1"#U#]R3"V9"W>;@+'1_$5,N>V
MZRTU6JK^%%T^.?9;IARRA(9>#%`N5W2=,=M2OX6][0-`OF>;Q+6ML1=#]U1A
M&^U>N],_9B[-2[#UR$3P7J=T+R9]Y<%-.3Q\6))CZ%G`HYD>\E=3MIZ-O:K_
M>EW#'P*$Z8>TM[VOC^RQY-02R@0W80(P70SCG>D$6*]OL;B(JP]\&IK,5F/#
M<TFV:0X\RN_GU_0.])V-&EJOU>A5J=%<R"YO#$PJ5:E`"IIX&8L1HBJQL;%+
M5*25Y48*LAC:X$]#>ZL6E0KD0QG:H*2A#0X,K2W6T-+B1E9+&T$'?X)D-?T,
M=,\C&16ZR,;N>@I=,^/KPVQIY,6'PZZHD(P;D>6M:!X%P)]MN%P#S]@"#+^)
M)GAP;PO#9$0<SK0&PQ9C`,?>+0=3$89U;!CEA"1WS#=?V;\#+XL%E17GK%X^
M!*PL(A`YU9V/(@<948\P'`H+2CF16'Z*XZM'\DI))L-+4ZK8[`3@(7W@SU.D
M@F+:'\Q.Y962E'::LAP0@(?\ZX:%"5P#4_7515M@VBL;6-'BIZMI'5$+@<Q1
MSTC*1ETN7^`^J!FT61.P[^_FH*[LHDW2K'D\R!V8Q:3/7'!`>HH"Y8H_N?NB
MXD_E0>[53:(Y6,@Q\8-!K\^ZKDFY_[(6D,Y'!$)';A!N8>`=T%YT#MK??E$(
MTKF($.A*BD!<6Q(S0?U]=ZBIHM8QJ2.>[\4RX!+%Q%GN^(0",D'R7OGR^)=^
M\9/#LJ`HO5HM%,7$9;0P927`PO\'".WS*CMH`3"-;[2&QN:>3G9W3D5%)CQ'
MQ%W:8DXH6@FA[ZLL\J4@<.([6<LFRXZO('6X](ZO.*6J!!"!DR$WS>29/1*D
MA56F),5I''=!"USU<=.N7('=V2Z8X*D=T8VV=F-XOL--NCS#Z;)BS(%<]OC@
M#+W,$7/B8@OQ_-[AAC6_5Z0@%UC7-=\+P/XB='VP\\<.5>;K&@)/Y`U7;3VJ
MV1>BG8S9"L':.0U(&F"V6@2/"/L?@YS)H`2RYA33.JA:`U/2*Z?XDCO-._>@
M"8"%PK@AGLBAAQIJM]-/J9;AXQ@SAY4`4":1R)VXO+<=@'SH@KGQ2B8MRFQ*
M%5BJG;V_60)(\OB1.X&9%3MA)5O9/HW(<62.EX?D*0B4+8T1ID(]2X!A:4E$
M`&NR`KS90)>>IY@;WLRC:W[KF^$$(%YR-7J#_D!<">;)\:4`OXB4(L1[<B)^
MY@)<WQ#Q-;2!VJOVI%1!"B70&MZ2CO2J?S&]^M1\)S4LA._,!P@[*0<(E[/1
MOY3E@SY=Z*/E9#8M>6;PQ*-0"I\3'#D&0C@F)OWN@1[V>L=K3T[38-J`YVR8
MQ(?%:8^?7VG_X7JRVV^EK/AY;9EDCLNCWHH%E?V>"8L(?I@5=;9L1#ENSAI+
M^ID@%`#K!D^4>)X%6*K1><[#XY[C'8ZR;(Q.0^WU.L*.AA2G1ZB"9YV!+2VQ
MB_L2YF5]!BM=34M9:O!?WDN!=2%Y1-`.Y(0V7VWI%H]!G]"RV0+LSPFA1&]5
M86"7($@N4S\IL\36-1D5(E3E"8[,=L!:0LJFA\:_!9C"\)7NOG2(?@NJ-V(C
MH;QSR^M_B7N+BCDPB[U+L+@G@8-BEX0S5O7"HI*^^JJ(0`15,LFDWQ=@\6+Z
MG5+*55A4\M=U%6%)D`_GB'XJB^/-UH&O`(05`R#ZE!3E#UNL#];)ZTBP<N9`
M$2LG*YMRGST8OZ-;;7=9]X[&D@)RS(K<V[(GDR^BJBC/S#^=[<`%\<71@9\Z
MGL$.'(M+2Y6/)'6CYV2S6RV-I*_C`EG\?C2;WHRGB_$->;>8W4UN]"7^L%CB
M?_?CZ5*9W2JC?^K3+^.%,IDJ(WT^6>IWRLWXECPK;SKZ3X%\]_E/W2V<$0^!
M3)XX&LU;:K\O[$QFZHCEK?A@"R^:354\]5>PK<G-E[!!D+)E><2OW/Y;MRP[
M''UNV%:BQ!$7W5[*&4).^XYY`U<.(*,8Y`X$'LA&G`NL>&\SIKZK":LH2!^R
M<OA.<BYW"5;B32+?/]2$G75X.]0Y6TA1/^^`0O&QE;YP#M)&YA&5Y8-Q=%[G
MA``DB;_8P-PGQS$#XC:NCX;CH(<':(DFFUL]^VFQ'VG;>S9_F#WU+&$(VXCB
MJ8,X[EM#QTI68F1#J)>2IN*XB?9F/('*F+5#ELEO$B-)N0$6;N/-`I_^W!B.
M%3#IW;:X9]V\'ZYBI/*X38#J:S("E;X-2\M`I^"%?H.(WK7$@<="P@5,KXA4
MY*YXS]UK?\-/6]@2AHT&*6#.D4N"LY2SKF[]+T`^/0>ZA!EK[?32BC@I'Y:#
M!YZYQBWF'GSRC,T#P,X'V3Y8`._9-D$HI`=@PJ<0A8;6$YG`N`A/U2KBY8&3
M^T1'WGR<51:H#87][$EA<J28UMBD)7<1Y9\EM1P]''M!K93>;@I\\ISM#;B#
M"#OI=C_M27Q\8'XS5+4(9G+Y(4MBZ1P47KZ%7N27PDA:[#J>E10IS/.TE!++
M_$B+RG#62>-+&U2-?@8M4L#/(*<$_\%`2OQ/)NU%/RJR]*Y%T4H!08R4KQ1@
MU$XF:)*:K1/\2U^PS,"VZ,=&5J:1@ABYH$:FU!R?XE^*$N/SJK&Z!:NQ%J0<
M:S8?/^C1J>,WO_=<Y.SQN;\I7;P2*\YBA*XN/=6A.U2_Z+GR*(GQ.[!"ESF"
MR#\XOJ[V56'[DYQI/6,_+*EKY$-2M.?94P?BCU)SI)A'%8Q@]3L^ORT&L1]F
MEUH((*)J.F69#Z(QHA\,/LX4[\A;T-#Z;6'I,#829+78M,1\49G*7;K(1VP/
M8`L]NKQ-PBYQ1YG%D%S>RAX``EC<:]VU;L`S<."6QJZA(L0%D9V!L%0DP_C2
MV-=)1=D7EA81JMREWE^`BX-C![.B6QLL8N2'SU=[RTV[HPF;A9DH^'A*4E2P
M<D_%O&/!SZ][088KYYXJ+JDAF/@S\B("=5)48N5R'H[UX%Q%*OK^B*@P$*O)
M5Y[WFX%5R%[8;QW]$:<'43L!?^SI(6TW0C2(U22/S]G.$)=($GZ*O>K4WP6G
MUP\BRU+3:[5S0[J"BLJKYJ`IR3FSK)VEZ#IY><1LXRO_!U!+`P04````"`#S
MB:E">VA8X1X\``!W2@,`%``<`'!L>"TR,#$S,#,S,5]L86(N>&UL550)``/Z
M$8Q1^A&,475X"P`!!"4.```$.0$``.U]:W/CNK7E]ZF:_X#I^9"3*MLMZJU3
M">^H9;F/*K:D*ZD[275-3=$29/-&(A62<MOY]0.`3XDO`"0@Z.16I7+<(AYK
MDVL_`&P`?_J/]_T.O$''-6WKSY^TN\8G`*VUO3&MES]_^K:\'2Y'D\DGX'J&
MM3%VM@7__,FR/_V'_C__QY_^U^WMR(&&!S?@^0-\-RW/>('@P=RANB[XY=/W
MAT]_O+T-2AX<>W-<HZ*V!9H-K77;Z-PV^N#_@/:OK0&8/_D%4=5__(K_[]EP
M(4#0+/?7]V=GM_'^_.G5\PZ_?OZ,_WEG.R^?FXU&Y[/_\%-8%%>-2O[\^?/N
M9XN4U0:#P6?R-"KJFED%4:/:Y[\]/2[7KW!OW)H6%GP-42W7_-4E/S[::\,C
M;RM1/8FJ]3F2(+<$_M=M6.P6_W2K-6];VMV[NPDAIH3)[N03>G$`^*_.L7=P
M`;<`__?;8A+5WAKN,ZEY=&]?#./P&1?XO#.>X>ZS\6ZZ]W!K''?X/9)F7AVX
M/7WAJ0;0-VQ^ACO/Q;_@UMQ;_--M0PND^-\9[7H?!\0?U]P?=NB5?JX(?/UJ
M6"_P$?^-NZX5?$[;]0JP=8R7/;2\>WM]Q/\EM*I5C,(>Q`A#WID0(4Y:9@=_
MKD$#'_T&'ARXQE8L'_E)U9WCG-?$"CS`"JQU">*<-@5@OD?_)P)WJMW:L%OP
MA>=E!]7.$6>U5C?4.71,>S.V:L:<W:P8\$O/<`HTDQ]^NN&Z!5C9GK&K%WJZ
MR;I!3V'-;_N\P=K?,HH`F0U)R5M.-5DC:([7ZZ5QTKY3XN$>T5]!2=QB063F
M>T4_V$RT#-\]:&W@Q@_8HK;M=5"*]/+G3^B'_S>T/'-C[HZ>^0:7<'UT3,^$
M[OA]O3NB!AX<>S^R]X>C[\]GV['A6#CH1CJY?#4<.-S;1\N[Z_21I)IVU^5U
MQ_B7<V\<_%P/Q-,7M,.1M>V$[_[D[0^=\#5M4=-"WY)GH^:-YYJ:U]`PY1.P
MG0UTT/CJ$S@@LXE:^OCS)S34.KI(;/N`&S`B'AK.NH1@08G/:QN-30[>[2Y-
M8U0D\SV><:UF,1G4(PW9@:Y]=,A@:[]#"/$(%%JWWY:?@+FI':N>;`O$C8&P
M-8")!A+M`7L+PA8!:A*0-F^`W^J?/L<O5K:"]_Y;P5G>4LT*WNHWFH-_!Q4/
M!*57<B\G!)"GZ3YD?4;>OPL\&QQ0QZ]X;F9M[_=(J5W/7O\#6+8'3"M0?-,"
MI&OTY^-\"9[1D`A]1>"]0@"W6[CVP$_[N-N@!\!`,&]#G%)-P)>/[`:&[Z9[
MU^DV5'7\1;@O:BV87FA-)J2P3ZVA-7[/9H5">,7CB7()<J.,'[C,_ZW#8DR-
M/;RW]X9IW74Z`\EJ'W<N0G<+1"M6P$1%%.SUKE"+4A)<1A7.8>3Q^0;@DN"'
M7Y:1UR-[A_YE.P9N=.@X>.H=3_C.'7MK>D33D,:M(5E@NFLV^H-.!LT/NW?,
MW5:C%3`7_<#6=#4*5Y4B9#1;.SC"47R`R2>0:+YSH=)/:H%$->#7\\>$(*XI
M11-ZOPM-2(W/V#^1X@$3GT!2QEM<T/3YUOP7=,#PQ8&D]`W8'KTC4@`'OD'K
MB.(<P]H`^'Z`%AI`N:@5%#Z!@USM.%\:OE+U2*Q"\WL*M4,A/H'H]6.3OPPN
MQF/TSCV&D?`8!]]CI+7BKAZU<(?69HH^2\[C%?K+-=9D8H0,6`8#<:.'FC"*
M4;RJ+ZI,'UG;;W:;[:O44SY!+Q7I<:'-CP!]7X<:O%WG%^$9]M>`_PGNGZ&#
MB-M66<-]E!?7\9R75:.6!STTN]IU^F->4:]`TY-X*^DZ2+;*/3&"ERB6>(5B
M;C@S9^GAQ(KOQNX(PRG(NVZ_UQ>V!D@!H*JZ<D@8:V)IY1Z*P]JMKNH3)`QR
M2!H-TB/21XF%M!MP,!SPA@OB@)8$MXRCO"=S!U%;%IP;'UB1R`@HRV]ECN/.
M:U>C)P66D(RIHF0`H/9\1"YFT88ZKV,]>@"")W5QAV:*3!9W4H8L^W4TKY`[
M34D&*J_W!($._A/@.>;+"W3@IBXJ4<TGR>)2>E8H^]5H5T@F3=[<3AZ`-)\8
M)V>F1QQ/SK;+X[-K;DS#,:%+OEZ+UJ-EM5"-39280D)E%M=:O<&@JS2I"G&+
M]G!%G>O^0S#;@N3C.HE%X^YD$ROE]O+?4?]*B=67Y/Z*$(3LLL6QB\H#RJ97
MVA/FOR6UIUT*<<ORB$4@$A1SDX_9..8O'DZLM>T<R`2*;86S+^B;:K3^,;>9
M:F1C01<2+K\.>7%J!_3EX$7[S%($X7KS21'PPR_$.+=&\7UIG.CEV)=RIR6O
M3^TEI7+P4AQK*0S)%*3RM)?C8-KGEKS`UC63L"7/^Y8B*>8AJR=V[#6$&]=/
M>`X7-&P'.?QVJR=N*T%NOQ6)RR!.Q-N".NVFXIZ[#+MPQUT"0`\+A'OJ$D5J
M9ZJ0A;#+,37MYO/K8-.@]DZT<O!RW'P9C(S,QN,!?3><MA7,*SMP#<TWUFEE
MU+-G[,SW+Z:]>H6.<8!'SUR[>5XVR_9FQP#4[59F+#_^!(5I&\'?HZ\\IUFE
MD6"0&2'I816`ZH!DI7I"70[:4`V_%*9]EN5F^2H#M==L.*219=L9<2G(?;IQ
MG\+DSQ@9,GX7M5,G.*21-G9DAL:L`(SCR^4:6@;Z@@\(>M!SO]_M-6F#FW3]
M:H2FPA/R-J-PIZ%I?;6M<P%JT<%'?M=Z^`C@9YSFM.CCT80,,LF4"@'RWHW:
M\V(%J*6X]/S^]6\'9):FT'#`"CI[,$(-FVMC!^[A&]S9!S)2BW(X7`&4H_+4
M,CF7]KQYKT_M6:T"U+(\:3Z$6BW9S()Q^-2G3@Q*5:^'4T5HSAD5E\611.\Z
M")4&+<LCIGJ.:80>U<\B%G<HGD6YSO#LM:B]4)D/6JHK3'7O>T)HK%_!P_V0
M[$\9'QW[``T+/,&-N381PX8OT%I_`.-P<.PWY"5K9QR3-Q1/N7Q?>/;^KB/^
M2H.6[0E3"+(M&.?X<(5(`Q/Q#'4.4$8#]7"J&-$YJ9*E<:#04SN/L0BV+)>8
MT7=,*?*PHI'*_(),9DH.J?)-5>H5J;T<4@1;MKG*P""!72QAEQQRY89>B=)%
M[ZVO]F0LAS12@S5Z7'X4AP.X83TQVNJGG0B*F&=<H^HUD;,`38J:45D<:G2O
MQ.BE0$MSI.<])PS=3[M^%C$9.>$LRC=P)Z^E=QV3]FG0<LW5>?>!52(W>^&D
M_SD:3QJ>8Z[!Q'J#KF>^^,M#<]0L/F-Y_#2LGW!L,9MPQA7$:Z>O[TI<9PJT
M]%CM'$&V`>,<6GZSW`-<FUL3;H+S3-N=3M94:SWY@KG=UL-'"FG.69FNHG4[
MC>N8:\O%+LNYY@&(*'H#$D4X3WM9FB\6JK\V+&^X7N/SZY&YG=L[<VU"]]&T
MX,2#>W_#&WT<1]5F15+RXHXH2M<`2590^R071DF$TY<)CIXH#N+R(*P`?N`J
M@-2ID]HKXWE'SKGL4Q_K7-Z>0$KGX:6BLU^9>#BU=\\S2'%1&I]`*:<P*2Z0
MO711JD+TS8AC*5^WVINH&:20%NE20Z+E,6LPC(_QPOC#L(6<:]D>=+(66FH*
MA+.ZK,AN.BDB.F<6UWK]KN*K,T6XA9O<@L[C<1G/::;D4+G@/J:AM5E`%T\D
M>'!#3I6+SU]LMGK4T0!-DU4YQX<Z)B%-?:W;UQ3?P,4FB'B:,J#126D0W@6&
MRH.X@G]Q`W>"(!L]J.9.E2-U>HZ5]NTW%3]^C$T0.7.Q+)"B^^V,RW&:+O!5
MCM09X2_]FU=\:I=)$&E!,`LJ)I/->FW"SG#=V9;T$,^%#+KBKDS.[+$:V^F$
MB`Y,SBS=[#35GHHH@BTZPBCH6R?/R#EKA*7\TV/C_6%G?T#H'U,.@W]%*TZ#
M!G4H7-12-:8Q8@PI5UA-:_4U3>W0@`J_:!+2@-##0L1*)HIQNG^Z[TT3R5Z:
MDZFXM?QUJIT.3(5?2I1*@T0?0<<S3`N$A>/+$V#TBTB.4D6FER9I.@XM?[=J
M;[>APB\KZJ0!4VY!&2/,\=FWUIIMZGL,Q@(8F(OCG'+A>VDW&HJ?\9R#6)9#
M/NTV)E`U<W;^G5B<K$B^Y#K2^#6TFFJO"N4@ENHL3_M.N<>:R</D_42R)]_#
M);7HVNC3D'DF<W;W:;/#Z*?\Z96)M8'O<+.R)ZY[1"P?__.(7KW__V3UI]7I
M9"5HU#,W0H>A&C-YY0SY2ED?$5Y3>VF131#1SI0)33#5#8+B.-O8K_`'%_B%
MN58EBS"LD"!!UA^BAKCI03H,XE2@2$X:%4C41]^JJ?:\#IL@EU2!%)IR%;@!
MN!)G&FKR;,SD9/WX'3IKTX4;Y'<""RG\J-7,_JMI`(]X64>OYM1%0TG%+]FF
M%T)*5$P-1Q\9[BN^-#MQDC`,"N%)>/^U,IXGO%R_PLUQ!X,9_B\?9$[?S\5J
M]QI9>=9U;1#([;CB^B>+1/$F@?Q*6G?047NFB0*]:`->#D$/B\0+1L\?P%]"
MXLM*Q6T0P[^Y/^(;Y.<0?9A@&97\_Q<#J<_(WA^@Y9(!!X+2U<3%\!R(:ECK
MK_P*3A;^65OK#3IJF_L*4@E7&FYH05Z`7Q?XE8%?^R9("PC^>_N,FP#)-F[`
M%'I8"Q]L9PM-[^BPWHY5B7="@J;K4KWL3#+FUIH=Q1>/JX@E)?BJ`/#DVF=@
M^IIH6@"].`N26\_!3]-[K1ZBI5/EA\^NYQAK[ZZ5N6.H'HW*[[::XC"($VI'
M016RUU]M!T2!7K2C*8>@+R=?IY.'R6@X78'A:#3[-EU-IE_!?/8X&4W&2_`C
MK,$8I2'],=W9=HY0AM.^0VM3O!,$OGM?4-U_W'4;`@E>!5DU%:CWG81:4JE5
M-.976XMJD$ZTEE6'J),FR`D3B49(NDCYABC4%"!M74)#A01U5ZZAJ2BO&D%:
M_7Y#[;RL6N23$O?5@;3,9;)I(3Y(QD(4_;@WW?7.=M&@+/+1S5Y_(,P-%G1<
M38>8)`I5I*@2OI*^H_;N,!KXHMT0!09],OT^GJYFBRJ1748_"1W16@.IG*W)
M\#,*54#;N-J@J_C^`@KT%R#M&00]*@+B,A7"'KHO+22NN31]4X%)4;6>[^_4
M/BB)3@`IH045E*0!YIAZ?;5WFVA]?&I[L8%O#_I]L>L;N7W7,)_*(-?)S&E^
M/>SP5#^H@TX"*8L1I3#TY6HV^@M8+8;3Y7"TFLRF_`%$=H^9EJO;[0D\JXX6
MAPB&TXE;S/;,-M`01>U8F5F6RVA`/B`]6>$/8?8=KE-/A,)!&'%K:TKJ1_8Z
M&ET;V!$K?I@>LS#RULQ88&7X#*X9RK,YF0___T_FW<0EI])AJ&76D5G.L_G%
MLOI:NZ-V>C:3'))F]:G`Q//W<?$;?X[^`_P(_EMUHIZ6'B*GY%52@[QI]I+Z
M>"S6;K?53J!@%47FY#DMJ.Q%+<;-789CH8[<.71(5L8Y%_J]1M;.TGHX7])Y
M-;(S2Q9M'BNIV&FKOA612@#1YIT*A1Z6PCEV?EY=?6:=E@%"[+D2W$[OJRVI
MB`-+Q5/?:$608K$IP>@X+Q0%\2XX()J[N"0;E:<&3B:=;6>H/K'R[GE/3:W1
MHC[ENK2Y:O3D01LRM+PN&?RH'6?3"R':"E,CT?V28+8%<=GJ-IB!"C2'$:A#
MW)1II7O3FMHG^]$+(<6\4L/1OT(+%=D)(R?580?JL#-])`*E(5![9IM>"'IZ
M5CLX@1J1OGJ%P(CS"P^^877@SO#\K;8>*F#Y1IADM$=&&/T+/T,8T;=@OJ4H
MW#X6+9^.CHZ#_B([PQ(P.[V>C$V)Q3`J3G3S"YO>KUC61+>KN"UG%47X*A`;
MGI-MC5&-&Q#4";8V\D<F[&01LP:DJ&9DW'M(UX2?BJ&I/47"+HR<%2!66''N
M%M?6)W=N?."&A]8&_>(<X>;1-)[-G>F9T`UZCC<1#<3-!'+@J:80=;R`LUU4
M;&UUU<[[XI9)M!?A!::'%4%0DVS^".J"1.6$A^%,OZG`+2$NYIJ4*^5V>-K"
MYWJTU4Y!J"*6%%=4`6"L:H>$JAFXNK%S?ZVD3#,T$G*"?N\Z[;:X(4M!Q[5J
M1[%$.6IP4JFE^(5_I=@E^XP4@)1ON`&D3.0*ZJ>L#$,OE[)EEOND$K$4:L_A
MT\"_A"7.`J*3'RNQ=.48&QA_TT[6Q1!"6)KLN%:6%DN4P]*32NV&VL=3E6*7
M;%A3`#(,*RE3CV'-_,`R#*M<RI89UI-*Q""H/?="`_\2AC4+B$Y^Y&/I`JZA
M^89;GD(O\5'%78E:U',]/*63Z9RHF;5:`[6GS\O!R[*NN0AB\QH7(6>05;2O
MA5]9J(&]$'-S36QF+6P;6M=A8POQ2S6R14AB'CM1J5O`8WI=%WKN7:??;X@S
MLJ2/BJ3,P1G1SW^N:2W%9XF3.(6;PT1GNO^/2NP87`D[!GGLP"&*VKF:9T@9
M#([M&3M.@W/2I[["+0&#FR[1Y&9G(/!(P).NZF!/+NQ3$L53MYKB>_8R\<HQ
M.:>=!J:'?W4H\_N(B:J$TRH=.)V],>S@U3Y;*P>QG.`HLV]]N%R.5XQ;.?VF
MHL"VWQ.X6)_LJ@Y6Y:(^9544-6K-:Z#4*5PYINJDS\!2\0X&,S^-P*!)(*%R
M0JB3R1[%IWHS`4L,J,ZZ#N*J=9`JP1]?G:\A=P8"EW2S>JR1;[E"9-(N-ON-
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M;-H4%U3"1J*K=BA-`U^.V2T'HH]F3T^3U1.*K!DG1N_A%J)(?;.`;]`Z1@D^
MO6Y/7").=I_5&$HK1TC.G/*M05_MO)M"W**M:%'G>O@0!$\Y)U9+/J00NWD!
M0J:L94YY,J&H]OQ7"7(I-K(80\Q-QW_.Z-#/6I^BMQ9]SJZX"#2WVUJ9621-
M#CD355J#KMJK3670)=O,\_XSS&9<I&Z6RC">\EA:9D(35;`=Z%PK3T/PES"D
M:1@UV%+3@ILOT$)_>',$PI\P?K`=_(_@=S?YO0<"M]LPPZG,ZJK2)]C.V%2[
MI?B0BU<D"3:<!Y<>U`-!`8`+WX`@0VIK.^2'\*E;R?)SLDJ41[@.G<KR((Q-
MD0A3^2$CIU"R/`X?//WAV_1^"293L!@OY^/1"LP>P/AI_CC[^W@,%I.OOZV6
MX-M\AI^O)HLQGAWAO*MK"G'24%L3YX>27553AQ+0J;NW<+%!MZ/V:D@&6M%&
M/]VEGCAG"_U8!Y?$WO,FB$OY][B18GC]1^T9BTR\4HQ=5L\1K9@7&A*'C:#O
MTFN(FXI(]%2-4<600T*=E&JH?A9"!EK1QBG=I9[XJ086"<ED%<NB5!KK22D\
M>E7;*F7!93!*_"FL&1T'":R[&CB%+[A.7=V$OUI+W`I36?>UL8]6N`Q*YE1M
M:`.USRNB%4&B"2S"D;2+9&'??RJ*SJ+MYD7I7&1A<ZKB]>EKYW,@@VQ;7(@F
M;:"!!3U\&/#:.)CXT08-F]<FM-8U<SU*Z6T.VN+VD=.B$$O]?%EI-2"1DX^T
MZ*H5X5R42QOX,SPYAIY[VP,S-X2,Y175@]04`/W'PI-WOQ=%"&21,G7`BDI_
MG`R_3!XGJ\EX":9C,CLZ&LXGJ^$CN!\_3$:3\73T=VZ=B/=2=KOBKGY/=U@;
MT?,%R.!T5+C1&*A]Z$@^:(GV^K3GI&7FS`HK^FZB0V[AQ"L*JY.93!VUCS,I
M0"T[=#[K_VP[;AVS&N?[VYJ#S/OE1)&Q=K=?*D\^-Y-QF.*'*Y:#EV\DSQ!D
M&LLZ@MB\+RPZ;)7-V*+0-&M7:OO:_'D*O>SP,P='M+<W$7@R;O!-=))<[]>Z
M@X$,XUI71@JM&!D,399O7-%`*8U;HB5-=7YJ1'G3JDH^H^BX4Q(;BZ+/\_3/
MJUF'S0`N.P9-0PCG;&WK!2!+O*\E$(V[27I"<8E*A5T+(&J^5(5\3495US-N
MRL=_$6MZ!B+/JM81G19\<-$!ZF5H7!2F9GT!;$+4SMZF$T!VL)H/17^<3;^"
MU7CQ5"5B1<9\A6SY/7SVDA:_V>P+#%DS.ZW(6EI!(K[F5-`:3;5S28N!"S>T
M1;WK^.DMB0WP\QLP?E_OCAM\8$PX$_"$[T#F"1E*OJ\8*WL!HJ8-:TX%;`6N
MDZD!<CFFM!!#%!)\`-,"2&@+KO$K`S]-[Q7]>X>:L/V;NN,[N]F(2RYOBL_'
M=T\.R-<$WLJ=WW$U`C,)%)*XJ%*SHZG-XW+PHJUN*0+_CK#$32%NE:M":#ZQ
M$(-[2<ZF#&]AI3[ZW]62-D`OQ0"7XPBXRW/*[!Q:+GK)0VM#VIC;*$2&GNE`
M?-P,^A7_`/>'G?V!?TCLT7)S9SKZXM;!:D9;327$O[I0C^KOJ=M7>]%#D,2B
MO8P8V'K0+$EJ\U7]M&7RX+1MD-QRC%Q9+?/APA@OQ!7^>QB+E-,5T)/647M5
M7Y3(4MR[(/")@1D^:,!O`4+@F"^OG@N.!V1/XGX8[8"#AW+>!T:!(>+\PP-N
MAFQJ;'<'XE8?BKJNJ*%L0D7J5EQMH*F]@DL#7[C7+,>@AV5NB$/SHOQN4HYC
M-S;=UQ;CERY,X;3'**S6:FN:VAMXJ/#+L>442/3Y8C8?+U9_!\/I/1C_Y[?)
M'!],<8-3M-DXO/0,CUCOV?;!M`QK;1H[Y"U,_#&BM8[VH",N.YL&035*\\D8
M,INJ-G:83;5W!C/)(=I<LX#11[/I_7BZ'-\#]-=R]CBY'Z[0/[X,'X?3T1@L
M?QN/5TON]>.L[7'=;E=<^%'WUDLJ`6(VIPOW&\I3-P^T>)[F]*PGG_PAW"8V
M]#S'?#YZ>(X->#:8&^P#Y*+/*226D,G'5-R0MSE5[:FE`M128H3\_O7T[BS6
M^W'06'&V#8YNO.MI/8'WX"2[JD:Z$M3Q<?+)8JUF4VV>9<$5;?(R^M3Q;WA;
M>/!K'82*[]:[*D;%L+,IA=2P/5`[Q2H;,`6M!CZM+/B"@K<-G^7*[!Q%>$NR
MM70Q_CZ>?ALS7C\P-AS+M%[<.726K\CC?C%<<XU&3O?F[HB`WO6[`W'#EY+.
MJW&06;*0E&45.VW%5_OI!!!M"ZE0Z&$I@(H!4NX&D))DABDHRT;I!]N!YHOE
MK]&N/U:.8;D&28KY:IC6H^VZ7^`6E5D9[WA_;$/<3<0,2*IQO9K((?%96NFU
M6VJ[?W9A1"L$,R(]J`'"*B!1!^!*X!=<[8\WX)G4!*BJ!%T1,I)26U=28R^F
M5EK]CJ;V"AZ/.%)&:QS`](?)=#@=3=!`;C(=S9[&X)9];O<KM*!C[)"_&F[V
MIF7BZ3'/?(/C]P.T7!1]-9I]<8ZCI/=J"L`N6DCZLIJ]?D_MD[CI!!#M"*A0
MZ$$I$@>=E@-!04&,%C.Z5(/2Z2%H255\M1XR*PVU)WGIA9`T5*4&I'\=3\<+
M9*KQ8MSP_FDRG2Q7B^%J\GT,QG^;XZ4+QA'M5^0BR$5]"VCNGX_(\Y";^_P$
M3KB9)5(Y[YJ-0>;928?=.^9QJ]$*6(Q^8&FX(ILK21`1FZ$5,I>@]B(SCSC"
M#3D[)MVO`U`E<%H+A-7`+)D&+X'\O:LG?RH\9_PRG8;B<0N'.%+"<PY@^B-T
M7122O_B*@,,;YZ2R!,9KS:NGO):.9%BMD=K;/WC$H>?\QEX?<7MD/YQXP]^/
M#'^:[^B?@>&WG>!OL@:."0)>[#?H6`3I#IB6ZYG>$4/V&SK=WW<P'`^%7?[-
M5D@*B%ZV?P/\!K[!G4TRH0#T0S`7M4925C=WK`J'!MUSQ]Z:^%B"EL#LID1/
M516L"'*L/W&IWJ"O]ID5:;#B@YVS'G7R"_!_JH%#0H[S$<NAU-$])Z60XO?5
MGO;+@LL0-_`?TY/1L?YU,5LNP7PQ>Y@P7Q.VMO<PRHN+C_KH:.+.@,CIM!K+
MJ"6);W[*KH!?JN*3<67011NTDO[S4B>7*_0?G#&\Q*ON.)5XN)J@`MQ)E%/H
M^5#P;#:*ZWH]<1=9G/15C:IEL$.&GI5#@X"FVJXU&[`4LYC9M8[/#G_$MO%A
MM@"KW\8`<6XRNQ>3Z"%D<4^)1(_4)`%ZVSOTG@\H9,;U["UZ\WL46N,$P=MG
MW`J*G3=!*UJWU^VIG??!)8^4:0(>9#'M$=W!\K?A8DQ.T)\]/<VFR`K/1G\!
MM^#+<#D9D<GC^\GC-V2?&<^)\(]$L5Y.U*[1%W>O2D:/U>A/)T)T)$16Z69+
M\9SA`M2BHX3\KO7H$?"?!=D8-3)02`P@EX&I>""[=+^CJ1T5%,&6$AL4`-"#
M*'3ZE1A,CJ-R<#*%BYN$+IEBS$IMR)PD/:]=D4GE6$[.MDD6)6&[V@XZ%[-P
M(Y;3<7!P#7D"_$=UD8=F44D6>;(/1CI_'XH?R9*+64H$E]<[&B4_S8?3O_]A
M&81HDRD*T1X?AU]F_K@8#+\NQAQ7O^=_3:K%&UG42B_#9+\IM;<UY&*6M:"2
M!T!?O4(PLO<'P_KX@PO(Z,$_Z#"Y\&&\.)#,X3`N92R"-1(\6(Q72**DH4YS
MT!(V#BCLNQI;6<4*F5M6KZ_X_8E4^$6[6AH0^B*Y.)<HQI?91_F]Q>3U79['
MZ9R^PHHX]ZS=:"D>*M**0$'G.O+Y*.'HB_%R/%R,?O-G9,;?QX\S<KH&9RY?
MV&VB3WRJA_5B6A`Z:"P4(,#'>R"7W,NZT#PS/&!HN!X.\TEP3FB:5DB:C=JA
M+(\XLNPV`Z;8C"=-.,[L2U0+33K[$4E<U&EWKI[]L0A<],>62.V%3QYQF.W\
MBG^FB0-?N>'G.%^)BSU4HT.U%2`]IF0V3M<1W+"((VLDRH'M-)S/RK6[`19D
M'YR2??YH*-SI],0=Z1QV4Y7GN6!C#H=%NJV&VFE1YU#%QQXG_>GAOZL21LA:
MOBC"I"9IXR*MMM96>W=*"JN42=GS7G6^,T#^"O&9M'`S?(..\0*GQ_TS=&9;
MDDPQ.WJNA\P:,GSG>15:KS409Y?X0%4C96TO(J0P;X.#IN(7CU833+0]K81.
M#VN#H#KPZ^,SG$@++DBT4?FTDJJ<$V+CKU'Y4OZ#M\%NKZMX\G]%R:3XIFH8
M];^.)U]_P^FVP^_CQ?#K&$R_/7T9+W`&&%EG7*9RP;[A3%VR^O@T_Q;E0L3)
M8[<54\6&FXWI?_6Y86XFUL@XF&B(_02Q8'?M;M;<8SW:6-AS-:5C$RK4K.):
MJFL/!7K1#JH<@AX7`;C,K6F!H!3XX9=C3#,?;O[KZ'IDQ]G*S@$0YL_"#5YS
M14-7,H8>!W<7D),SYTBT5U1B[M@OCK%?P'\>3=?TX!(Z;^8:SM$8V=XLX-I^
ML4@/=YVN4-6XB%!5E4Z1+Q'K\V4`]=IJSP-<]+V(MT&7$TY/=([/>CXS=B`V
M=C=^S(V3Q%%$GD1Q`T(<@``!(1(00+D!$1@0H`$^')#`<UU&5$BT_]]&M,J7
MN+01U5K][D#M^?Y+OQHI`YX+"ZDG[>0ZT3IPX`XO"&([2S;<`)\-C+/+([)C
MAT`,PE2MT1*7'I?JKIJUH$`?GTE]7K39':B=3Y$'670(D=.O[O\>N&6^T8I_
M,C_6$MM"*G5O[PT3<;W7$T>YS"ZKT8Y2BNCDZ<SBG;[B)^T7P19-P8*^]>!B
MD>@A^.$_KF=_=E\$!\7OS^Z?DRZUY[@[4'M4E@V8GFAOT'FV*^QD37>NHU_)
M]AER\H[W"L&!N&G6]5L/D1-NPOW,X21<6^`1.]E]5EW:I9,C7N?-+*]UM8[:
M=J\8N/BD@8+>]?`IB`[8Y_/#)1]34(:!=%)F)!]DOUVD\'VU!ULER"4E)A1A
MT(?K]7%_]$<E]W!KKDV/DY[^@FQB/0GQO]T4%R.F^JO&2AKXT6U?Z;*];D?M
M-(%<S**-8U['_BC9O4DNX=?&.*UQW92+\1=P#D<\:J=7YX.F9YT?ORT]P_'X
M+&`N"/T+?#$M;!7!%P-574/PBVGY.QM9SXXH^I;:E7-1H^)BKZ'VQMI\T*Q<
M'%N<6[=R(>AC\L\::!@>H78V&'>'[Z:++P<6>1]L0=<5R<DF5>K*X\QJ6J^O
M^,9#*OS"W3<%B-3T#AKBX,?,5Q@'73VB@'6"_B3?MBF>L5%_-=&T`'^*FW%9
M]"Z[:M]MD0]:&@O/>]:C)^`'?@;(0U[BS;;I*VF35ZN+NV:("D)-]&23,N,"
M^8+J.+3JJ3U7Q":(-&;3H"D]")6D8OXVG'X=+TD"9NH6Y0KWRP<X5^0H=403
M<0?SG?95$^MS<*?H[9?#UD7MN?=LP-+HFNPU:83)[\S<RK]J7=!(7N)E\1EC
M^<Q[S[M]M6^!*$`M<S2?BR(]G*^1A6+&\#)9F![%9[[)GN+W[Q2@EC>.S\5P
M-I#G(.#$=8]P<W_$^YO]#"-_UL#__<%V@NPCO$.UTQ<YG&<!4P-OJPA^0FF&
MAGJ#YA6PG5D@\4$`!RK=ST'R'P._7I`$'&06NS?A4[QV'U:7HT-"5D^O08=2
MRZVL#;4[G8'JTQ9<$DE9GN7#1I5ABAKP''.-_^4GFQH_#6=396ZY`.H4_B2/
M,+.Z37%9,G0@!*I2D:!4*I1HH#?HJ3[&9!'DHF[G'`V5NT&5_!)U>ID,ALCW
M+A=2!39ODF@`K\@JOG[()LGEO4<*4Y@,[GL#,PZUUH;["GZQH(</5L"_DT7(
MM>UZ[A\%^0OR<.;O?AB_0V=MNF3+>;<E<HZ=%9!`Y:%]`52*E--8;Z#X0>K\
M0EW4UQ0A.PG-DEN+P-!Q4$_^-.GSQ\EFRKGQX1]8B2.T&Q`T?0/"QO$-H8'S
MDJ>#\IV68CK(YLQR&FOUM8;:!V95D.KR3JX0GQ[^@OU:L-7.O^S:'R'!8+>?
M?X.O95NW\2]UN[WOQNX(L\;AW8;T2;QL+$(4C5KL$AW+:Z<W:%_!J@FK/!?R
M;H6@"@=4I*:XZ;LR%LET50HI#ZV#RFL'3R9=Y:"K1*!+NJ5B:!4F[NI3I)-Q
M>T/@#@T:#.(4ITA,&H4YF5%J7>44=[8<E_0NYV!HO$K-LW1YY)#N1"ZC`TQ.
MXVP.Z2IG$W($N;B32$'BFI^K3R7R1L.=P>`B+D+>;`"3^#1JDSM!U%)]QP&G
M3)=T*47`:-R+7R1H()IRJS'>*F&6=+^CEF(Q^:/<Z9[NX"HGV2B$NKB?*H17
M88I-P'%_L123P$N.L).\ZW0%;B.J@JR:UM7[3IA.S\MKM:>XAZLNG&A75QDA
MTXF>"??H3]^1T)(T=@']O-R9FNKJ)]_IECFM]DBBLN*7LM4CH!2_60O4PG'?
MS=F`C_NHR+GAS!RR4<=WZ\C#D\G(NVZ_)RY?CP)`-1WCDC#C@,G<RLU>6^U#
M].F%$.VZJ)&<'$MY@]R2`_"2$2GN#\OP(,U/D1!'>"''!BI%^-0)@S25B552
M>Z:/10QZTE<ZC9`!TAG[#XC];[@<-]/]5(CAT7M%G^E?:'"&OK^X.;N"CFMC
M=KE$&8Q.54*V1NWES7+P$DUV-H(SL@;7;L6EZB>M:+,LG[1%9CA5B1@)M;<%
MT,"7;W;SH)PQF)>Z)Z$^/O7=6IL[>'(([<H>H8A][MAOY@9NOGQ\<U'(;\T.
MT#$\TWH9KCWS#8T0$,CHM(V^N%,41`"N<3PLZA5F#I/KZJS75'N:69S04J>]
MZD1^/AT6M0WP4=%^Z^`7W/X?\6/<!0C[P'G:O^!N@&G]$40]@;@K[O-41.J"
M^&FTW[TY*9YUJZLSK35H*+X#7:C<\N?H:I;@Q+@X^((8)\SA"ZT,3MO8X0/I
MT:_X;Y+,<?1M"K`CDV)$??S*&%*C]H;6!O\'GT6!1I+D=#YO9#C.!VJ9#$'O
MNIU.5]QQ.E08*L;9G&)&(3=5??Q9.VHGE+,)0J]AE4_F80*F?QD^#J>C,3FP
M;+C\C5P&2_X8_^>WR??AXWBZ6H+A"GP9?YU,I_@.651R/EY,9HR7Q3(21\A!
M/^KI1^HT((:OIW8J+)L@K/K!?680$RQJ[1BCWVO5"S_O`WE&!QHNO(?^?Q%O
M^@(G%!F0B%`26IF+526GE6:SK79&!(<TPB<EF2'I9-B&4XS('XE:-^%%HV%%
M\$M8E3%WEHL\@W]#A1E44AAB`M6>9>&2AV&L8WO&KDXO4XQ,GXY78#(=+<;#
MY1AIQ]C_ZX_^`;(YSH===7;0C=('@[-N@Z1"I,):.^MB\L/N':M`J]$*%`#]
M4-)6=;HSX4PRO*"BUNYT&^H/*R@DD&'ZRV'H8;$H71O,MJ>)W&((VKL2@J:F
MKRC>JZ9XF@N=!%*FE.BP4.=&B^&JUKP2LL9`6=BJ]K0II03T;-W8ZR.>9C32
M][771-A&PJS"!'/]M,2`OW=L7+V'!P>N30)ZN+<=S_R7_[>U&;HN]";[@V$Z
M6*Z[IM;(S$/,I"U]N]4H7`E_R&:&1LBTLMH7R7%((SIH8(>D)ZN`9!V`*@%2
M"\35Q).>)K!0F?2I@(/UFZB=\<(AC91`A!W7*?/QC,E/]*8AV-@_+6SMM^8[
MBDX,7)DQ+N&A#56,HC+OT[$+ZR=1>ZJ#0QI9,0T[-'WU"H'Q\N+`%P-1'K[C
MXU<@6:M]L7!&&%Z2Q7>&KX^.@\_C\^?\T4^&!XP=X1-T_1*V2W;C>PB9^;R#
M@<80A3*M\U]1L.\WY?IM/4,+;DT/8.[ASTQ:>@V+WX'ASK51,^O=<1/V]VHX
M+QB\85JH9QA>)8W>TW%'%I!)6[CHJ3X'",*G)MY5XJ\X^$G'&)O_^Q:]+?\W
MQB!OO-W"M3?;CM\12NL%+M!;FEG94U%W_9XF[H1/%B35;$4UF4-;P=1*IZWX
M2@*'-*(C0W9(NE\%JTY8">!:P+9`[B*#!'T1DM.EN+ZD@DJF5LCT]N](8T)Y
MI`26/,CT\</#>$3NH!O_S;^%#BR&JW%T(]W,7U!@TY8'VX'FBS4B+GG]L7(,
MR\7)4K;U%?E"G+WUS7*@L2,IWX-!MRO,N[`@J:8MU60.M86IE5Y+\5W!'-*(
M]B[LD/2@"@CK@$0E@&L%J<@W(*XJ05_:S7]#A6FGQFY,S9!!A=J+>ESR4&C-
MP-<:BXRC.!.B>+#I#Z9E6&C,M\.C(WL/;TA*[2][5&/W@09T0<"V,9'[PLTR
MG]X<]CVSELBYS;9S!Z?H>A]S)`.Y`OO@#R@;VD"<HZ$#44UCN`4-=86R@5ZO
MI;9?89)#M$=A`:,GW`4>G>`:>-@2U@&D$HAJB54$,1Y$14U(NPVZ%MK-.ZW;
MUP9JNPQF622Y"U9<.BZ,U<(-U()_8OL\<6IB#==K^X@3JXP/?-TQGG%<KYTC
MDLTTGLT=V<:!"(/&L<)\!!^H:II2VXL(%8>SP7Y?\=7_2G*)]C%5P.D96;1X
MTCQL`01-D%FRH!&0:$6NX@F9,[M&Q4M-I/$VB,+PEMK^JZ)D4B;7JF'4PVI8
M\8Q0\0X)Q3-P76-'+K'!:TAXL6=GH_]#F/>`<424#W8!U]!\P[UBIG7$721`
M`T&4@A4*6:Y.B>K]7E_MV6@&*2[GH\ZAE'JDN()(WHL9_JA&_/30AZ8^#LJQ
MZ;I^]B<DD33L84,5NP9L^6-EB+R$$U4BCL+V7J%3TYCH'FZAX\#-`KY!Z^B3
M1MSA-J7]UZT6Y>+EJ\1Y762XU#Z7C%8$^6X@$T>>#P@+@Z"T,(I+&FA<BN(4
MPX=476R0U#Y$DEZ("PT*<N"<Q/^;D.*.7^@DYL?'[4>I;#A!SK8J!_\3"_6#
M>.:/+P<M<:L@A7W7S?UBL?)YGZS71Y_GRAB?AB_?I*<PY)GS1$$A+)85P\NF
M,4W4GJ@8AI-J)R;3BG"Q.#T33EZ`;M9'[>C4JN#X^>C(JF97DVFL\W#437EZ
M>?/9G]M&'T5`5Z8&);+(M^_%@/*,?7S88E"-^Z1%#LI(BN>541&*`#^W#6+9
MKBWN*97F0B%_&2Y]1!*<W+.S`^.])[MXO8#Q',$0S,1*K#D\V,[)0OO0VL09
M$4TT0,RZ5BMS$Q=S\_4H015ISI6!OBW\M;K7,=W)+I0L#\*,+'8E$RNYZ`Q0
MY?.L*+S+ES,SJ@*U:';Y7H^BY'H-MB^G>-XYOU!2?0@S/'V.6GXU_,V'AU`[
ML`^!TO6":AOP]2A&>E,PITU3>U,\OU#TFE%MBS`WPMB5H$`K$5.1:]E"9;D!
M!^)+3G2&<>_L%'I91T\'>>[)HZ<1JWIM<0MJ]$"JJ54E@4-U8FE$ZRE^-3"[
M,*(C,&9$.KY*H>#FA*AFXN8$\7HBY.Q-E?4D=?`F2R-X#Z?:"W8<TC"$8/R'
M;K+C(OI"+@(X)/1E&VF)(5Q+HHF%5JO;4<"IU#/U58?\[+H33])HO:[:,V'\
M0JGC<\Z0\?@>[KGD"@03,J=\10J6FBW@^>+(?+9_+]%<2BHI\P7\^'1R!O3#
MX^RO2_"PF#V!A\ET.!WAJSF&H]7D^V0U&2\9)YUST."U4]=+13DM<=NIZ($(
M42`Z@4LT)[,1K=>[2H4I$.9"KB@?49D+BFK6/?PII(W,X8\2>D([_,EL!-NX
MJQS^%$ESR>%/`:YX^!/>@V9&&E+ST"<#12(RZ4L?^A3@D:4P^?*SZTTB%N^W
MU5['X1=*'7]SAHS'[]0]]*$AF,RACXH*1COT*?SBV'3^_C0LD.J20Q\*?*FA
MSV3Z?;Q<B1CZ9%PZBB.<S*/QA2I2!A`A"D0G<(GF9#:B]7MJ7VG"+LR%7%$^
MHC(7E'5GMG@]D3GT44)/:(<^F8W@U$*U[_3DD.:20Y\"7.FA3]85T*(T)!F9
MB-L+P(Y'EL+DR\^N-R>QN-K;>?F%4L??G"'C\3MU#WUH""9SZ*.B@M$.?0K:
MZB';V1]<9Q(/E5B7'/S0`$R-?F;S\6)8>?0S(2>XXF/Z2!PC=&TG[JNR)A3"
M3K`\64[K=Y4?NJ?Q2C#^J4Z)7?=_#8\V'7J>8SX?/7)JB6>#N>$PYR;G?#=1
MUEDPW;*,:K(<5ENU4X>S`<LRA.FN">UVZ`<V6LV-#YSS&Z04KR'<N`_HX\WP
ML3K9ZQ_=;D^8G6-$4XV:U44/R<O>4DOQ^\$Y)1)M;_E@Z6$UDOO^2UB3W"B%
MXFQR@E3U!6YN.HDYM.$Z5"E]L`-[4X.&XH-77I$HM*F.@Q\XX>G#O7\BV_9H
M;?R)(-39(;AY*KP9&CCFRRLJ=#S8^+EG.A!W1FX]X-.OE3U<__.(VBG:`M/K
M#80[J7(@]2@5E\#GZD352$=3>Q*571A9#HD:4>R+T#@@J!/M[+WQM_;>D/U8
MG'M[>5@CU@.IJ"?Y?J>\E>`LG+;:*W-<\DCV."S8:M_L.X>6Z]^U2CS=W':]
MV#]]\:\W'=F6/W+W[YAO]7OBTJV8\534FAK$CW2'HZVNXOM,N&42[G(X@>E!
M1:(S_J#GM"X(*H.3VM*42I`3NAJMRG!)'(T-&BW%!T/<0LER3KP`_=NLL()5
M&!C5KVYC_XYP3+3,LX[DZ5F`1+R&Y8O,HEIQ*UW%-Z!P2*."ESJ%1.^?@GH2
M5$7(ZHK:JI):F6%K!5E"M=<)><21LJK#`2QYEIX17%45'O7R02:[Z_4VB=G!
MB>L>#?0Y9MN1O=_;UM*SU_^80G+?-L'HXL.$,F?A,H]&8FN[HEY4E2-2#;:&
MR$A6[55-3HF$>Q,N6'JTTH/K@;`BF&V!7Q60N@"OG*+?PNIRE(+F(+UK4(JT
MOV#_5HJ?4,PID1ROP85-CW0!C4C<5P-UY-]#C?YIAH_6R`/)T06JP_.N01G2
MQ^;Q6"ZUKR?DE(A>&ZH=F,<'+W85F`2Q#B!]6/NNPB6N(M`1&%;GUX^,.X!/
MERK:G8;`1!MZ)/5I$KO(65I4WDJWI?C2#+LT,@,L.DAG&G-^=7LM2YD\W!$S
M9%=:70I#,(I6NHWK&930BB,]^*($=J8VX=7NM2QH)M%@;S4CG\T=OT-G;;IP
M@S%T!"Y@EO5?HVI0BI>I$#EUNX,K\AI%,DCU%05`SCT$":""LB`J+(SC_=\W
MQ_L<',>#/\57!ZF%H&?Y&W2>[5I,?!$@/?P%FW/_+3+.)"WQ./R+@=I$HQ4\
MOB`#H#NMVVRWA1GM[$ZKL9A:D)"Z>15Z[8;:="T&+MH0%_:NDZ>WS_@Q2#ZO
MEY1"PNU+D#(51&=7(%L*-4WM"<LRZ%*"XQ(0/C^!S\\U/S\]PR-+6;,MWASZ
ML+-_QEMXVP.!X6Y1SQ6IRB13Q->B6F23F-K7.5'A%VY2*4#HH]GT?CQ=CN\!
M^FLY>YS<#U?H'\L5^L_3>+I:@MD#2.PXYMVTOSP>#CN"QMB%:";6UG;V1%$B
M7)U&NR6.YG0@*C*>5]*(_+0-:(-V0^UQ'JLHPE6"#8^^_#:?/Q(]&"[^#B;3
MA]GB:;B:S*8`_2]QZMCT/O/X93"=K7"QV>-W_"!6HU^EZ9&8F$9%/4H'/;0-
M-)NJ;X!@%45.4,0&2IPR\6O0;+N%#MX1:&W(@#A<9!O9KD>60OM9SBAS29>Z
MV?JT@A5]EF(4MT$NI[L>U:`31J:3H4*D)VN`L`JY%-.?:(PR'$@UX72G2>=1
ME^Z%?H#B>ZA][#B[,-)]`16L.&L'I^8`R_;`!_3`P3`99]$Y&$*5HJ,NP=.)
M.8QO7^W-:NS"R$K'849V:MCMT+#C=5$_!><D/XTU`V>(VMW@MA]VQLN=5CJQ
M[L+UW8O]]GD#33_41W^<1_CHI]-VJ[&[&&)(W]-2:F>,I;"*CB;..]2C'P#^
MA8TRHZ.#3^MZ,-VUL?L[-)RQM;DW/'BGE4XNTK(GKXMJ1*(&'G(JMT)3[>GN
M0MRBN5;4N1X\!/Y3@!\#]!S@`FPLO`^L,,XIL3ST]K-&C<W&H)%URGJFLZ9I
ML1H!.3&'=*2J3E83U-Z=QR2':+JR@-'#PF18Y1<'B?+<$W)AN[Y:S)&'MS</
MZ#<4L&7RE\>FYO91#Z?+H9_3.%U#:ZH=598@ET75[.YC<@;&U2\`2(DJ=,1&
M.ORB90G8?&2,>JB3BOFPLXD8E]>::B=9%.*62\+3SE,4)/Z]`@%]"D=A6K?L
M0&%6^IVT7P_YBB&?4^^TM.([A?-!RR)=JN>8<8&UJQ9,KA"@NZ96=BH$*\UP
ML_6P*Q/@.:E((<5//4EAE46AL,.8.?@7-KKXD=\(57:,W<3:P/>_P(\[K5]7
MJ);9?C4"T4$.F9136O%$@0+4HMF5W[4>#!."9X`\!.@I%^7B77LD6\R='3W7
M,ZR-:;W<:8.Z[%9Y9[60D468,V865FVHG==%*X(DSI;AB`B<."'@!OAE0:(P
M#Y\?S!UT1LA=O]@.MD9US1]FM%X'8XOAGE+TM.Q`[0GI/,AR*)CJ-Z0<>0#"
M)SP$6\`7$\_(6-[4V*-PO%_7`#:K^3HH5@+XE&/GA1MJCQ_R0<OA64;/(=/B
M1P`_8Z/:RC&P`5Q^[)_MW9W6JXMC)^U6(U<QQ)!5IZ44O]\F#58TBU(]ZL$O
MP/^)<>5U1SXBW&3O"PA/MNKTFN(V.]%AJ+A\RREGM+!+5[^O^$8^%C&$+P?3
M8]&CLB!O_Q3?\8.,M!"2@JP@_5.)9W3UR2ZB;E?M*)-5%'HUJ)!TQ@CJ9!<A
M_RZM<7`,X1(Z;^8:9O<=0$-_S;8+N+9?+/-?<.-/=)(4H4?3@A,/[EWDT;6&
M,"]1,]B*8;+H-Q>%V#5WU.DHOM],C,#"0WL1J/6P51`TF^O\;D#<-M[H'K<>
MKDB0]L$/W`,@73#F!M0CX`(>;,?#(.[MO6'B3=&:N*V@8C"K8#C*WV.]]B/5
M7Z?;4#NY7*C<UV%-LL'7;E1N@-\1(+;EA]\7HW7Y"BWH&+NAM1EN]J9%)D$\
M\PT&<<\3W#]#YZ[9ZH@;A%)!J*;[G%*&JDQ7O==7_%1\%C%$*QH#%CTH2U+>
M3TN'0T_PPZ_`2/X%="%Z?:\(Q3U\@SN;'#)V"J'=ZHN[QIH"0#7B<TD8TIZF
MLM;I]]4.:QFD$$UZ>BAZ6)20/E&X(N.7ZU>X.>*#^>KQ=%\^8E\W?#?=NW97
M$W=(JVCTU71-_KN-MFZ)[EGK]EIJ^S99KT"TB9`DAQ[V@\/+^N/2YX_3T!3W
M?&%+M3*>=Q"K4%F2ECKFB4!6RR;EO$51ALCO#E-6[9EMH7)?F\E)@A=J9\`/
MTA6C8<$W>%M(ASX>\$`"H?MJVQMD%[5V0]R$6':GU72;6I!0.W,J#+HMM6>4
M"G&+UHZBSO7HX0T('P/R_`9\=6R7<==#V0<5L@9Z"6:F%CGS*K0ZO8':R_HE
MR*4L819CT"-FON"?.2DYA1[^?OX`9""4B*BKFNB7#3I%.E*LU6]TKX1J2;P,
M!+,]8U>18(F>]15N#YCA(TY>+8R?3P;BOFGLB(%H=L7[X&2?-3&M1(P4Y4[*
M#[K=P74P+P.V-/^;[COI?M%3$#VNYGVSOZ58YRN-DOFN][0\]AUJYW\6`Y?K
M>+,@Z)B2^_!73B[^U7;^,;'(F?NN_Q7%S:YF=UH3&\L$2='QM,*@J_@)@H6X
MI=G(C,Z31A(_QE?C!@6JF<F<+RK63DJD9KZE/*N`U?TJR1DBEVLK,S'H(34/
M_N\I3B9_>$1_H1_#G]#_X2DD],O_!U!+`P04````"`#SB:E"<.^+LR8:``"D
M>0$`%``<`'!L>"TR,#$S,#,S,5]P<F4N>&UL550)``/Z$8Q1^A&,475X"P`!
M!"4.```$.0$``.U=W7/BNI)_WZK]']C<ESD/(9AOIL[L78:0.=3-`!68.7N?
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M^SEH^6?+?U<9#`9W_E_C5UV#]"(TJMS]]]?'A?:*UNJM86&4-`3?<HV/KO_P
MT=94SX<V\?4D5:V[F-W4-_"GV^BU6_SH5FG>MI3ZNZM'))XP0^[D!E"NU0*<
M'=M$3VA5PS^_/4W20<8OW"V,%\M8&9IJ>4--L[>6!V*>VZ:A&<B]1YYJF"X0
MX[?\ZJ#5IQL0W&TD'TSJW_`#5]WHT6O>;@/JY!KKC0F@W14GS;.U'TM'M5Q5
MPV"SD./QIR8+*#J$%-XT3:PW9'FV0T>!P;W_$PE1B>:BDO%_[NCDLQ$HGZ7Z
M;-))R>,NII%MZ<ARD0Z_N("'CHW[9]7$5FWQBI!'0Y>F/;L7(6SAP?]KP,V=
MK68;Y*BTFJ5IKFU?EL39:O2J6B_(G5@C=6/`=^_1"NN=1:5SF&+-T+C;JN)$
MSU4'WGA%'@PGDX$#[D,G5S5&JOOZ8-H_:35#6_$F\=[6MIB8H:6/P>9XNXFU
MLIVUKZ\41.G(L$H<4$4D;8NTD-C=TK<FFJVBA[N1O=Z`;PJ4TT_]AFM3C:B-
M@UQHV0?C$1Y$7S`\$[[1;B@-I79;NS=<S;3=K8/@PV+R93IYF(R&TV5M.!K-
MODV7D^F7VGSV.!E-QHO:AY#*WZ+>,8L<_:^`&?3N(9"R'OA\$3NFK85OF>HS
M,C_=P(/_.6UQ^.QZ#DS6]5:_4U>:]>XAHDG_>J6ZS[ZGN75O7U1U@YWRYATR
M/3=Z@L%OWC:4T&?]6_@XH]M#3DSL1=M.))=,5C)Q\B?7>K/1)S)%4A.*]JAH
M36K1T(GH7CGVFED"GEV(4]O1D>,O\?"_F]K&,6`X>;M/-_!AZP+I]@93MQ_D
MJJ.=*.;ALB)\XV[CVXA;[=4PCT84O$$EMB%0KQOFUC/>T`)I6Z`,N)BJ:W1O
MKU7#JG<Z`\Q(3X@>YG1^AC9BQW?FX^J"^7]"(%-#P[;V%2!SOZ+U,W+JS6ZS
MU2-P1U9(FB;YZ"2K3&+-9.:Z1.4$%%;(<9#^&(@MM3V_,0\Y+O+?/$.MQ^^:
MN07+_`!0XZEK&\A@MAJKCH6C)W/D^%!]WI$;&+X;;KW3;8BSS.+H+CZ8:/7Q
M@H@PVHAB(TZ,ND2#E0%5N:>0D6W")QN[K6]HZ#AXZ>)[LV""IK:EI?PY&98(
M+=-@T!8VUW"CLO@XFH?.Y6?#7KZ"F[]!('P-5GF:[6SLP.V/;'2C/VC0SDST
M[7(9+.+D'0V-@D!5=3*;KXR_D)/&O4*M)FG-7(M64,$0*D&S:DK``5]_.AH,
MQ,W5G&@L;F&Y*Z&L,,DU<(F*%0U;$3*1VR%::,A2@:)OEKM!FK$RD!ZZ=.U.
MIR7,PTGM]HQE=-CD\J>]-[7])O62^?CK7!26`=YX89S)1U6GC(CKF8427),4
M,%-Z\=?+EAZ9CZIZ?;'.@H@BOOO];H_:WR,T4+8$TW@)9=BJJ@P?[*V38)O9
M@.Z_7[8$4S@)!=BNG`"CK;F(?]_5:0\ZBC#OD-CE^5-XNJS%<'&6,Y*KP'1B
M.5;>3`RD\2ESF2^RT[;?(LA![M>`X3(!WQ(=RPMBR7\!6:([<.Y.]Z-AH0F,
M,-</2C6Y[';';?*QG6>9#W;>2W0-!`B3RFOC)TPBS=,M]K]FJ\7VV04CI.+D
M')]"ZJ4=J07QRI4%9Z1@N;Q5=;DW=VP-(=T-YI[(9-J.6U?:K1YI+XB/HY;:
MKQSZ0`=+52,X7PT3N9YMH;FZPW.F#Q1ICY0XRH^_+8=$,WFJ:B`@S4<"]5X9
MGN]3@F^I(?\LCX](AU;*3$W+H0+%T:AJG`%6&VO;\O.WYJHS<_QEFOY=-;<H
M6G/4N_U>7V!Z1"X!LN@.$U*APG2JIC!G+F"':PQ]O=-7NA?.[F0D40ZEXXYV
MJ);=*U3+W^].,`<(?S!D[K<(F?O+V>@?M>73<+H8CI:3V;1@LG[.B43F!/V1
MJ;HNK$9PNWM%&73%C1IBCV<F0D]<=XOT>U!;4'L$JA8F!"?SA<?O,.,:+M+K
M2K?;$I>'QTX0GRP'*D$>)%(71^V*1S?U&C4%A7:G0_)<^:]595$5-DQ"S>A5
M33.R!XP?,E?]4V_K#0+CC%G$(T81IRL%*)+.T.3C%NM3IUKZ%`RB"<S2[TA?
MVCY"CCO^UQ9X"_[WMPQ:X<@2LH5)1T/QJ3FK_26T%FY1`H_=4GC<T\!E8!05
M:314V.&29BN3A_B%&$F.XB?R.%YO3'N'4+`3B,)/<1+7H$%]^BZK)>'JF26.
M2#VI6:WJ!L;XB&6EV::.5(_EE2>!G:KN-NP/^/MNR>>=[\L$6\+M7H.TF<TK
M62BU8T[Y;@R,T<PWY/E*[ODFTS$5<\ZA<"A#B$#S`)`\ZP23_6J;>JR$4]M#
M<;&"]J#?%YB2F-4WIXP^-O;VJ7U4FE#ZT#PW:LI>[80E;$I3.DU`<1,QVPX"
MBIO`(MP`TS%/*K&E9V=2`5*?X;L_ZMV&0&[/H8S+P&60<C1F>:%YQ9[T^>:@
M>6P.)M/OX^ER]L0V]`D5"ID'>EP.:D]/K`/-7E]<_9B,CHN/=4*C>^U3E-;@
MHOSP':Q,DHJ&*S4@O_1X;.5O:9ZSD5EX<%(Z5N)B\.?YC0P\$=6SV^T)/'%+
M2\<E763R'@,S6K_P8&X6J"P8E+'E5ECPL"KNK^QZ3U4/1'!0&-/'9J^U33"^
MU-F2N<V5Y12S\7G%HY-FH76$W^X8"E@$B-L4H:.AY,43`T)5#5<?9]D=0]#O
M-<2E,>5T7I9V,&!RQ:GVYT[PK<S5<^U#4`N>93)/+23_BR^F236CMPY6#A^F
MA.O9Z1'+(O#>8,HFH[Q%=B&@KM@+.'<(-_PA')]FA]]'L^G]>+H8W^/?%N"8
MWP^7\.'S\'$X'8UKBS_&XR7+$IS^4H:B[KD[5W=8N$-+AR?.%L`TU&?#])/+
M0^GO+;[`VI@%Z"EN$HXZ6SJJCL+&ZYUVAY01(H3+9,<\I^NSI!H?.*`#Z8H-
M`(N.S+Q7Y.S9;XN;*#(ZEEU'TD"JJOL_=%VPP<=@=8C']#DI!ZG'XH807Y`"
M"H!_X+#<FVKZ13.\D>HX.W#B_3-M]:[(_#\J$O@H/I6TXE0-5FBJ;@B?D(8`
M!ACF4^0E)@)2,3B^EI#4<PD:00M$5:V=;]WWS+L)[I66(G#IE-YQ"5I`B<(5
MAS;H8@/`=UU1VHHX9SG950F"3N6TJ@4``G@2N`C<I3GHBJ-P4ZF/C7B.#E1U
M%L?7]UE(_XPL^,6;FZH5(/%@._A#^-S%Q=)":]8;"%P(,Y-S21TY"ZMX]J_8
M<;BY8V^0X^TP`OYUAN`4;W#<RS>/[>Y`G+)D=7U)O:"&H*J3/QFG@20S1`;)
M]4Z_WQ!,JT!-')!GL217U^.4X"!WP1`+,-QK"Q8C_Y4%I30)/%[/2I)-J!F1
MQN:`F$C#1\)G[B7DB9N%K90(*F,TML+>JM_V$X(UV#;>=NB1KQ[@YI(2^BQ-
M,?(AN![KP"9\"K2$V'\1.XVG;=85I=OM7Y")2VGPR;26P_OU.,F%)[?]"C&)
MEKB%4F;7Q97XR!0EU[W=KKBP;VJWO#6:1DPI9IF,156GY4?;>EDB9WV/GKT$
MYTJS*3`IC-QIF3I``4-5Y^8YLMS@K*2_#S*W`2OD&8Z?`05/\8.@\`A^D(B@
MN42LZTJK+_`P`&=JR]0YD<!?STQ<V)'$AWM/SB`E4&^+JVY/2P5O[6)D.=UK
M(ZU5*C##713*[*'^_P,PA%#TDNC\`4CO\N/%3G`N6317XF8H1JEE*OX!'E4-
M5R<X!W[#XB^BY2^?U`]XOY[Z]VRRQM<`&%YTS=C(]H])(0L?DJIW^P(SA#,Z
MEL2)H(2FJD6J3R'#Y]J[X@(_IQU*H@@Y2%2U%G4><-@^MI32/![Y)HQ\E$)5
MZ<NO*FRS2'Q^;+9Z,"P5;*1JPF+>\&'?%];HB"R1DD\!%XTIQNKA+CDA2><7
M6(N>AUP1,W[%`<SSSW6VZ,YU+I;PX^MXNES49@^UV7S\-&0MLD0\X1EW[29K
M<1PBQ72<&[I#<:-[:7<4D4>YB9T67V.'&RZPM.AT>N)"QE$W7`P>-?+12"4R
M60'[EGZ>Y(MJ6.ZC#;8=7WXUZ%+7ZS[^=CD"R^3ABFWH60:EW;P*BS*R79A/
MPR%7[RF]KCCB#_JZB*KN^=@ORM/XE3_^/`@4U4(O>(+DIZI"EE_<-?6+`\8E
MN)FTCBMPB4L?2O1T$2T]61.FL5K5@/$3X`>]X*/&]S`R3=L_4#!^QW<M(7`#
MFL&MXV*L4F;G)5DI!D#D#RP7-5M?'#4(G3XA8_V\A=G97PX$QTZ1/DL<0/4]
M#E)P@.@U,31<CD-5E/.JAI)S!U#G*F:P:%0GAC0^0&6]&!9"^-*Y<(#CDU0@
MUB#'^9@WHD8SM'P9B]9)LVC,O,L?'3^T;TNVJ>\+LI"CFOC(@[XV+`,#B6\W
MCFU]H]EOBYO\<KHO:?IC`D7^F'C1"3`,>UDO`8)X<5V'@2_P$!^AQW(\X#S6
M0Z$/Y!5Z,4_XP7:0\6(%26?:+E%Y'L=7,`R?T0K>6:KO,`H:`@NK,E!2CI-4
M%*HHDMB07W?8O"28.I.CI=GKB=M</>BK'!.1SFXDX2L(%K-9A^.JPK@&M8;7
MB(:YA9FEWN\.Q.V0YG1>CA%@0"32BLI%HO\$,_@*S`[?8,Y\0=,MOBASMO+Q
MF&T]UU,M'3`ZAD;IM006MRE&5#E*Q`'`2+DDCAX+W"KN,&X5XYWBT1_#Z9?Q
MHC:9UD;#^60Y?*S=CQ_P+1[3T3^Y;1[/5J-7U7I![L0:J1L#OHOKVF@&]A@*
M[R4'"0/X+GC;@C["&VR57G!GBY";'XE=GK/KLU[;EI\$$=ZKJS1:XJ@_Z8[+
M.*<40S(=,Y7GTN^ES*[_H>M&T/M<-?18E4,VVEU%F.0R>RY#BK10E+CM3./(
M93(MQGWC:T&>D*?B^F"1`Q8)H"TP1X_<YP6TD)"BDL>]_+O)1;.ZPYDUO-IW
MT&D(,SZ'?177U;B=(RF[_L7A[;!LG5@62%WSS2=-$<@^"9T2!+FGPIB-Q_CF
M<*"]*5Z`CWPO3F>5&I%=N2>Y#-J5AD2R2B$^_<R&*.J%G%"@D@+-217\]M5D
M86X04(:7@8[',+?A!;^;6/$#\^UF2Z#(CSLL0>+9/%]-]F8Q@:<C)?:0"2\#
M-7'=+=+OMW@#?1X@X,MSBG[Z?W+Q\&T*OE@XEPC16DT^<,>&S?6DUA4XA7D*
MA7]QQP$2#<'7,^?1((N29"!3U37=4/_?K1L<5%[:*0&6:'<%QUG7.`O#E\'8
M+[:#D(_E?.MHK_#&W+%?''7]A,"!<`T/+9#S9F@H@/<):?:+Y?=0[W2[`N]-
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MV>VF1H`NWR3.9<_+A"L],^/\3.$N[TSAVH>Y3_DK\@Q--7^[2.;P09>%TXC9
M!HKHJG<B2D)3Q:;WTP7^7[4TA&NTN/5.5^!.[#F4E6`EBT7]*9"]FH0.H3.N
MV-"9F+&52&<'<S1S_.X"'STZ#%7O]GM]8?Q1$%#"2#F)Q3'B=#4)+\SQN000
M@2\^W'JOP-M?2,<`#"ZA*,<=2Z8@6;A<S>8_23'.=]QZ1:J!CH:+/VH/C[,_
MN58#':GNZX-I_RQ>#/1@]L2;VI9FF.@@:K^T<3=SQWXSH,W/NV]`T,2*RQ(,
M-<]X"XK)Q@K6%W=]C@B"SPB6$],)8"7?;`MT58F=<C$@%U&'@Q!L-GA5=<KN
M$32O&8$<UK;C&7\%OUNZ7]=ZLMZHAH/E4&\JC1YU/2_Z=J]/70IB=C5NS#FI
M:IRQ%U-A22[3G5\TY9OE()B0L?<S&'0%5H-E(47Z<7M:PZHPTO([FD7K665>
MWQC>UAB7^&KU^^+"/PR42*]Z;+=D9L!<U11X&CSP[4R.\;SU4\HP*D'A>3&6
MCYD@Z77PU/R=";K\*<6%J]J&UG]F+503S5:`-N#K[?`UM?Z&D5\;LZXTE('`
MR9>.BBO4NR+PRI^U<$;E=_`Q7'2/@I\)4,--@GUUI*[2%3;?TM-1W+4][>/H
MFGH0>K\C+D:3VS^7T72.1*,QPH945:,1!9`4=J='"8-CJ&GV-BXJ[N=:8*D+
M++1/0T-98^1T(F%'3/Z8"[]I9&*!H0#1^-?<-@:MBPZ/1.<RZTLJ1M5=X:</
MFKFZPR,&ARTUS=E"H\F+DAO]GKB3H,6(DGBV9L:TJBM[6$20%@[A[9#$A4.K
MU157])2=GN(S.G2B(:2[#Z!L47K/;)78S`9B9JLPSN/ZFP.DXX3$#16VMKF,
M%!ZBC&,/Q:&IJK-[!KRBSN>5,E)23HZV.QUQO.;V7_8`.DF)84-,?K^W:,I4
M"J;8L7-3`E.M5E]@Y)B=H#.&C;J+\DNU?VT-!QV$TO#E/?MH6JO7$WCI)3TE
M(D<2F]3CH5001?DGHL*[@"$B#[:3M#/^-@$!8X`E/)$J5KDHR9%7PPKA*;_M
M+JIF9V!\R;6!&-.=G+]/MT$.K4Z[(_"@*P,E98^LS&4$"XJQZ>[(.J:XKB&R
MMND`6W&;2NST%!]1*14]1/'%N78)#\GEU#:I\-HY>20P2CU/'BL0-V=D]<S[
MZ`0%:PD5.$.=*J`F8F`5G"0FOZM7$N[%@O3R;^((M'9"[A0\V]J=Z;7XDUE?
M&'OTA%S.M),N52R"UO5L,*5>N'C1J9)R/2)_%B37E00Q6M'LM81>8TI)B'QC
M,@\M^;,:Y1J3E%N-5:U11(\*UK*VN#O(Z0F1;TSFH74]96D9+R9>K9#F[ZEK
M?M&<)\!T9F&$AI:.?^!(V9MJXK5-O=]3Q!T39J&DQ"5T4<"J6A^;S'E0.>YX
M?5;O=OH#8>:'A9(2#5!1P*ZG`#&C":*"4?"]8UP7KF0)#V'><9P=3#%^"1L0
M;:<KCC,J&BXW"DZOKV('Z=IJ&A>]TBH31['UN,L<!D(XDVT8G-1U9@>IVJ6>
MMYN-Z<.HFA&,$VME.^L`^`C03J,M\-8K.B)*=$(+P!2I3>7"WI'/-+$22?1!
M2DW*EG]3:1`K%!`SJIF;YZ,61<?!\=9(,50JL-.7:UYFL)##1:X!A+C>YK[2
M)D:#9&&(.D+=K!RZ40R%"NQ"IKHI)G+C%.FP%F&8.%UO-I4V*6.$J`C9;<DA
M?09^KWBG]/RZB4KMMG9O:]NP;&+\JVKIM;$%K^UJ"=PC%BC*)$8M8>OKMT-H
MAKDP8E:C^TWPQJ#1)Q2J)]=FHVBQ^.(@:GT)WP0SDW<-O(NT^HO]=J<C(_#C
MX)=C]PT>'33+9;@5Q#4N`D=FL_1Z\-FEVH!B'5/]8*HO=:6==[<!K7`.VI5!
M.FF,2G-?0>;0F4?+JWM80M25X%)/CF/HH'T9Q)7'>(G3%8/8'@Q74\U_(M5Y
M@"<PX39ZG`5WU(-,HDMGOL1$%&;A!0H8<4":4<\77Z(/^01(!J#$I!<*$2X=
M%=^;MMBMGVT37\["26P'[<H@JC1&2TPKH=F(]CE]0B\&9M#RINH:;'N?EY1(
MS<L@K!RV2\Q9H9;9"%IQ5',"*Y7W?Z`=4,_+(A+;ET=JZ8R7F"U"$_'P*]LF
MYN+8E0K"S1PDE]:%#,*C8+_$9`WJ8?=@F,@9`=TOMH-UCY?H"*W+(+5LILM,
MCJ`WE,?WE1Q<YSK@%0/)[TP>>5)"4N;6/Z]X8KO(/2RS^?AIN)S`"\*NRW-G
MJ_"0`/R5S_UXX_7&M'<(A5>%DB_.&)J^XL%OLQ4^,_5BX8+JP<K"WWUXC&\L
M57J*N.J?G(DM'A(-^T`ZF82H\'>GUQ27A$E'`Q?[(5Q)XB@?,ZY5W?[D`_D3
MVMB.?Y]P?-&IDN=\E#T\CVDN/DJ?0*M!4CAIYQZ](=/V=\]#)?J*UL_(J;=;
M_;Q@;'%`*`B0:'SF*TLT3!F!E7L+Y0NR8$HU<8%'?6U8_N+>,][0(3O-EL![
MHZE(N$I-8097[OV<X)!X[(_M?>>.,A"F'2F=%K>+"^T5Z5M<:X6/.H27B'>5
MO&#2&7E^(DCF,J*H52).Z1&-OMSFEC?[GW=[:Q1<_=Y5\B+1\NCA,?5\\HXN
M#G$<*1`^O4BCW)<60HJ1%655LF0NC0PN&M&0>,G$%M&03',%RJMT9_+<4&2[
MT0R2&PU7,VUWZR#X,)E^'T^7LZ?)>%'[$`FK9J]JT5T(NQJ&SK9PQ/"WVH=[
MY*F&Z;*$(1.W*NRU(6Y^WWK8=.'H8]SDGL&]`]7KDVJI\_*I4SLN[E?'C3ZI
M/[^"/^@8J@GZJ+2;(B]](O3)R;%ED,W^+$,>!%4-V,6<_VD[/R:67]?2#5@7
M5_F3W*D$XD\'H:IG$V+6'W"8`VSF%]O6?=8;XFH7DCN50/[I(%SQ086SIS(A
MM13$3F53Y&'Q!;Z_6/JAJXMI[DFIAU2&KZ<\V$DIAW3O,_P+_N\97&UX\G]0
M2P,$%`````@`\XFI0D_E*^@;"```#48``!``'`!P;'@M,C`Q,S`S,S$N>'-D
M550)``/Z$8Q1^A&,475X"P`!!"4.```$.0$``.U;W7/B.!)_OZK['[Q^RCPX
M0)C9NZ2&V6/XR+B.8"HPLW=/4\)N0+6VY)7D!/:OOY:-P7R$L8FGQGO+2R)+
MW=*O6S]W2T)^_\LR\(TG$))RUC(;UW73`.9RC[)YR_P\MMKCCFV;AE2$><3G
M#%HFX^8O'_[^M_<_659'`%'@&=.5\84R1>9@]*F/NM*X,K_TS3>6M98,!?<B
M%T4Y,V[JC:95?V?5_VG\RWA[U[PU1@^)X%)Z=])=0$`,1<0<U)`$($/BXK`+
MI<*[6NWY^?D:.U/$I\MKEP<UW5N]V6P@<!\"8*K/1="%&8E\U3)_CU!P1L$S
M#;24R;O07^;I*Q%>3H5/=\1US347<Q2M-VN4:<>XD,JS*#@N[2E14ZL0:B@!
M@KH;!<YRZ'!F[>EI(4]M]+*HWM62QHVH]';Z?VZFDHW:?QX&X]C=)GK?,&+_
M$\;0(PKY$->EM6%(V8ROJ[`29_FW._UG2B0\PLQ8QC6"^W#"8;JYYA+?C?QX
MB,&V`W/=PT+`K&7B-%GI;'Q%A6LT)I703FF9D@:A#VD=$>[!T&M+&[>WM[58
MJH:3'8)0%&0MA;YQDZXXK9Z*'DCNVKCMN5:*NSR844;S>POE_\+>\LD4_'R.
M0M&_L*-"`1*C98'7$#7^+_RE$4X0O*$+GQ_ME_-![*@.9QXP"1X6)/>IIU/>
M1^+KP#]>`"AI&M1+?.6Z4UD4WP9=BF_[PG^HUV\,RQCC+,6I#<L=9]CM#<>]
MKBZ-G8'=;4_PX6-[T!YV>L;X4Z\W&;^O[7>T/T:$]CCL0US>B\=KY;7$*<7=
MR)1?;Y]Z^34W;W=^%>0Q"%S3P,MJZ]J4%]^!+IL9E,ZL0^2B[_/G'=I([L[*
M)<X_\A%G/,%_#[WA9&PX?:/3'G\R^@/GUPN%*DLA9-""L#E(FW5(2%$75[O4
MI0APM4<IZGKEDNI=05+%G/K4'M[WQH8]1'J-[$E[8'1[?;MC]X:=_UYH]F>D
MV8@@3K4`17%&#CD7EDNZG\LFG7&U8\";"PFK2D),EPXN%6/3]_(E+Y=DS7/2
MI3/J/;8G-@I<*/2GH-")P,5+CEIO7T>H2XRJ#L&ZW(WT++:9UV.*JI7-9EP$
ML;%;$GE`6;D4:B!MTK&S1<(\(P%B9)!<&/+C&&*S)[2-"PJ9+$4;9=*A$1\%
M=*ET?2XC`?A@#[]@X'`>[=XE_U1C\O5INA?YX,S2RE6'!R%G.A%U01'J9PDB
M><D[M+?UFR1JO$`3XRI%:/"9L<%H;$&^,:[6."\IIQJ<FI"IOQ-65*EQI7DR
MKAA7R?`7,OQ`,HSIG%'<>Q-<@K@NCS#UL_D(5[KN3KZ1)"PYXQR$DK%]/[1Q
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MS6&BJ('<ZDEH_/QJ..=!>06.G8FEN/>7JC`?,FKK\EFLF!$YC0V+I#4G),R-
MXZAB#7PETYI7X]%^EB4!BOLZ_[U)O1ZOF,6J\&QE]=*'UZ.!I;LH#&6C%)=*
M<$DD=)(YPR=9Q<W3ZP$Q0MV8-HTB:+9:2=':=G`F#DG=PBA2'5TH`8$*17$(
MJ5)<.@O$?O:X35:/#.;ZM]I\@=878D?K]0$_"R1GYLN`4*<`K+]%B!&T3'WE
MSP<I>TL0+I7@S.)ULQ/N;IZ^?DN.4=_7Q[$M4XE(WYG5WR?<39.[J"W3@RE5
M:6V(R8A[D_B2KA>)]8^5,II*156DG^X%C\*6F8A3!8%I)'=ZDYJ`HXU$K&QL
MT=V<LH]K7%P/\@1M(?2](=T\$GQ&U7A!!(S0(H@_$<F86TSMN/59.Y-UH<II
M)B9LK:W[SV%C%W"I[M+8C^T`V47_2,K,:TL)R@Y"0H56V!I81*>J<WOJQ^\V
M#BAPXY>Q.)?TOJUDW?+RS)YE)79*V3R'C;T@]/D*`%$/T3/KIP<(IB"VMIV6
M^NXV)=\*W7D\()05,.HE,RH+_!X#@9+HY4>@P302,KG'\P@N8)SP')&4-.:M
M5864OO&NN0*\'_.RV0S'QAVES0:43*E/]4<2?2Y&R1<3JY%/DG?K]XB&N['F
M#-7*NN&!8A94*#\BJUTK#UNJ&C>'1$4"=BZ?Q0?7$UBJCSYF]:U1.42_G?O.
M>RE5.D0>BR(=,'!-@OU3CY*=VRY?C[>6CGM=PQ3,0>0`[:@%B'L,/'+`,>5F
M`!^V5/9]&,WH'V@M<[D(>3+4?E0_(5*Y`(\AR07P9%_PP)8RTNYU9AT>H$OB
M!>\0E#/K+4-]JS,S8T7UJAH:1NMC](^43Y"#)`0<P)6GY[>`3N4F_!$D$.$N
MNO`$/@\W"\0Y90!ZC;:>LR%D0GTAI:I.]1AW%Q@*>9]'8G]*C[55;NI2D`X[
M6$@>::HL_,E"'*Z$CS96UX1G_J(!VZ;JP3]UOV"`[[+N(Q/D\\I7;0]Y$O=D
M=[.21_8[V.>IN\5*GWA$T]B+YUJ:.9.*-UQ:T]7?7.@3&WE`TGSBU2-N%(9)
M!?&=V2Q..8@_-B==?72X5%GNYE>IPEHS^0TW.?;$Q_\!4$L!`AX#%`````@`
M\XFI0ORR&XW^*```MK\!`!``&````````0```*2!`````'!L>"TR,#$S,#,S
M,2YX;6Q55`4``_H1C%%U>`L``00E#@``!#D!``!02P$"'@,4````"`#SB:E"
M9ZM_6$H*```&<P``%``8```````!````I(%(*0``<&QX+3(P,3,P,S,Q7V-A
M;"YX;6Q55`4``_H1C%%U>`L``00E#@``!#D!``!02P$"'@,4````"`#SB:E"
M..4,A7<,```8G@``%``8```````!````I('@,P``<&QX+3(P,3,P,S,Q7V1E
M9BYX;6Q55`4``_H1C%%U>`L``00E#@``!#D!``!02P$"'@,4````"`#SB:E"
M>VA8X1X\``!W2@,`%``8```````!````I(&E0```<&QX+3(P,3,P,S,Q7VQA
M8BYX;6Q55`4``_H1C%%U>`L``00E#@``!#D!``!02P$"'@,4````"`#SB:E"
M<.^+LR8:``"D>0$`%``8```````!````I($1?0``<&QX+3(P,3,P,S,Q7W!R
M92YX;6Q55`4``_H1C%%U>`L``00E#@``!#D!``!02P$"'@,4````"`#SB:E"
M3^4KZ!L(```-1@``$``8```````!````I(&%EP``<&QX+3(P,3,P,S,Q+GAS
M9%54!0`#^A&,475X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"``#JGP``
"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E3IAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUES</a></td>
        <td class="nump">$ 3,568<span></span></td>
        <td class="nump">$ 3,861<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_OtherGainsLosses', window );">COMPANY'S SHARE IN COLLABORATION AGREEMENT</a></td>
        <td class="nump">400<span></span></td>
        <td class="num">(133)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF REVENUES</a></td>
        <td class="num">(971)<span></span></td>
        <td class="num">(1,320)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">GROSS PROFIT</a></td>
        <td class="nump">2,997<span></span></td>
        <td class="nump">2,408<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
        <td class="num">(7,754)<span></span></td>
        <td class="num">(8,847)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GrantsAndReimbursementsReceivedOrReceivable', window );">Less - grants and reimbursements</a></td>
        <td class="nump">2,431<span></span></td>
        <td class="nump">2,003<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ResearchDevelopmentAndEngineeringExpenseNet', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
        <td class="num">(5,323)<span></span></td>
        <td class="num">(6,844)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
        <td class="num">(2,103)<span></span></td>
        <td class="num">(1,629)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
        <td class="num">(4,429)<span></span></td>
        <td class="num">(6,065)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">FINANCIAL INCOME - NET</a></td>
        <td class="nump">108<span></span></td>
        <td class="nump">161<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
        <td class="num">$ (4,321)<span></span></td>
        <td class="num">$ (5,904)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</a></td>
        <td class="nump">$ 0.05<span></span></td>
        <td class="nump">$ 0.07<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE-BASIC AND DILUTED</a></td>
        <td class="nump">92,184,220<span></span></td>
        <td class="nump">87,821,078<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrantsAndReimbursementsReceivedOrReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Grants and reimbursements received or receivable from governmental institutions and collaboration partners for research and development expenses incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_GrantsAndReimbursementsReceivedOrReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherGainsLosses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The Company's share in collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_OtherGainsLosses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ResearchDevelopmentAndEngineeringExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research and development expenses, net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_ResearchDevelopmentAndEngineeringExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate foreign currency transaction gain (loss) (both realized and unrealized) included in determining net income for the reporting period. Excludes foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements. For certain enterprises, primarily banks, that are dealers in foreign exchange, foreign currency transaction gains (losses) may be disclosed as dealer gains (losses).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 52<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>May 01, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">PLX<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">PROTALIX BIOTHERAPEUTICS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001006281<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">93,503,268<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 870<span></span></td>
        <td class="nump">$ 61<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
        <td class="nump">$ 497<span></span></td>
        <td class="nump">$ 68<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph g(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6793087&amp;loc=d3e301413-122809<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Inventory at March 31, 2013 and December&nbsp;31, 2012 consisted of the following:</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif; MARGIN-LEFT: 0.75in" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">March 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> <td style="TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">December 31,</td> <td style="FONT-WEIGHT: bold" nowrap="nowrap">&nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2013</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2" nowrap="nowrap">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" nowrap="nowrap"> &nbsp;</td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="6" nowrap="nowrap">(U.S. dollars in thousands)</td> <td style="PADDING-BOTTOM: 1pt" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; WIDTH: 64%">Raw materials</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">2,418</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> <td style="WIDTH: 1%">&nbsp;</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">2,118</td> <td style="TEXT-ALIGN: left; WIDTH: 1%">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Work in progress</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">341</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td>&nbsp;</td> <td style="TEXT-ALIGN: left">&nbsp;</td> <td style="TEXT-ALIGN: right">192</td> <td style="TEXT-ALIGN: left">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">Finished goods</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 3,014</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="PADDING-BOTTOM: 1pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"> &nbsp;</td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,729</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total inventory</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 5,773</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="PADDING-BOTTOM: 2.5pt">&nbsp;</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,039</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">&nbsp;</td> </tr> </table> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfInventoryCurrentTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>a.</strong></td> <td><strong>General</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.5in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>1.</strong></td> <td><strong>Operation</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the "Company"), and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#39;s proprietary ProCellEx<sup>&reg;</sup> protein expression system ("ProCellEx"). In September 2009, Protalix Ltd. formed another wholly-owned subsidiary under the laws of the Netherlands, Protalix B.V., in connection with the European Medicines Agency ("EMA") application process in the European Union. The Company&#39;s two subsidiaries are referred to collectively herein as the "Subsidiaries."</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> On May 1, 2012, the U.S. Food and Drug Administration ("FDA") approved taliglucerase alfa for injection, the Company&#39;s first approved drug product, as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that the Company developed using ProCellEx. Taliglucerase alfa was also approved by the Israeli Ministry of Health (the "Israeli MOH") in September 2012, by the Brazilian Ministry of Health in March 2013 and by the applicable regulatory authorities of certain other countries. Taliglucerase alfa is the first plant cell-based recombinant therapeutic protein approved by each of the FDA and the Israeli MOH.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Taliglucerase alfa is being marketed in the United States under the brand name ELELYSO&trade; by Pfizer Inc. (<font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer<font style="TEXT-TRANSFORM: uppercase">"</font>), the Company&#39;s commercialization partner, as provided in the exclusive license and supply agreement by and between Protalix Ltd. and Pfizer (the <font style="TEXT-TRANSFORM: uppercase">"</font>Pfizer Agreement<font style="TEXT-TRANSFORM: uppercase">"</font>). The Company, through Protalix Ltd., markets ELELYSO in Israel.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Protalix Ltd. granted Pfizer an exclusive, worldwide license to develop and commercialize taliglucerase alfa under the Pfizer Agreement, but retained those rights in Israel. The Company has agreed to a specific allocation between Protalix Ltd. and Pfizer regarding the responsibilities for the continued development efforts for taliglucerase alfa. To date, the Company has received an upfront payment of $60.0 million in connection with the execution of the Pfizer Agreement and shortly thereafter an additional $5.0 million clinical development-related milestone payment. The Company received an additional $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States, which was considered to be a substantive milestone for purposes of revenue recognition, and, accordingly, was recorded as revenue during the period in which the milestone was achieved. The agreement provides that the Company share with Pfizer the net profits or loss related to the development and commercialization of taliglucerase alfa on a 40% and 60% basis, respectively, except with respect to the profits or losses related to commercialization efforts in Israel, where the Company retained exclusive marketing rights. <font style="COLOR: black">In calculating the net profits or losses under the agreement, there are certain agreed upon limits on the amounts that may be deducted from gross sales for certain expenses and costs of goods sold</font>.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In December 2012, Protalix Ltd. entered into a Clinical Development Agreement with Pfizer under which Protalix Ltd. will continue to manage, administer and sponsor current, ongoing clinical trials relating to taliglucerase alfa. According to the terms of the agreement, Protalix Ltd. was eligible to receive a payment of $8.3 million upon the achievement of certain near-term clinical development goals. The goals were achieved, and the payment made, in December 2012.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> The Company is cooperating with Pfizer to obtain marketing approval for taliglucerase alfa in additional countries and jurisdictions. Currently, marketing authorization applications have been filed in a number of countries.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Currently, patients are being treated with taliglucerase alfa on a commercial basis in the United States and Israel. In addition, patients are being treated globally through the Company&#39;s clinical trials and related studies, compassionate use programs, special access agreements, named patient provisions and other programs designed to ensure that treatments are available to Gaucher patients in light of recent shortages of approved treatments. On July 13, 2010, the Company announced that the French regulatory authority had granted an Autorisation Temporaire d&#39;Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists. This ATU allows Gaucher patients in France to receive treatment with taliglucerase alfa before marketing authorization for the product is granted in the European Union. Payment for taliglucerase alfa has been secured through government allocations to hospitals. In addition, taliglucerase alfa is currently being provided to Gaucher patients under special access agreements or named patient provisions in Brazil and in other countries.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to taliglucerase alfa, the Company is working on the development of certain other products using ProCellEx.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>2.</strong></td> <td>Liquidity and Financial Resources</td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> In addition to the approval of taliglucerase alfa for marketing in the United States, Israel, Brazil, Mexico and other countries, successful completion of the Company&#39;s development programs and its transition to normal operations is dependent upon obtaining the foreign regulatory approvals required to sell its products internationally. In accordance with the terms and conditions of the Pfizer Agreement, the Company received a $25.0 million milestone payment in connection with the FDA&#39;s approval of taliglucerase alfa in the United States. A substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all and the Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Obtaining marketing approval with respect to any product candidate is directly dependent on the Company&#39;s ability to implement the necessary regulatory steps required to obtain such approval in the United States and in other countries. The Company cannot reasonably predict the outcome of these activities.</p> <p style="MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 1in; FONT: 10pt Times New Roman, Times, Serif"> Based on its current cash resources and commitments, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"><strong>b.</strong></td> <td><strong>Basis of Presentation</strong></td> </tr> </table> <p style="TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2012, filed by the Company with the Securities and Exchange Commission. The comparative balance sheet at December 31, 2012 has been derived from the audited financial statements at that date.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in">&nbsp;</td> <td style="WIDTH: 0.25in"><strong>c.</strong></td> <td><strong>Net loss per share</strong></td> </tr> </table> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Basic and diluted loss per share ("LPS") are computed by dividing net loss by the weighted average number of shares of the Company&#39;s Common Stock, par value $0.001 per share (the "Common Stock") outstanding for each period.</p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &nbsp;</p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> Diluted LPS does not include 7,373,768 and 7,471,571 <font style="COLOR: black">shares of Common Stock underlying outstanding options and restricted shares of Common Stock</font> for the three months ended March 31, 2012 and 2013, respectively, because the effect would be anti-dilutive.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accounting policy related to the nature of operations of the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NatureOfOperationsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BasisOfAccountingPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 6, 8-16, 60<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (in shares)</a></td>
        <td class="nump">12,421<span></span></td>
        <td class="nump">17,095<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 36,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Certain Employee [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (in shares)</a></td>
        <td class="nump">12,421<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of options</a></td>
        <td class="nump">$ 28,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common stock issued in connection with exercise of options</a></td>
        <td class="nump">12,421<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EN3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">40 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Protalix Bio Therapeutics Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013

</div>
          <div>Pfizer Incorporation [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009

</div>
          <div>Upon Filing of Pediatric Investigation Plan to EMA [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2012

</div>
          <div>Upon FDA Approval [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Upon Near Term Clinical Development Milestones [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NumberOfSubsidiaries', window );">Number of Subsidiaries</a></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Pfizer Agreement, upfront payment received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 60.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MilestonePayment', window );">Milestone payment triggered</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 25.0<span></span></td>
        <td class="nump">$ 8.3<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementProfitSharePercentage', window );">Pfizer Agreement, future revenues and expense sharing percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40.00%<span></span></td>
        <td class="nump">60.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive</a></td>
        <td class="nump">7,471,571<span></span></td>
        <td class="nump">7,373,768<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementProfitSharePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative arrangement profit sharing percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_CollaborativeArrangementProfitSharePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MilestonePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_MilestonePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfSubsidiaries">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_NumberOfSubsidiaries</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>plx_SignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>plx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-4<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 171<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 40<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 128<br><br> -Paragraph 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from collaborators during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromCollaborators</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory Components) (Details) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
        <td class="nump">$ 2,418<span></span></td>
        <td class="nump">$ 2,118<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
        <td class="nump">341<span></span></td>
        <td class="nump">192<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
        <td class="nump">3,014<span></span></td>
        <td class="nump">1,729<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
        <td class="nump">$ 5,773<span></span></td>
        <td class="nump">$ 4,039<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before last-in first-out (LIFO) and valuation reserves of merchandise or goods held by the entity that are readily available for sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryFinishedGoods</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of unprocessed items to be consumed in the manufacturing or production process. Also includes purchased parts that will be used as components of a finished product.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryRawMaterials</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross amount of merchandise or goods which are partially completed, are generally comprised of raw materials, labor and factory overhead costs, and which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWorkInProcess</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E4FBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="num">$ (3,357)<span></span></td>
        <td class="num">$ (26,077)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares)</a></td>
        <td class="nump">93,489,809<span></span></td>
        <td class="nump">85,630,157<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,388<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="nump">347<span></span></td>
        <td class="nump">129<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-based compensation related to restricted stock award</a></td>
        <td class="nump">1,020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="nump">28<span></span></td>
        <td class="nump">7<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (in shares)</a></td>
        <td class="nump">12,421<span></span></td>
        <td class="nump">17,095<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss for the period</a></td>
        <td class="num">(4,321)<span></span></td>
        <td class="num">(5,904)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="num">(6,283)<span></span></td>
        <td class="num">(6,457)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares)</a></td>
        <td class="nump">93,502,230<span></span></td>
        <td class="nump">90,822,252<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="nump">93<span></span></td>
        <td class="nump">86<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares)</a></td>
        <td class="nump">93,489,809<span></span></td>
        <td class="nump">85,630,157<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued for cash (net of issuance costs) (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,175,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-based compensation related to restricted stock award</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options granted to employees and non-employees (in shares)</a></td>
        <td class="nump">12,421<span></span></td>
        <td class="nump">17,095<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss for the period</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="nump">94<span></span></td>
        <td class="nump">91<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares)</a></td>
        <td class="nump">93,502,230<span></span></td>
        <td class="nump">90,822,252<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Additional Paid-in Capital [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="nump">180,145<span></span></td>
        <td class="nump">145,814<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,383<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="nump">347<span></span></td>
        <td class="nump">129<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-based compensation related to restricted stock award</a></td>
        <td class="nump">1,020<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="nump">27<span></span></td>
        <td class="nump">7<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss for the period</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="nump">181,539<span></span></td>
        <td class="nump">171,333<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Accumulated Deficit [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
        <td class="num">(183,595)<span></span></td>
        <td class="num">(171,977)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued for cash (net of issuance costs)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition', window );">Share-based compensation related to stock options</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Share-based compensation related to restricted stock award</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options granted to employees and non-employees</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss for the period</a></td>
        <td class="num">(4,321)<span></span></td>
        <td class="num">(5,904)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
        <td class="num">$ (187,916)<span></span></td>
        <td class="num">$ (177,881)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to employee stock purchase programs during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=20435746&amp;loc=d3e565-108580<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued and outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <p style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>NOTE 3 - STOCK TRANSACTIONS</strong></p> <p style="MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> <strong>&nbsp;</strong></p> <p style="TEXT-INDENT: 0in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> During the three months ended March 31, 2013, the Company issued a total of 12,421 shares of Common Stock in connection with the exercise of a total of 12,421 options by certain employees of the Company. The aggregate proceeds in connection with such exercises totaled approximately $28,000.</p> <!--EndFragment--></div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -Chapter 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>36</ContextCount>
  <ElementCount>92</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>11</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementOfChangesInCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>102 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>103 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesPolicy</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>302 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Schedule of Inventory Components) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/InventoriesScheduleOfInventoryComponentsDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory Components) (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40301 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_ProceedsFromStockOptionsExercised had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN CAPITAL DEFICIENCY (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</Log>
  </Logs>
  <InputFiles>
    <File>plx-20130331.xml</File>
    <File>plx-20130331.xsd</File>
    <File>plx-20130331_cal.xml</File>
    <File>plx-20130331_def.xml</File>
    <File>plx-20130331_lab.xml</File>
    <File>plx-20130331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
